The interaction of the prion protein with lipid membranes and implications for prion conversion by Sanghera, Narinder
warwick.ac.uk/lib-publications   
 
 
 
 
 
A Thesis Submitted for the Degree of PhD at the University of Warwick 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/133932 
 
 
 
Copyright and reuse:                     
This thesis is made available online and is protected by original copyright.  
Please scroll down to view the document itself.  
Please refer to the repository record for this item for information to help you to cite it. 
Our policy information is available from the repository home page.  
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The Interaction of the Prion Protein 
with Lipid Membranes 
and
Implications for Prion Conversion
Thesis submitted for the degree of Doctor of 
Philosophy
Narinder Sanghera B. Sc. (Hons.)
Department of Biological Sciences, University of Warwick
September 2001
Contents
Page Number
Contents ii
List of table and figures viii
Acknowledgements xii
Declaration xiii
Abstract xiv
List of abbreviations xv
Chapter 1: Introduction
1.1 Prion 1
1.1.1 Discovery o f the prion protein 1
1.1.2 Search for a scrapie-specific nucleic acid 3
1.1.3 Human TSE diseases 4
1.1.4 PrP gene structure, organisation and expression 5
1.1.5 Properties o f  PrP isoforms 6
1.1.6 Structure of prion proteins 9
1.1.6.1 NMR structure o f recombinant PrP 9
1.1.6.2 Model structure o f PrPSc 12
1.1.7 PrP biosynthesis and metabolism 13
1.1.7.1 GPI-anchored PrP 13
1.1.7.2 Transmembrane PrP 16
1.1.7.3 Transmembrane PrP and disease 17
1.1.8 Conversion o f PrPc to PrPSc 19
1.1.8.1 Cellular site for PrPSc formation 20
1.1.8.2 In vitro conversion 22
1.1.9 Species barrier 23
1.1.10 Models for the conversion o f PrPc to PrPSc 24
1.1.11 Function o f PrPc  27
1.1.12 What causes cell death? 28
1.1.13 Yeast prions 29
1.2 Membranes 29
1.2.1 Membrane proteins 30
1.2.1.1 Integral membrane proteins 30
1.2.1.2 Peripheral proteins 30
u
1.2.2 Lipid composition o f the plasma membrane 31
1.2.3 Lipid-lipid interactions 36
1.2.4 Physical properties o f lipids and their effects on
bilayer structure 37
1.2.5 Membrane structure 38
1.2.6 Interaction o f lipid-anchored proteins with lipid 40
membranes
1.3 Aim s 39
1.4 Layout o f  this thesis 42
Chapter 2: Biophysical Techniques
2.1 Electromagnetic Radiation 43
2.1.1 General properties o f electromagnetic radiation 43
2.1.2 Polarisation o f electromagnetic radiation 46
2.1.3 The electromagnetic spectrum 48
2.1.4 Absorption o f electromagnetic radiation 50
2.2 The Theory o f  Fluorescence 50
2.2.1 Fluorescence, quantum yields and lifetimes 50
2.2.2 Solvent effects on the fluorescence spectra 54
2.2.3 Fluorophores 55
2.3 Circular Dichroism Spectroscopy 56
2.3.1 Theory of circular dichroism spectroscopy 56
2.3.2 The physical basis o f optical activity 59
2.3.3 Optically active chromophores 60
2.4 Infrared Spectroscopy 63
2.4.1 Physical basis o f infrared spectroscopy 63
2.4.1.1 Diatomic molecules 64
2.4.1.2 Polyatomic molecules 65
2.4.2 Protein secondary structure 67
in
Chapter 3: Expression and Purification of Syrian Hamster Prion 
Protein (SHaPrP) Residues 90-231
3.1 Introduction  70
3.1.1 Expression plasmid 70
3.2 Materials and M ethods 73
3.2.1 Materials 73
3.2.2 Safety issues 74
3.2.3 Expression o f SHaPrP (90-231) 75
3.2.4 Purification o f recombinant SHaPrP (90-231) 76
3.2.5 Refolding o f recombinant SHaPrP (90-231) 80
3.2.6 Characterisation o f purified recombinant SHaPrP
(90-231) 80
3.2.6.1 Determination o f protein concentration 8 0
3.2.6.2 SDS-poiyacrylamide gel electrophoresis and
Western Blotting 80
3.2.6.3 Mass spectrometry 82
3.2.6.4 CD spectroscopy 8 2
3.3 Results and Discussion 82
3.3.1 Expression and purification of SHaPrP (90-231) 82
3.3.2 Characterization of purified recombinant SHaPrP (90-231) 84
3.3.2.1 Analysis by SDS-PAGE and Western blotting 84
3.3.2.2 Mass spectrometry 84
3.3.2.3 Spectroscopic characterisation o f recombinant 84
SHaPrP (90-231)
3.3.3 Summary 89
Chapter 4: Binding of Syrian Hamster Prion Protein (SHaPrP) 
Residues 90-231 to Model Lipid Membranes
4.1 Introduction  90
4.2 M aterials and Methods 92
4.2.1 Materials 92
4.2.2 Lipid vesicles 94
iv
4.2.3 Binding o f recombinant SHaPrP (90-231) to lipid
membranes 94
4.2.4 Quenching o f tryptophan fluorescence 96
4.3 Results 97
4.3.1 Changes in the tryptophan fluorescence upon binding
of PrP to model lipid membranes 97
4.3. L 1 Interaction o f recombinant SHaPrP (90-231)
with negatively charged membranes 98
4.3.1.2 Interaction o f recombinant SHaPrP (90-231)
with zwitterionic membranes 99
4.3.1.3 Influence o f ionic strength on PrP-lipid
interactions 103
4.3.2 Acrylamide quenching o f PrP fluorescence 113
4.4 Discussion  118
4.5 Conclusions 128
Chapter 5: Secondary Structural Changes in Syrian Hamster Prion 
Protein (SHaPrP) Residues 90-231 Upon binding to Lipid Membranes
5.1 Introduction  130
5.2 Materials and Methods 132
5.2.1 Materials 132
5.2.2 Lipid vesicles 132
5.2.3 Circular dichroism 132
5.2.4 Sample preparation forA TR  FTIR measurements 133
5.2.5 ATR FTIR measurements 135
5.2.6 Analysis o f FTIR spectra 135
5.2.7 Electron microscopy 139
5.3 Results 139
5.3.1 Circular dichroism spectroscopy 139
5.3.2 ATR FTIR spectroscopy 142
5.3.3 Structural changes monitored over time 150
v
5.3.4 Electron microscopy 150
5.4 Discussion 152
5.5 Conclusions 158
Chapter 6: Membrane Binding/Insertion Kinetics of Syrian Hamster 
Prion Protein (SHaPrP) Residues 90-231 and PrP-Induced Membrane 
Destabilisation
6.1 Introduction  159
6.1.1 Fluorescent probes at membrane surfaces 159
6.1.2 Fluorescent dye release assay 161
6.2 M aterials and Methods 163
6.2.1 Materials 163
6.2.2 FPE-labelling and stopped-Jlow measurements 163
6.2.2.1 FPE-labelling o f lipid vesicles 163
6.2.2.2 Check o f the asymmetric labelling o f lipid
vesicles with FPE 164
6.2.2.3 Stopped-Jlow fluorescence spectroscopy 164
6.2.3 Calcein release 168
6.2.3.1 Preparation o f lipid vesicles loaded with calcein 168
6.2.3.2 PrP-induced release o f calcein from lipid
vesicles 169
6.3 Results 170
6.3.1 FPE-detected membrane binding and insertion kinetics 170
6.3.2 Calcein release 181
6.4 Discussion 190
6.5 Conclusions 196
vi
Chapter 7: General Discussion and conclusions
7.1 Binding o f  PrP to lipid membranes induces protein
structural changes and can alter bilayer integrity 197
7.2 Biological Implications 201
7.3 In Summary 206
References 207
vii
Figures and Tables
Page Number
Chapter 1: Introduction
Figure 1.1 Schematic representation of the biosynthesis of PrP
isoforms. 7
Table 1.1 Content of secondary structure of purified SHaPrP 8
Figure 1.2 Representations of the three-dimensional structures of prion
proteins. 11
Table 1.2 The lengths of the helices (A, B & C) and the P-strands (S1 & S2)
in the NMR structures of different domains of recombinant PrP. 12
Figure 1.3 Schematic representation of the topologie forms of PrP. 14
Figure 1.4 Model demonstrating the relationship of PrPSc and ClmPrP in
TSE diseases. 18
Figure 1.5 Schematic representation showing the probable sites of PrPSc
formation. 21
Figure 1.6 Models for the conversion of PrPc to PrPSc. 26
Figure 1.7 Structures of commonly occurring fatty acids. 33
Figure 1.8 Structures of the commonly occurring glycerophospholipids in
mammalian cells. 34
Figure 1.9 Structures of other lipid constituents of membranes. 35
Table 1.3 Lipid composition of normal adult human brain. 36
Figure 1.10 Model of the lipid organisation of raft domains. 39
Chapter 2: Biophysical Techniques
Figure 2.1 Wave representation of electromagnetic radiation. 44
Figure 2.2 A right-handed circularly polarised beam. 47
Table 2.1 Common spectroscopic methods based on electromagnetic
radiation. 48
Figure 2.3 The electromagnetic spectrum. 49
Figure 2.4 Elliptically polarised light is formed by right- and left-circularly
polarised light of unequal intensities. 58
Figure 2.5 CD spectra of protein in the (A) near-UV region and (B) far-UV
region. 62
Table 2.2 Wavenumbers of characteristic IR vibrations. 65
Figure 2.6 The different types of molecular vibrations that occur upon
absorption of IR radiation. 69
v i n
Chapter 3: Expression and Purification of Syrian Hamster Prion 
Protein (SHaPrP) Residues 90-231
Figure 3.1 PlngPrP plasmid. 72
Figure 3.2 Purification protocol for recombinant SHaPrP (90-231). 77
Figure 3.3 Purification of recombinant SHaPrP (90-231). 79
Figure 3.4 Analysis of recombinant SHaPrP (90-231) by SDS-PAGE and
Western blotting. 85
Figure 3.5 ESI mass spectrometry of purified recombinant SHaPrP (90-231). 86
Figure 3.6 CD spectra of recombinant SHaPrP (90-231). 88
Chapter 4: Binding of Syrian Hamster Prion Protein (SHaPrP) 
Residues 90-231 to Model Lipid Membranes
Figure 4.1 Ribbon diagram of the three-dimensional structure of recombinant
SHaPrP (90-231). 93
Figure 4.2 Equilibrium fluorescence spectra of SHaPrP (90-231) in solution
and in the presence of POPG membranes. 100
Figure 4.3 Equilibrium fluorescence spectra of SHaPrP (90-231) in solution
and in the presence of POPC membranes. 101
Figure 4.4 Equilibrium fluorescence spectra of SHaPrP (90-231) in solution
and in the presence of DPPC membranes, pH 7. 102
Figure 4.5 Equilibrium fluorescence spectra of SHaPrP (90-231) in solution 
and in the presence of raft-like membranes of DPPC/chol/SM 
(50:30:20 molar ratio). 104
Table 4.1 Lipid-induced changes in the wavelength of the fluorescence
maximum of SHaPrP (90-231). 105
Figure 4.6 Blue shift Xmax of SHaPrP (90-231) with increasing lipid. 106
Figure 4.7 Changes in tryptophan fluorescence of SHaPrP (90-231) upon
binding to POPG membranes in the presence of salt. 108
Figure 4.8 Changes in tryptophan fluorescence of PrP-POPG complexes
upon addition of salt. 109
Figure 4.9 Changes in tryptophan fluorescence of SHaPrP (90-231) upon 
binding to raft-like membranes of DPPC/chol/ SM (50:30:20 
molar ratio) in the presence of salt. I l l
Figure 4.10 Changes in tryptophan fluorescence of DPPC/chol/SM-PrP
complexes upon addition of salt. 112
Figure 4.11 Quenching of tryptophan fluorescence by acrylamide at pH 5. 114
IX
Figure 4.12 Quenching of tryptophan fluorescence by acrylamide at pH 7. 115
Table 4.2 Stem-Volmer quenching constants (Ksv) for SHaPrP (90-231) in
solution and in the presence of lipid membranes. 116
Figure 4.13 Stem-Volmer plots for the fluorescence quenching of SHaPrP
(90-231) by acrylamide. 117
Figure 4.14 Amino acid sequence of SHaPrP (90-231). 122
Figure 4.15 Different representations of the three-dimensional structure of
SHaPrP (90-231). 123
Figure 4.16 Schematic model for PrP-lipid interactions. 127
Chapter 5: Secondary Structural Changes in Syrian Hamster Prion 
Protein (SHaPrP) Residues 90-231 Upon binding to Lipid Membranes
Figure 5.1 
Table 5.1
Figure 5.2
Figure 5.3
Figure 5.4
Figure 5.5
Figure 5.6
Figure 5.7 
Figure 5.8
Figure 5.9
Schematic representation of the ATR set-up. 134
Assignment of the IR frequency regions for the different secondary 
structures in proteins. 13 8
Far-UV CD spectra of SHaPrP (90-231) in solution and with lipid 
membranes at pH 7. 140
Far-UV CD spectra of SHaPrP (90-231) in solution and with lipid 
membranes at pH 5. 141
FTIR spectra of SHaPrP (90-231) in absence and presence of 
lipid membranes. 144
Normalised amide I region of the FTIR spectra of SHaPrP (90-231) 
in the absence and presence of POPG membranes. 146
Normalised amide I region of the FTIR spectra of SHaPrP (90-231) 
in the absence and presence of DPPC and raft-like membranes. 148
FTIR difference spectra in the amide I region of SHaPrP (90-231). 149 
Structural changes of SHaPrP (90-231) in the absence and presence 
of lipid membranes following incubation at 20 °C. 151
Electron micrographs of SHaPrP (90-231) in solution and in the 
presence of lipid membranes. 153
Chapter 6: Membrane Binding/Insertion Kinetics of Syrian Hamster 
Prion Protein (SHaPrP) Residues 90-231 and PrP-Induced Membrane 
Destabilisation
Figure 6.1 Schematic representation of the FPE method. 160
Figure 6.2 Fluorescence properties of FPE. 162
x
Figure 6.4
Figure 6.5
Table 6.1
Figure 6.6
Figure 6.7
Figure 6.8
Table 6.2
Figure 6.9
Figure 6.10
Figure 6.11
Table 6.3 
Figure 6.12
Table 6.4 
Figure 6.13
Figure 6.3 Schematic representation of the single-mixing mode configuration 
of the stopped-flow spectrofluorimeter. 166
Determination of the asymmetric incorporation of FPE into lipid 
vesicles. 172
Representative kinetics for the interaction of SHaPrP (90-231) 
with FPE-labelled POPG membranes, pH 7. 173
Kinetic parameters for membrane binding and insertion of SHaPrP 
(90-231) with POPG membranes at pH 7. 174
Kinetics of FPE-detected binding and insertion of PrP into POPG 
membranes, pH 7. 175
The dependence of FPE-detected kinetic parameters for the binding 
and insertion of PrP into POPG membranes on PrP concentration. 177 
Representative kinetics for the interaction of SHaPrP (90-231) with
FPE-labelled POPC/POPG membranes (70:30 molar ratio), pH 7. 179 
Kinetic parameters for membrane binding of SHaPrP (90-231) 
with POPC/POPG membranes at pH 7 (70:30 molar ratio). 180
Illustration of a series of fluorescence spectra of calcein release 
upon binding of SHaPrP (90-231 ). 183
Summary of the extent of PrP-induced release of calcein from 
various lipid membranes. 184
Representative kinetic traces of PrP-induced release of calcein 
from POPG membranes. 185
Kinetics of PrP-induced calcein release from lipid membranes. 186
Representative kinetic traces of PrP-induced release of calcein 
from POPG membranes at pH 7 monitored in stopped-flow 
measurements. 188
Kinetic parameters for PrP-induced release of calcein from POPG 
membranes at pH 7. 189
Proposed kinetic model for the interaction of SHaPrP (90-231) 
with lipid membranes. 195
xi
A ckn ow l edge m en is
I would like to thank my supervisor Dr Teresa Pinheiro for providing guidance 
and support throughout this project. Also, all the members of the protein structure 
group both past and present whom I have had the pleasure to work with. I would 
especially like to thank Saffron, Ela, Sunita, Ian Sylvester and Jurate for their help, 
advice and friendship; Caroline for her continual encouragement and for being a good 
friend and Shibar for his help with the Molscript and Grasp diagrams.
Many thanks to Prof. Jean-Marie Ruysschaert and Dr Erik Goormaghtigh at the 
Université Libre de Bruxelles for allowing me to visit their laboratory, for providing the 
software for the analysis of the FTIR data and for their help and advice on the FTIR 
experiments. I would also like to thank Dr Catherine Vénien-Brian at the University of 
Oxford for patiently looking through the 100’s of EM samples that I bombarded her 
with and Dr Ingrid Mehlhorn for helpful suggestions on the expression and purification 
ofPrP.
Also, I would like to thank my parents, sisters and other members of my 
extended family for their love and support over the past 3 years even when they didn’t 
necessarily understand what it was I actually did! Finally, I would like to thank Jagbir 
for his love and moral support over the last 3 years.
Xll
Declaration
I hereby declare that the research submitted in this thesis was conducted by 
myself under the supervision of Dr T. J. T. Pinheiro at the Department of Biological 
Sciences, University of Warwick.
No part of this work has previously been submitted to be considered for a 
degree. All sources of information have been specifically acknowledged in the form of 
references.
Some of the work presented herein has been accepted for publication:
Sanghera, N. and Pinheiro, T. J. T. (2001). Binding of prion protein to lipid 
membranes and implications for prion conversion. J. Mol. Biol in print
xiii
ABSTRACT
The Interaction of the Prion Protein with Lipid Membranes and Implications for
Prion Conversion
Prion diseases are characterised by the conversion of the normal a-helical prion 
protein (PrPc), to the abnormal P-sheet isoform (PrPSc). Biophysical studies using 
recombinant prion proteins have helped our understanding of the structural events 
associated with the transition of PrPc to PrPSc. These studies were performed in an 
aqueous environment, however PrP in living cells is anchored to 
cholesterol/sphingomyelin rich raft-domains. Evidence suggests that the lipid 
environment plays’ a role in the conversion of PrPc to PrPSc. Therefore in this thesis 
the biophysical properties of PrP in lipid membranes were evaluated.
The binding of Syrian hamster prion protein, SHaPrP (90-231) to model lipid 
membranes was investigated by tryptophan fluorescence spectroscopy. Membranes 
composed of negatively charged lipids, zwitterionic lipids and raft-like membranes 
containing DPPC, cholesterol and sphingomyelin, were investigated. The results show 
that PrP has an affinity for negatively charged and gel-phase zwitterionic membranes. 
Binding of PrP to raft-like membranes was also observed. The interaction of PrP to 
negatively charged membranes involved both electrostatic and hydrophobic lipid- 
protein interactions, whereas the binding of PrP to raft-like membranes was 
predominantly driven by hydrophobic lipid-protein interactions.
CD and ATR FTIR were used to investigate the secondary structure of PrP in 
lipid membranes. The interaction of PrP to negatively charged membranes was 
accompanied by an increase in P-sheet structure and EM showed extensive aggregation 
of the protein. In contrast, the binding of PrP to gel-phase zwitterionic membranes and 
raft-like membranes induced the formation of stable a-helical structure. No evidence of 
aggregation was detected in the EM images.
The ability of PrP to perturb lipid membranes was examined. Evidence for the 
partial insertion of PrP into negatively charged membranes was obtained and the 
resulting p-sheet state was capable of disrupting lipid membranes, leading to total 
release of vesicle contents. The a-helical membrane bound state of PrP did not affect 
the integrity of the raft-like membranes. These finding support the view that the 
interaction of PrP with lipid membranes may play a role in PrP conversion.
xiv
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Chapter 1: Introduction
1.1 P rions
Transmissible spongiform encephalopathies (TSEs) are fatal 
neurodegenerative diseases that occur in humans and in a variety of other animals. 
In humans, TSE diseases include Kuru, Creutzfeldt-Jakob disease (CJD), fatal 
familial insomnia (FFI) and Gerstmann-Staussler-Scheinker (GSS); in animals 
include scrapie of sheep and bovine spongiform encephalopathy (BSE or mad cow 
disease). Examination of the brains of individuals with TSE diseases shows 
spongiform degeneration and astrocytic gliosis (review Prusiner, 1998). So far, the 
occurrence of TSE diseases in humans is rare, however the recent cases of new 
variant (v) CJD in the UK has been related to the recent epidemic of BSE. This has 
lead to a new urgency in the study of TSE diseases especially since there is 
substantial evidence to suggest that vCJD may have been caused by the consumption 
of BSE contaminated products (Bruce etal., 1997; Hill et a!., 1997).
1.1.1 Disco very o f the prion protein
There has been a great deal of speculation regarding the nature of the 
infectious agent in TSE diseases: suggestions included small DNA viruses, 
replicating polysaccharides, membrane fragments and proteins (for review, see 
Prusiner, 1982). Scrapie infectivity was retained after the infectious material was 
subjected to procedures that altered or destroyed nucleic acids. However, methods 
that modify or hydrolyse proteins were found to diminish infectivity (Prusiner, 1982; 
Prusiner et al., 1982). These observations led to the proposal of the ‘protein-only’ 
hypothesis, which states that TSE causing agent is devoid of nucleic acid and the
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essential pathogenic component is a protein. According to the protein-only 
hypothesis TSEs are a result of a conformational transition, in which a normal 
energetically favoured conformation is converted to a disease causing isoform, either 
spontaneously or by exogenous introduction of the altered conformation. The term 
‘prion’ was introduced to distinguish the infectious agent that causes TSEs from 
viruses.
Scrapie infectivity was purified from Syrian hamster (SHa) brain, through a 
series of steps, which included multiple detergent extractions, limited proteinase K 
digestion and a sucrose density gradient (Prusiner, 1982; Prusiner et al., 1982). 
Analysis of the fractions enriched for scrapie infectivity revealed a protease-resistant 
protein of 27-30 kDa; the protein was named prion protein (PrP) 27-30. The 
protein was absent from similar fractions purified from normal brain. The
determination of the amino acid sequence of the amino-terminus of PrP 27-30 made 
it possible to subsequently carry out molecular cloning studies of the PrP gene. It 
was found that PrP was encoded by a chromosomal gene and not by a nucleic acid 
within the infectious material (Chesebro et al., 1985; Oesch et al., 1985). The 
normal cellular PrP gene product was determined, as a protein of 33-35 kDa, termed 
cellular prion protein (PrPc). A protein of identical size was also detected in scrapie 
infected brain extracts, in which proteinase K was absent from the purification 
protocol and was named scrapie or infectious prion protein (PrPSc).
Proteinase K digestion studies revealed that PrPc was completely degraded, 
whereas PrPSc was partially cleaved to produce PrP 27-30. Furthermore, no 
significant difference in the specific infectivity of preparations purified with or 
without proteinase K digestion has been found (Mckinley et al., 1991). The findings
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suggested that PrP could be present in at least two distinct conformational states: a 
protease-sensitive one found ubiquitously and a protease-resistant one identified in 
the setting of infection.
Over the last two decades, substantial amount of evidence both in vivo and in 
vitro has accumulated supporting the protein-only hypothesis (reviewed in Prusiner, 
1998). The strongest evidence for this hypothesis has been provided by genetic 
studies carried out with mice lacking the PrP gene (Pmp0/0). These mice were both 
resistant to prions and unable to generate new infectious particles. Re-introduction 
of PrP-encoding gene restored their susceptibility to infection (Bueler et al., 1993; 
Manson et al., 1994).
1,1.2 Search for a scrapie-specific nucleic acid
The lack of pure preparations of infectious prions and the fact that the 
minimum dose of purified hamster scrapie necessary to establish infection contains 
-100,000 PrPSc molecules (Prusiner et al., 1982) has led some researchers to suggest 
that these preparations may harbour a unique virus. Despite intensive efforts to 
identify a nucleic acid within the infectious material, none has been found to date 
(Oesch et al., 1985; Meyer et al., 1991; Kellings et al., 1992). These studies argue 
that if such a molecule exists, then its size is 80 nucleotides or less. Despite the large 
accumulation of evidence supporting the importance of PrP in TSE diseases, one 
cannot eliminate the possibility of a small nucleic acid molecule bound to PrPSc as an 
essential component of the infectious prion particle or a yet unidentified covalent 
modification of the protein.
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1.1.3 Human TSE diseases
Human TSE or prion diseases maybe presented as genetic, infectious, or 
sporadic disorders (Prusiner, 1997). Typically the diseases are diagnosed in adults 
between 40 and 80 years of age, however new vCJD appears in younger people 
(Prusiner & Scott, 1997).
• Inherited diseases: Familial CJD, GSS and FFI are all dominantly inherited 
diseases, which have been linked to specific mutations in the PrP gene. The Pro102 
-> Leu (P102L) was the first mutation to be genetically linked to GSS. Transgenic 
studies confirmed that mutations of the PrP gene could cause neurodegeneration. 
Mice overexpressing a mutant PrP transgene with a mutation corresponding to 
P102L spontaneously developed a scrapie-like disease (Hsiao et al., 1994). 
Polymorphisms in the PrP gene have also been identified and are thought to 
influence the clinical and neuropathologic phenotype of the disease (Prusiner & 
Scott, 1997).
• Sporadic diseases: Sporadic forms of TSE diseases constitute most cases of 
CJD and a few of GSS. Mutations of the PrP gene are not found in patients. It is not 
known how prions are able to cause disease in these cases; hypotheses include 
somatic mutation of the PrP gene and rare spontaneous conversion of PrPc to PrPSc 
(Prusiner, 1998).
• Infectious diseases: The infectious diseases include Kuru of the Fore 
people in New Guinea, where prions were transmitted by ritualistic cannibalism 
(reviewed in Prusiner, 1998). Sources of prions causing infectious CJD include 
improperly sterilized depth electrodes, which were used during neurosurgical 
procedures, transplanted corneas and the human growth hormone. There is 
compelling evidence supporting the proposal that vCJD is caused by the
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consumption of BSE contaminated food products (Bruce et ah, 1997; Hill et al., 
1997).
1.1.4 PrPgene structure, organisation and expression
The human PrP gene is present on chromosome 20 and contains three exons, 
the open reading frame is encoded by the third exon (Sparkes et ah, 1986). Since the 
entire protein-coding region of all known mammalian genes, resides within a single 
exon the possibility that the two PrP isoforms are products of alternatively spliced 
mRNAs is eliminated (Basler et al., 1986). Furthermore, no evidence for 
rearrangement of the PrP gene in scrapie infected animals has been found (Oesch et 
al., 1985; Basler et ah, 1986). Amino acid sequencing of PrPSc and PrP 27-30 
correspond precisely to the translated genomic DNA sequence (Basler et ah, 1986; 
Hope et ah, 1986; Stahl et ah, 1993). The difference in the properties of the two 
isoforms of PrP is therefore most likely to be due to a post-translational event.
PrP is expressed as a protein of ~ 250 amino acids; human PrP consists of
253 amino acids (Kretzschmar et ah, 1986); Syrian hamster PrP is expressed as a
254 amino acid protein (Oesch et ah, 1985; Basler et ah, 1986). PrPc is expressed in 
normal and scrapie-infected animals whereas PrPSc is observed only in scrapie- 
infected brain (Oesch et ah, 1985). The appearance and abundance of PrP mRNA in 
the brains of adult animals is constant throughout the course of infection (Chesebro 
et ah, 1985; Oesch et ah, 1985).
Immunohistochemistry was used to detect PrPc expression in the brain and 
the highest levels of PrPc were found in the hippocampus. In contrast, PrPSc was
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found to be minimal in this region and was present in the white matter and bundles 
of myelinated axons (DeArmond et al., 1987; Taraboulos et al., 1992).
An amino-terminal 22-residue signal peptide is cleaved during the 
biosynthesis of PrP in the endoplasmic reticulum (Hope et al., 1986; Turk et al., 
1988). A 23-residue carboxyl-terminal peptide is lost upon addition of a 
glycosylphosphatidylinositol (GPI) anchor to the carboxyl-terminus of PrPc at 
Ser231, which anchors the protein to the cell membrane. The GPI anchor has also 
been detected for PrPSc (Stahl et al., 1987; Stahl et al., 1990). Both isoforms of PrP 
contain a disulphide bond between Cysl79 and Cys214 (Turk et al., 1988) and two 
glycosylation sites at Asnl81 and Asnl97 (Endo et al., 1989). A schematic 
representation of the biosynthesis of PrP isoforms is shown in Figure 1.1.
Analysis of the primary structure of PrP revealed several unusual features. 
The amino-terminal region of mammalian PrP, residues 51-91 contains five glycine- 
rich repeats; this sequence is termed the octarepeat region and is among the most 
conserved parts of PrP in mammals thus implying a functional role (Harris et al., 
1991). The octarepeat region of human PrP contains the sequence Pro-(Gln/His)- 
Gly3-(G/-)Trp-Gly-Gln (Prusiner, 1992). The other region of notable conservation 
among mammals is a Gly- and Ala-rich hydrophobic domain from residues 113 to 
128 (Wopfner et al., 1999).
1.1.5 Properties o f  PrP isoforms
The isoforms of PrP have very different biochemical properties:
• PrPSc is insoluble in detergents, whereas PrPc is readily solubilised under non­
denaturing conditions (Meyer et al., 1986).
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Figure 1.1: Schematic representation of the biosynthesis of PrP. Mammalian PrP 
gene encodes a protein of ~ 250 amino acids. The amino-terminal signal peptide of 
22 amino acids is cleaved during maturation of PrPc. 23 amino acids are removed 
from the carboxyl-terminus upon attachment of the GPI anchor at Ser231. PrP is 
glycosylated (CHO) at positions Asnl81 and Asnl97. Mature PrP( is anchored to 
the outer surface of the plasma membrane and is sensitive to proteinase K. The 
partial protease resistance of PrPSc is acquired as a result of a post-translational 
event. Proteinase K digestion of PrPSc removes ~ 67 amino acids to produce PrP 
27-30, which corresponds to the amino acid region from 90 to 231. The protease 
resistant core retains the ability to re-infect laboratory rodents (Mckinley et al., 
1983).
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• PrPSc is partially hydrolysed by proteinase K to form a fragment designated 
PrP 27-30 (amino acids 90-231) while PrPc is completely degraded under the same 
conditions (Oesch et al., 1985).
• PrPc is removed from the cell surface with phosphatidylinositol-specific 
phospholipase C (PIPLC), in contrast cleavage of the GPI anchor attached to PrPSc 
by PIPLC does not result in the release of the protein from the cell surface. No 
evidence for the resistance of the GPI anchor to cleavage was detected, thereby 
suggesting that the polypeptide chain of PrPSc may itself interact with lipid 
membranes (Stahl et al., 1990; Safar et al., 1991).
• PrPSc accumulates within cells whereas PrPc has a rapid turn over (Borchelt 
etal., 1990).
Extensive biochemical characterisation failed to identify any covalent 
chemical differences between PrP and PrP this led investigators to suggest that the 
two isoforms of PrP were likely to differ in their conformation. Analysis of the 
secondary structure of PrPc and PrPSc by Fourier transform infrared (FTIR) 
spectroscopy revealed that the structures of PrPc and PrPSc were indeed different 
(Pan etal., 1993).
Table 1.1: Content o f secondary structure o f purified SHaPrP“
Structure PrPc PrpSc PrP 27-30
a-Helix 42 30 21
P-Sheet 3 43 54
Turn 32 11 9
Coil/Random 23 16 16
“Pan etal., 1993
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The results from the above study as well as others (Caughey et al., 1991; 
Gasset et al., 1993; Nguyen et al., 1995) suggest that PrPc is converted into PrPSc 
through a process whereby a portion of its structure is refolded into (i-sheet structure. 
This conformational transition is accompanied by profound changes in the 
biochemical properties of PrP and is most probably the key molecular event that 
underlies prion propagation.
1.1.6 Structure o f prion proteins
1.1.6.1 NMR structure o f recombinant PrP
The three-dimensional structure of recombinant PrP proteins derived from E. 
coli have been determined by nuclear magnetic resonance (NMR) spectroscopy. The 
structure of the refolded recombinant protein into an a-helical conformation is 
thought to resemble that of PrP . This is supported by studies with recombinant 
antibody fragments showing that GPI-anchored PrPc on the surface of cells exhibits 
an immunoreactivity similar to that of recombinant PrP prepared with an a-helical 
conformation (Peretz et al., 1997). The recombinant proteins also share many 
spectral properties with PrPc (Homemann & Glockshuber, 1996; Zhang et al., 1997; 
Zahn et al., 1997). Difficulties in the purification and low yields of PrPc mean that 
so far recombinant PrP is the only viable model of the cellular protein.
The first structure to be reported was that of the amino-terminally truncated 
segment of mouse PrP comprising residues 121 to 231 (mPrP 121-231). The NMR 
structure revealed three a-helices (A, B & C) with a disulphide bond connecting 
helix B with C and a two stranded anti-parallel p-sheet (SI & S2) (Riek et al., 1996). 
This was followed by the analysis of recombinant SHaPrP, residues 90-231 (Figure
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1.2A) which also exhibited three a-helices and two P-sheets (James et a l, 1997). 
The NMR structure of SHaPrP (90-231) revealed that the amino-terminus region 
from residues 90 to 128 is unstructured and this portion of the protein has been 
proposed to provide the plasticity required for the conformational transition of PrPc 
to PrPSc. The NMR results agree well with the FTIR study (Pan et a l, 1993); out of 
142 resolvable residues in SHaPrP (90-231) 63 are present in the a-helical 
component of the protein (44 %) while only 6 residues lie in the short anti-parallel p 
strands (4 %).
Eventually the full-length structures of recombinant prion proteins from 
SHaPrP (29-231), mPrP (23-231), human (/?)PrP (23-231) and bovine (6) (23-230) 
were solved (Donne et al., 1997; Riek et al., 1997; Garcia et al., 2000; Zahn et al., 
2000). The presence of the additional residues in the full-length proteins did not 
have a significant effect on the secondary structure elements. The prion proteins 
from the different species were shown to contain a structured domain that extended 
approximately from residues 128-228 and a flexible random coil-like amino- 
terminus. Differences in the lengths of helices B and C especially between SHaPrP 
and mPrP however were evident (Table 1.2); helix B is seven residues longer and 
helix C is ten residues longer in SHaPrP compared to /nPrP.
Superposition of the NMR structures of SHaPrP, wPrP, ZiPrP and 6PrP is 
displayed in Figure 1.2B. This shows that the three-dimensional structures of the 
domains are similar, as would be expected for amino acid sequences that exhibit ~ 
90 % homology (Schâtzl et al., 1995; Wopfner et al., 1999). There is however, some
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Figure 1.2: Representations of the three-dimensional structures of prion 
proteins. (A) Ribbon diagram of the NMR structure of recombinant SHaPrP 
(90-231) in aqueous solution (James et al., 1997) indicating the positions of the 
three a-helices (A, B & C) and the two anti-parallel (3-strands (SI & S2). The 
structure was drawn using the program Molscript (Kraulis, 1991) and rendered with 
RASTER3D (Merritt & Bacon, 1997). (B) Superposition of the NMR structures of 
the polypeptide segment 124-228 of SHaPrP (red), /»PrP (orange), /?PrP (green) and 
/)PrP (purple). Structures have been superimposed to obtain the best fit of the 
polypeptide backbone residues 124-228. (C) Plausible model for the tertiary
structure of /îPrPSc (108-217) (Huang et al., 1995).
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structural variability in the amino- and carboxyl-termini between the different 
species. The difference may be due to (/') the differences in the aqueous environment 
in which the structures were recorded, and (//) although the sequence homology 
between the different protein domains is ~ 90 %, species-specific difference in the 
sequences may nevertheless account for the observed variability.
Table 1.2: The lengths o f the helices (A, B & C) and the P-strands (SI & S2) 
in the NMR structures o f different domains o f recombinant PrP
PrP Construct Helix A Helix B Helix C SI S2 PH
SHa(29-231)° 144-156 172-193 200-227 137-140* 160-163 5.2
SHa(90-23l/ 144-156 172-193 200-227 129-131 161-163 5.2
h(23-230/ 144-154 173-194 200-228 128-131 161-164 4.5
h(90-230)c 144-154 173-194 200-228 128-131 161-164 4.5
ro(23-231 / 144-154 179-193 200-217 128-131 161-164 4.5
777(121-231/ 144-154 179-193 200-217 128-131 161-164 4.5
¿(23-230/ 144-154
h r...." ..
173-194 200-226 
Cry 1 „ „ » r
128-131
dm
161-164 4.5
et al., 1996; ^ Garcia et ah, 2000. gThe NMR data did not suggest a P-sheet between
residues 129-131 instead it indicated the possibility of a p-strand located between 
residues 137-140. This discrepancy may reflect the poor prediction power of the 
method especially as the p-strands are short and some assignments are missing, or it 
may show the presence of alternative native conformation for the protein in the 
presence of the 29-89 region.
1.1.6.2 Model structure o f PrPSc
Difficulties in the purification of PrPSc, such as instability and its ability to 
aggregate, have prevented the use of high-resolution techniques for structural
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studies. Studies with PrP-specific recombinant antibody fragments suggest that the 
structural transition underlying PrPSc formation from PrPc occurs within the region 
90-145 (Peretz et al., 1997). A model structure for PrPSc residues 108-217 has been 
proposed (Figure 1.2C) in which the unstructured amino-terminal region and helix A 
are in a P-sheet conformation (Huang et al., 1995). The single disulphide bond 
joining helices B and C would remain intact (Turk et al., 1988; Muramoto et al., 
1996).
1.1.7 PrP biosynthesis and metabolism
Three alternative topological forms of PrP with respect to the ER membrane 
were identified with cell-free translation studies (Figure 1.3) (Lopez et al., 1990).
• Secretory PrP: this form is translocated across the ER membrane and is the 
precursor of the GPI-anchored molecule.
• Transmembrane PrP: two different orientations with respect to the ER 
membrane have been identified; PrP is glycosylated with the carboxyl-terminus in 
the ER lumen, and the other, NtmPrP is unglycosylated and has the amino-terminus in 
this location.
1.1.7.1 GPI-anchored PrP
The first step in the biogenesis of secretory proteins is the targeting and 
translocation of these proteins across the impermeable ER membrane. A complex 
macromolecular machine, termed translocon, is responsible for the proper transport 
and biogenesis of proteins at the ER membrane (reviewed in Rapoport et al., 1996; 
Hegde & Lingappa, 1997). In addition to the known components in the translocation
13
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Figure 1.3: Schematic representation of the topologie forms of PrP. (A) Regions 
of PrP implicated in decisions about its topology with respect to the membrane: 1-22 
amino-terminal signal peptide; 231-254 carboxyl-terminal signal peptide; 104-112 
stop transfer effector (STE); 113—135 transmembrane domain (TM). (B) The three 
topologie forms of PrP are shown, setPrP is the precursor for the GPI anchored form 
of PrP. The illustration highlights the components of the GPI anchor, the 
polypeptide domain position and the PIPLC cleavage site. The transmembrane 
forms of PrP, 1 ""PrP and tmPrP have the amino-terminus and carboxyl-terminus in 
lumen of the ER, respectively. Both span the membrane at the region comprising 
residues 112-135. The glycosylation sites (CHO) at amino acids Asnl81 and 
Asnl97 are also highlighted (A).
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machinery (Sec61 complex, SRP receptor and translocating chain-associated 
membrane protein, TRAM), the transport of PrP into the lumen of the ER appears to 
involve translocation accessory factors at the translocon, the identity of which 
remains to be determined (Hegde et al., 19986).
In the lumen of the ER the amino-terminal signal sequence is cleaved by 
signal peptidase and disulphide isomerase catalyses the disulphide bond formation. 
The GPI anchor and carbohydrate moieties are also attached. PrPc proceeds through 
the Golgi complex where the carbohydrate units are further processed. Ultimately, 
most of the PrPc is anchored to the cell surface by the GPI anchor (Borchelt et al., 
1990; Caughey & Raymond, 1991). Analysis of the GPI anchor of PrP revealed the 
presence of ethanolamine, mannose, inositol, phosphate and saturated fatty acids. 
The lipid component of the GPI anchor is responsible for the insertion of the anchor 
into membranes (Figure 1.3B) (Stahl et al., 1987).
Recent molecular modelling of PrPc based on the solution NMR structure of 
recombinant SHaPrP (90-231) suggests that the GPI anchor attached to the 
carboxyl-terminus of PrP is flexible and as a result PrP most likely makes contact 
with the lipids/or other membrane proteins (Rudd et al., 2001).
Like other GPI anchored proteins, PrPc is targeted to detergent insoluble 
domains of the plasma membrane that are rich in cholesterol and sphingolipids 
(Taraboulos et al., 1995; Vey et al., 1996; Naslavsky et al., 1997). These lipid 
domains are commonly referred to as lipid rafts (Brown & Rose, 1992; Harder & 
Simons, 1997; Simon & Ikonen, 1997). Once PrPc has been transported to the 
plasma membrane it has a half-life of 3-6 h (Borchelt et al., 1990; Caughey et al., 
1989). The degradation of PrP appears to involve two distinct steps. The first
15
occurs in a non-acidic compartment bound by a cholesterol rich membrane most 
probably at the plasma membrane in which approximately 90 amino acids are 
removed from the amino-terminus of PrPc to produce a 17-kDa polypeptide 
(unglycosylated molecular weight). The acidic endosomal pathway is involved in 
the second degradation step. Depletion of cholesterol from cells slowed the 
degradation of PrP suggesting that the lipid environment features in the metabolism 
of PrPc (Taraboulos et al., 1995).
1.1.7.2 Transmembrane PrP
CimPrP and NlmPrP span the membrane at the same stretch of amino acids 
(113-135), interestingly this includes the conserved hydrophobic region. CtmPrP in 
addition can also acquire a carboxyl-terminus GPI anchor in the lumen of the ER, 
which inserts into the inner membrane of the ER (Stewart & Harris, 2001). A 
relatively hydrophilic region between amino acids 104 and 112, termed the stop 
transfer effector (STE) precedes the transmembrane segment. The STE plays a 
critical role in the determination of topology by promoting the integration of the 
hydrophobic sequence into the lipid bilayer (Lopez et al., 1990; Yost et al., 1990). 
Studies with the currently known translocation machinery (Sec61 complex, SRP 
receptor and translocating chain-associated membrane protein, TRAM) generates 
CtmPrP, suggesting that this is the default pathway of PrP biogenesis (Hegde et al., 
19986). This coincides with the proposal that PrP was originally an integral 
membrane protein and that mutations in the amino acid sequence during its evolution 
resulted in a change in the topology of PrP to an anchored protein (Tompa et al., 
2001). The generation of NtmPrP like secPrP requires translocation accessory factor(s) 
(Hegde et al., 1998b).
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1.1.7.3 Trammembrane PrP and disease
The roles of the transmembrane forms of PrP in TSE diseases have only 
recently been uncovered (Hegde et al., 1998a, 1999). Mutations within or near the 
transmembrane domain of PrP result in an increased amount of CtmPrP at the ER 
membrane, this has shown to cause neurodegeneration in mice with features that are 
typical of TSEs. Analysis of brain tissue failed to detect protease-resistant PrPSc 
(Hegde et al., 1998a; Stewart & Harris, 2001) leading to the suggestion that CtmPrP is 
involved in disease.
The substitution of the amino acid alanine at position 117 in PrP for valine 
causes the human disorder GSS. This mutation is of particular interest because it 
occurs in the transmembrane domain of PrP. In vitro and in vivo studies strongly 
suggest that this disease-causing mutation increases the production of CtmPrP at the 
ER membrane compared to normal brains and that this is the cause of 
neurodegeneration. Although TSE diseases are normally characterised by the 
accumulation of PrPSc in brains of humans and animals, in certain cases of inherited 
TSE diseases, neurodegeneration occurs in the absence of PrPSc plaques. It has been 
proposed that in these circumstances ClmPrP is synthesised instead of PrPSc. 
Furthermore, brain homogenate from clinically ill mice with a mutation favouring 
the formation of CtmPrP when inoculated into healthy mice failed to induce disease. 
This finding was particularly interesting since GSS caused by the A117V mutation 
has not been transmitted to laboratory animals (Hegde et al., 1999). Figure 1.4 
shows a model for the relationship between the accumulation of PrPSc and the 
formation of CtmPrP.
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1.4: Model demonstrating the relationship of PrPSc and <tmPrP in TSE
diseases. Transmissible TSE diseases arise by converting PrP( to PrPSc. This could 
be initiated either by inoculation of infectious material, spontaneous conversion or 
mutations in the PrP gene. Accumulation of PrPSc may increase the generation of 
CtmPrP by an unknown step (dashed line with question mark). Alternatively, other 
mutation such as those in the TM domain could bypass the first step and directly 
cause an increase in ttmPrP. Detection of PrPSc in brains may suggest that disease is 
caused by the first pathway and in the case of no detectable levels of PrP$c, the 
synthesis of 
etal., 1999).
Ctm PrP may be responsible for neurodegeneration (adapted from Hegde
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1.1.8 Con version o f PrP^ to PrPSc
Conversion of PrPc —> PrPSc is a post-translational process that occurs after 
PrPc reaches the plasma membrane (Caughey & Raymond, 1991; Taraboulos et al., 
1995). Studies with transgenic mice demonstrated that PrPSc molecules must interact 
with endogenous PrPc to induce the conversion of the latter to generate more PrPSc 
(Prusiner et al., 1990; Scott et al., 1993).
Glycosylation of PrPc is not essential for the formation of PrPSc. The 
presence of bulky oligosaccarides is thought to interfere with PrPc-PrPSe 
interactions. In circumstances where glycosylation was prevented the rate of PrPSc 
synthesis actually increased (Taraboulos et al., 1990a; Lehmann & Harris, 1997).
Many studies of the PrP have concentrated on determining the minimum 
sequence requirements for developing or transmitting disease. Rogers et al. (1993) 
showed that the deletion of amino acids 23-88, which included the five octarepeat 
units did not prevent the synthesis of PrPSc in scrapie-infected cultured cells. A 
peptide of 55 amino acids that corresponded to MoPrP region 89-143 carrying the 
GSS causing mutation PI OIL (102 in human protein) in a P-sheet rich conformation 
when inoculated into Tg (MoPrP, PI OIL) Pmp0/0 mice, expressing low levels of the 
55-residue peptide produced clinical signs of neurologic dysfunction and 
neuropathology similar to changes observed in patients with GSS. These changes 
were not observed when the peptide was inoculated in a a-helical state (Kaneko et 
al., 2000).
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Once formed, PrPSc accumulates in a number of cellular locations: late 
endosomes and lysosomes (Borchelt et al., 1992; Arnold et al., 1995), in the 
cytoplasm (Taraboulos et al., 1990b), on the cell surface (Vey et ah, 1996; 
Naslavsky et al., 1997) and in extracellular spaces in the form of amorphous 
deposits, diffuse fibrils or dense amyloid plaques (DeArmond & Prusiner, 1995). 
Evidence implicates the plasma membrane and endocytic organelles as relevant sites 
for PrPSc formation, but it is unclear which of these is most important. Also, it is not 
known whether the secretory pathway is involved in the conversion process. Figure
1.5 shows a model of the probable subcellular sites for PrPSc formation. Depletion 
of cholesterol from scrapie infected cells not only slowed PrP degradation but also 
inhibited PrPSc formation (Taraboulos et al., 1995; Vey et al., 1996; Naslavsky et al., 
1997). This observation suggests that various aspects of PrP metabolism occurs 
within lipid rafts rich in cholesterol and sphingolipids. The rafts may promote the 
formation of PrPSc by concentrating PrPc on the membrane surface.
Biophysical studies with recombinant PrP indicates the presence of 
equilibrium intermediates that are populated at acidic pH’s and show spectral 
characteristics of P-sheet proteins. In contrast, no such intermediates were populated 
at pH 7, suggesting that PrP folds via an alternative pathway at lower pH’s 
(Swietnicki et al., 1997; Zhang et al., 1997; Homemann & Glockshuber, 1998; 
Jackson et al., 1999a, b). This is of potential significance, since the endocytic 
pathway is implicated as one of the subcellular sites for the conversion of PrP to 
PrPSc.
1.1.8.1 Cellular site for PrF^c formation
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Figure 1.5: Schematic representation showing the probable sites of PrPSc 
formation. The major routes for cellular membrane trafficking in the biosynthetic 
pathway of PrP are shown. Both PrP isoforms are GPI-anchored to the cell surface. 
The plasma membrane and endocytic organelles have been implicated as the sites for 
PrPSc formation (reproduced from Caughey, 1991). Recent evidence suggest that the 
reducing environment of the cytoplasm may favour spontaneous conversion of PrPc 
to PrPSc (Ma & Lindquist, 1999).
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Recent evidence suggests that the reducing environment of the cytoplasm 
may favour the spontaneous conversion of PrPc to PrPSc (Jackson et al., 1999b; Ma 
& Lindquist, 1999). Ma & Lindquist (1999) showed that high level expression of 
mouse PrP in the cytoplasm of yeast cells led to the formation of a detergent 
insoluble protein with a distinct pattern of protease resistance that was identical to 
PrPSc isolated from the brains of diseased hamsters. These observations suggest that 
the expression of PrP in yeast cytoplasm, produced PrP in a PrPSc-like conformation. 
The above study also noted an increase in the formation of the PrPSc-like 
conformation under conditions, which prevented the glycosylation of PrP. These 
results suggest that blocking glycosylation and providing a reducing environment 
promotes conversion of PrPc to a PrPSc-like form in mammalian cells. The above 
results led the authors to propose a mechanism whereby the mistargeting of PrP 
and/or retrograde transport of misfolded PrP from ER to the cytoplasm for 
deglycosylation and degradation could facilitate the initial production of PrPSc.
PrP during its cell cycle is therefore likely to encounter different cellular 
compartments with specific lipid compositions. A particular lipid environment may 
be more favouring towards the formation of PrPSc. In addition, the different cellular 
compartments may contain auxiliary factors such as proteins, which may participate 
in the conversion of PrPc to PrPSc.
1.1.8.2 In vitro conversion
Despite considerable effort, it has not been possible to demonstrate the 
production of infectious particles in vitro (Kocisko et al., 1994; Hill et al., 1999; 
Horiuchi et al., 2000). However, PrPSc, isolated from hamster infected brain tissue 
can convert PrPc in vitro to a form that has proteolytic resistance, resembling that of
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PrPSc (Kocisko et ah, 1994). In this experiment 35S-labelled hamster PrPc derived 
from uninfected tissue culture cells was treated with 3 M guanidine HC1 and then 
diluted into a 50-fold excess of purified non-labelled PrPSc, a labelled proteinase K 
resistant form was produced, which was comparable to proteinase K digested PrPSc 
from scrapie-infected sources. The large molar excess of PrPSc used in the 
experiments made it difficult to demonstrate whether the in vitro conversion of PrPc 
gave rise to infectivity and not only to a protease-resistant form.
1.1.9 Species barrier
The transmission of TSE disease from one species to another occurs much 
less efficiently, if at all, than within the same species and is characterised by 
prolonged incubation times. Factors that contribute to the species barrier are:
• Differences in the amino acid sequence o f PrP: The introduction of SHaPrP 
gene into wild-type mice abrogated the species barrier (Prusiner et al., 1990). The 
properties of the prions produced in the transgenic mice corresponded to SHaPrPSc. 
This provided evidence for the direct interaction of PrPSc with endogenous PrPc 
during the conversion process. Differences in the amino acid sequences reduce the 
efficiency of such interactions. In general, PrPSc replication is most efficient with 
the shortest incubation times when PrPSc in the inoculum and PrPc of the host are 
identical in their amino acid sequence.
• Prion strains: Different strains of PrP can be classified according to their 
specific phenotypic profiles such as incubation times, distribution of lesions in the 
brain, relative abundance of mono-, di-, and un-glycosylated PrPSc and 
electrophoretic mobility of the protease-resistant domains of PrPSc. Each strain has 
been suggested to be associated with different conformations of PrPSc, which can
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convert its host’s PrPc into a likeness of itself (Bessen & Marsh, 1994; Bessen et ah, 
1995; Telling et ah, 1996). Variations in the Asn-linked oligosaccharides may 
modify the conformation of PrP and this difference may also account for the 
selective targeting of PrPSe to particular areas of the brain (Prusiner & Scott, 1997).
• Protein X: The involvement of another host factor other than PrPc in the 
conversion of PrPc —> PrPSc was proposed following studies with transgenic mice 
that expressed both mouse (m) and human (h) PrP . These mice were resistant to 
/?PrPSc, whereas those expressing only ZiPrPc were susceptible to infection (Telling et 
ah, 1995). Mice expressing both mPrP and chimeric human/mouse PrP genes 
(mouse PrP sequence containing human residues at positions 90-167) were also 
susceptible to 7zPrPSc. The results from the study led to the postulation of the 
involvement of another host protein. This protein is temporarily referred to as 
protein X. It was proposed that mPrPc prevented the conversion of /*PrPc into PrPSc 
because mouse protein X had a greater affinity for wPrPc than for /zPrPc. In 
contrast, /wPrPc had little effect on the conversion of chimeric him PrPc because both 
share the same amino acid sequence at the carboxyl-terminus. Further studies 
revealed that substitution of human residues at the carboxyl-terminus of chimeric 
him PrP genes prevented the formation of PrPSc by possibly inhibiting the binding of 
protein X to PrPc (Kaneko et ah, 1997).
1.1.10 Models for the conversion of PrPc to PrP^c
Two models have been proposed to explain the conversion of PrPc -» PrPSc. 
Both predict that the infectious protein interacts directly with endogenous PrPc to 
induce the conversion of the latter to generate more PrPSc. Passage of PrPSc from
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one host to another might then constitute infection by initiating PrPSc formation in 
the new host.
• Template-assisted model: In this model PrPc is partially unfolded to an 
intermediate (PrP*) which is refolded under the influence of a PrPSc molecule, a 
process that would have to overcome a high activation barrier and requires the 
presence of the additional host factor protein X (Figure 1.6A). Infectivity would 
therefore rely on the ability of PrPSc to bind and catalyse the conversion of existing 
intermediate molecules (Prusiner et al., 1998). Genetically inherited diseases 
resulting from mutations would increase the population of unstable intermedaite 
and/or enhance the rate at which this form spontaneously converts to PrPSc. The 
transition from PrPc to monomeric PrPSc is the rate-limiting step and the reaction is a 
first-order process. This model is supported by studies in which the length of scrapie 
incubation time has been demonstrated to be inversely proportional to the level of 
PrPc expression in the brain, which is consistent with a first-order process (Prusiner 
et al., 1990; Carlson et al., 1994).
•  Nucleation-dependent polymerisation: This model proposes that PrPc is in
equilibrium with PrPSc (or a precursor) and that PrPSc is only stabilized when it adds 
onto a crystal-like seed or aggregate of PrPSc, which acts as a stable nucleus. In the 
absence of a pre-existing aggregate, the conversion between PrPc and PrPSc is 
reversible. Aggregates of PrPSc would promote the conversion of PrPc by binding to 
and stabilizing the otherwise unfavoured PrPSc conformation (Figure 1.6B). The 
rate-limiting step would be the formation of a stable nucleus and consequently the 
nucleation step has to proceed as a higher-order reaction (Jarrett & Lansbury, 1993).
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Figure 1.6: Models for the conversion of PrP( to PrPSc. (A) Template-assisted 
model. In the initial step PrPc binds to protein X to form a complex. Next PrPSl 
interacts with PrP /protein X complex. PrP* is transformed to PrPSc, protein X is 
released and a dimer of PrPSc remains. (B) Nucleation-dependent polymerisation. 
PrP1 and PrPSl are in equilibrium strongly favouring PrPc. PrPSc is only stabilised 
when it adds on to a crystal-like seed or aggregate. Seed formation is slow, but once 
present monomers can add on rapidly (adapted from Weissmann, 1999).
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In vitro conversion studies exhibit many of the features of the nucleation- 
dependent model, such as dependence on exceeding a critical protein concentration 
for the initial formation of the aggregates and the kinetics displaying a lag phase 
(Jarrett & Lansbury, 1993). While studies with transgenic mice expressing both the 
SHaPrP transgene and endogenous rriPrP gene show that PrPSc provides a template 
for directing prion replication (Prusiner et al., 1990).
The propagation of PrPSc may actually involve a hybrid mechanism whereby 
a nucleation seed is initially formed, which then catalyses the conformational change 
of the normal cellular isoform (Horwich & Weissman, 1997).
1.1.11 Function o f PrPc
The function of PrPc remains unresolved, mice lacking the PrP gene (Prnp0/0) 
develop into adults without gross abnormalities (Btteler et al., 1992; Manson et al., 
1994) but several differences between the PrP-null mice and controls have been 
noted, such as altered sleep-wake cycles (Tobler et al., 1996) and synaptic behaviour 
(Collinge et al., 1994). Mice of certain prion-deficient strain were reported to 
develop symptoms associated with neurodegeneration (ataxia and Purkinje cell 
degeneration) that led to their premature death (Sakaguchi et al., 1996). A 
comparison of the knockout strategies used by the different groups later revealed that 
in the case where the mice became ill, additional deletions of the PrP genes as well 
as the open reading frame were made. Moore et al. (1999) discovered a second PrP- 
like gene located downstream of mouse PrP gene, the newly discovered gene was 
found to encode a protein of 179 amino acids termed doppel. In contrast to PrP, 
doppel is expressed at low-levels in adult central nervous system (CNS). However, 
the protein was found to be up regulated in the CNS of the ill Pmp0/0 mice, leading
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investigators to suggest that the additional deletions resulted in the over-expression 
of doppel in the CNS and as a consequence provoked neurodegeneration in the PrP- 
deficient mice.
Current work on understanding the physiological role of PrPc at the cell 
surface has involved investigating its interaction with copper ions (Cu2+). PrPe has 
been shown to have a specific affinity for Cu2+ ions (Brown et al., 1997a; Stöckel el 
al., 1998; Miura et al., 1999; Viles et al., 1999). These studies suggest that copper 
ions bind to the octarepeat region of PrPc. Mice brains had a much higher level of 
membrane-associated copper than PrP-deficient mice, which had a higher 
concentration of serum copper (Brown et al., 1997a). PrPc may be involved in the 
regulation of copper levels and therefore in the internalization of copper into the 
cytoplasm. Copper is an important catalytic constituent of oxidative enzymes, 
including superoxide dismutase, which protects cells from oxidative damage; the 
activity of these enzymes may be affected in prion diseases. In fact, it has been 
shown that in Pmp0/0 mice, the activity of the anti-oxidant enzyme Cu/Zn superoxide 
dismutase is reduced (Brown et al., 1997b) which indicates that PrPc may play a role 
in cell resistance to oxidative stress (Milhavet et al., 2000).
1.1.12 What causes cell death?
It remains unclear whether the accumulation of PrPSc or the loss of function 
of PrPc is the cause of cell death. Hypotheses that have been proposed to explain 
neuronal cell death include: direct neurotoxic effect of PrPSc (Forloni et al., 1993) 
which may also involve the destabilisation of the plasma membrane (Pillot et al., 
1997) and increased oxidative stress in neurons as a result of the depletion of PrPc 
(Brown et al., 1997b).
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1.1.13 Yeast prions
A great deal of evidence supporting the protein-only or prion hypothesis 
comes from the non-Mendelian inheritance phenomenon in yeast. Two prion-like 
traits in yeast Saccharomyces cerevisiae, [PSI+] and the [URE3] have been 
identified. The [PSI+] phenotype propagates through a conformational change of an 
otherwise soluble protein, Sup35, to a P-sheet rich insoluble complex, as a 
consequent there is a loss of normal function (protein ensures that ribosomes 
terminate correctly at the end of the coding region). The inactive complexes have 
been shown to capture newly made Sup35 and convert it to the same form. Similarly 
[URE3] phenotype is caused by a conformational prion-like change of the Ure2 
protein (nitrogen regulatory protein). The altered conformation encourages new 
Ure2 proteins to adopt the same prion-like structural state. No mutations in the 
genes encoding the two proteins have been identified (Glover et al., 1997; Lindquist, 
1997; Sparrer et al., 2000).
1.2 Membranes
Membranes are asymmetric bilayer structures with a thickness between 60 (6 
nm) to 100 À (10 nm) and consist mainly of proteins and lipids. The functions that 
are performed by membranes are indispensable for life, they not only provide a 
barrier between different cellular compartments but also allow communication 
between them. Membranes are held together by non-covalent interactions, which 
enables lipid molecules and proteins to diffuse in the plane of the membrane.
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1.2.1 Membrane proteins
Membrane proteins are responsible for most of the processes performed by 
membranes. Membrane proteins are classified into two groups according to their 
interactions with the lipid bilayer.
1.2.1.1 Integral membrane proteins
Integral membrane proteins are embedded in the lipid bilayer. The simplest 
integral membrane proteins will have a region of hydrophobic amino acid residues 
that span the membrane only once and hydrophilic residues will be in contact with 
the aqueous solvent on both sides. Other membrane proteins have several regions of 
hydrophobic amino acid residues, which span the membrane more than once.
1.2.1.2 Peripheral proteins
Peripheral proteins are bound to membranes primarily by electrostatic 
interactions. The electrostatic interactions may be disrupted by the addition of salt 
or by altering the pH. Peripheral membrane proteins bind to the surface of integral 
membrane proteins or with other components of the membrane surface. Other 
proteins may be anchored to membranes by lipids, which are covalently attached to 
them.
Fatty acids such as myristate and palmitate are attached to the amino-terminus 
of a number of proteins, which participate in their binding to the surface of cell 
membranes.
A diverse group of proteins are anchored to the external surface of plasma 
membranes via the attachment of a complex glycosylphosphatidylinositol (GPI)
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anchor to their carboxyl-terminal. Examples of GPI anchored proteins are PrP (Stahl 
et al., 1987), placental alkaline phosphatase and acetylcholinesterase (Ferguson & 
Williams, 1988). An advantage of the GPI anchor over that provided by 
transmembrane domains is that it allows the protein to diffuse much more rapidly 
within the plane of the membrane. Specific enzymes can be used to release the 
protein from the cell surface, which suggests that anchoring may be regulated. GPI- 
anchored proteins are found in detergent-insoluble raft domains within the plasma 
membrane that are rich in cholesterol and sphingolipids. These lipid domains are 
insoluble in non-ionic detergents such as Triton X-100 at 4 °C and solubilised if 
warmed to 37 °C (Brown & Rose, 1992; Friedrichson & Kurzchalia, 1998).
1.2.2 Lipid composition o f the plasma membrane
The major components of biological membranes, lipids, are amphiphilic 
molecules with a hydrophilic head group and hydrophobic hydrocarbon chains (fatty 
acid chains). All organelles possess more or less the same lipid groups; however, the 
amounts of the different lipids vary among the organelles and are found to change 
with age.
• Glycerophospholipids constitutes the main lipid mass o f eukaryotic cell 
membranes. This group of lipids is derived from glycerol, a three-carbon alcohol. 
The fatty acid chains in glycerophospholipids usually contain between 14- and 24- 
carbon atoms. The 16- and 18-carbon fatty acids are commonly found in 
membranes. The fatty acids can be saturated or contain one or more double bonds, 
all in cis configuration. Structures of fatty acids that are found in mammalian 
membranes are presented in Figure 1.7. The majority of glycerophospholipids found 
in biological membranes are 1, 2-diacyl-j«-glycerophospholipids consisting of a
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glycerol backbone, two fatty acid chains and an additional group is attached to the 
phosphate, and this is usually one of several alcohols (Figure 1.8). In addition to the 
fatty acid chains the alcohol headgroups are responsible for the properties of 
glycerophospholipids. For example, negatively charged glycerophospholipids have 
glycerol (PG), inositol (PI) or serine (PS) as the headgroup. Zwitterionic 
glycerophospholipids carry both a positive and negative charge i.e. have no net 
charge and contain choline (PC) or ethanolamine (PE) headgroup (Figure 1.8). The 
acyl chain in the sn-2 position is typically unsaturated in most glycerophospholipids, 
whereas the chain in the sn-\ position is normally saturated.
The other lipid constituents of biological membranes are:
• Sphingolipids: The backbone of this group of lipids is derived from 
sphingosine, an amino alcohol that contains a long, unsaturated hydrocarbon chain. 
Unlike with unsaturated fatty acids, the double bond in sphingosine is in the tram 
configuration. A commonly occurring sphingolipid is sphingomyelin, the structure 
of which is shown in Figure 1.9. The amide-linked fatty acid in brain is 
predominately stearic acid (18:0) (Agranoff & Hajra, 1994).
• Glycolipids are sugar containing lipids: In mammalian cells glycolipids are 
also derived from sphingosine. Instead of a phosphoryl choline group attached to the 
hydroxyl group of sphingosine, as in sphingolipids, one or more sugars are attached 
(Figure 1.9).
• Cholesterol: This sterol is abundant in the plasma membrane of 
mammalian cells (Figure 1.9).
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Structure Name Abbreviation
‘COOH
'COOH
‘COOH
‘COOH
Laurie acid 12:0
Myristicacid 14:0 
Palmitic acid 16:0
Stearic acid 18:0 
Oleic acid 18:1 (A9)
’COOH Linoleicacid 18:2 (A9,12)
•COOH Linolenic acid 18:3 (A9,12,15) 
Arachidonic 20:4 (A5’8’11’14)•COOH acid
Lignoceric
acid
Nervonic
acid
24:0
24:1 (A15)
'COOH Cerebronic 24:0 
acid
OH
Figure 1.7: Structures of commonly occurring fatty acids. The “Ax” gives the 
position of the double bond(s) (Agranoff & Hajra, 1994). Ionised forms of the lipid 
are referred to as myristate, palmitate, etc.
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Typical structure of a glycerophospholipid (l-palmitoyl-2-oleoyl-sn- 
gIycero-3-phosphoR)
Negatively charged lipids, R—
NH3+ H
HOCH, C
H
COO HOCH, CH,OH
OH
Serine (PS) Glycerol (PG)
OH OH
Inositol (PI)
Zwitterionic lipids, R=
H H
HOCH2-----C ------NH3+ HOCH2-----C ------N(CH3)3
H H
Ethanolamine (PE) Choline (PC)
Figure 1.8: Structures of the commonly occurring glycerophospholipids in 
mammalian cells.
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tSphingomyelin
Phosphoryl choline 
unit
Glycolipid: cerebroside
Figure 1.9: Structures of other lipid constituents of membranes.
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Lipids make up about one half of the brain tissue dry weight. Table 1.3
presents the lipid composition of gray and white matter of adult human brain. 
Table 1.3: Lipid composition o f normal adult human braina
Constituent Gray matter (%) White matter (%)
Cholesterol 22 28
Total Phospholipid6 69 48
PE 27 24
PS 9 8
PC 30 15
PI 3 1
Sphingomyelin 7 8
Galactocerebroside 2 5
sulphate
Galactocerebroside 
^  :— ___  ~
5 20
PE and PC with a ratio of 4:1 in white matter and 1:1 in gray matter.
1.2.3 Lipid-lipid interactions
The formation of a lamellar bilayer is the common structure of lipids in an 
aqueous environment, however amphipathic molecules can aggregate in the aqueous 
phase to form a variety of other phases including, micelles, inverted hexagonal 
phases and cubic phases (Epand, 1998). The driving force behind the self-assembly 
of lipid molecules into bilayer structures are hydrophobic interactions, which occur 
among non-polar groups when present in aqueous solution. Hydrophobic 
interactions arise because interactions between polar water molecules and non-polar 
groups, such as the hydrocarbon tail of glycerophospholipids are unfavourable. Van 
der Waals attractive forces between the hydrocarbon tails and electrostatic and
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hydrogen-bonding attractions between the polar headgroups and water molecules 
stabilise the bilayer structure.
1.2.4 Physical properties o f lipids and their effects on bilayer structure
The fatty acid chains of glycerophospholipids and sphingolipids can exist in 
an ordered, rigid gel-state or in a relatively disordered, liquid-crystalline state. For 
pure lipids these states can inter-convert at a well-defined transition temperature. 
The transition temperature is dependent on the degree of unsaturation. A cis double 
bond, such as that present in oleic acid, introduces a bend in the fatty acid chain, 
which interferes with the packing of lipids within the bilayer and results in lowered 
transition temperatures. Whereas in saturated lipids, the straight fatty acid chains 
interact favourably with one another, as a result the lipids are densely packed within 
membranes. The length of the fatty acid chain also influences the transition 
temperature; long hydrocarbon chains interact more strongly with each other than 
shorter chains, resulting in higher transition temperatures.
Cholesterol is intercalated between the lipid hydrocarbon chains with its long 
axis perpendicular to the plane of the membrane. The -OH group of cholesterol 
hydrogen bonds to oxygen atom of the C=0 group of a glycerophospholipid head 
group, the hydrocarbon tail is positioned in the non-polar core of the bilayer. 
Cholesterol has a profound effect on the physical properties of glycerophospholipid 
bilayers. It moderates the fluidity of membranes. The presence of cholesterol can 
prevent the crystallisation of the hydrocarbon chains by increasing fluidity of the 
hydrocarbon fatty acid chains when the system is below the phase transition. 
However, an opposite effect of cholesterol is found when the system is above the 
phase transition. High enough concentrations of cholesterol can sterically reduce
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motions of the hydrocarbon chains, thus decreasing fluidity. The heterogeneity of 
cell membranes with regard to both the polar headgroups of glycerophospholipids 
and non-polar fatty acids, as well as the presence of cholesterol, maintains cell 
membranes in a fluid state over a broad range of temperatures. In this state the 
membrane components are very mobile within the plane of the bi layer (Jacobson et 
al., 1995).
1.2.5 Membrane structure
The inner and outer surfaces of membranes have different lipid compositions 
making them structurally and functionally asymmetric. The exoplasmic side of the 
plasma membrane contains mostly PC and sphingolipids, whereas PS and PE are on 
the cytoplasmic side, which means that the outerleaf of the plasma membrane is 
mainly neutral while the inner is negatively charged. Cholesterol is present in large 
amounts in both sides of the membrane (van Meer, 1989). There appears to be two 
pools of cholesterol in cell membranes, one which found in the fluid PC regions and 
another that is associated with sphingolipid to form phase-separated domains. A 
model for the organisation of cholesterol-sphingolipid rafts is presented in Figure 
1.10. The principle that governs the formation of raft lies in the high phase 
temperatures of sphingolipids and the preference of cholesterol to interact with this 
lipid (Harder & Simons, 1997). Rafts have been isolated from a wide variety of cell 
types, which include muscle cells, neurons and endothelial cells (Brown & London, 
1998), they also appear to exist in endocytic compartments (Kobayashi et al., 1998).
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Figure 1.10: Model of the lipid organisation of raft domains. The outer leaflet of 
membranes contains sphingomyelin, glycosphinolipids, which are shown in dark grey and 
PC lipids (medium grey). Cholesterol intercalates between the lipid fatty acid chains of 
sphingomyelin and glycosphingolipids. The tight acyl chain packing is probably responsible 
for the detergent insolubility of lipid rafts and the proteins contained within them. PC-rich 
regions are less densely packed and more fluid than the cholesterol and sphingomyelin 
domains. The inner leaflet contains PE, PC and cholesterol (repoduced from Harder & 
Simons, 1997).
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1.2.6 Interaction o f lipid-anchored proteins with lipid membranes
Studies with lipid-anchored proteins suggest that protein-lipid interactions as 
well as lipid-lipid interactions are responsible for the attachment of the proteins to 
the cell surface. Electrostatic interactions between positively charged amino acid 
residues in some myristoylated proteins and negatively charged 
glycerophospholipids are necessary for the attachment of the proteins to the 
membrane surface (McLaughlin & Aderem, 1995). For example myristoylated 
alanine-rich C-Kinase substrate (MARCKS) is a peripheral membrane protein 
located on the cytoplasmic side of the plasma membrane. Membrane association 
requires both the hydrophobic insertion of the lipid anchor into the lipid bilayer and 
electrostatic interactions between a region containing positively charged amino acids 
and negative glycerophospholipids. The lipid anchor alone does not provide 
sufficient energy to anchor the protein to the membrane (Peitzsch et al., 1993). GPI- 
anchored neuronal glycoprotein, Thy-1 has also been shown to make direct contact 
with the plasma membrane (Homans et al., 1988).
1.3 Aims
The availability of recombinant mammalian prion proteins has enabled 
structural and biophysical studies to be performed. The three-dimensional structure 
of recombinant mammalian prion proteins have been solved by nuclear magnetic 
resonance (NMR) spectroscopy (Riek et al., 1996; Donne et ah, 1997; James et al., 
1997; García et al., 2000; Zahn et al., 2000). Biophysical studies have been directed 
to decipher the mechanism of PrP conversion (Swietnicki et al., 1997; Zhang et al., 
1997; Homemann & Glockshuber, 1998; Jackson et ah, 1999a,b; Wildegger et ah, 
1999). The above solution studies have provided valuable information, which has
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helped our understanding of the conformational transition associated with the 
conversion of PrPc —> PrPSc. However, PrP in cells is localised to cholesterol- 
sphingolipid rafts. The lipid environment of PrP appears to play a crucial role in its 
cell cycle. It is probable that the transformation of PrPc to PrPSc occurs within these 
raft domains and therefore lipid interactions are likely to feature in the formation and 
propagation of PrPSc.
The aim of this thesis was to provide a detailed insight into the 
biophysical properties of membrane-bound PrP. The interaction of recombinant 
Syrian hamster (SHa) PrP residues 90-231 in a conformation resembling PrPc, with 
a range of lipid membrane systems was investigated at both pH 7, to represent the 
pH surrounding the plasma membrane, and pH 5, which models the acidic 
environment in endosomes. The plasma membranes and endocytic organelles have 
been proposed as cellular sites for PrPSc formation. This PrP segment corresponds to 
the protease-resistant core of PrP and contains the structured domain of PrP.
The specific points addressed in this thesis were:
• binding properties of SHaPrP (90-231) to various model lipid membranes, 
at pH 5 and 7.
• structural changes in SHaPrP (90-231) upon binding to lipid membranes, at 
pH 5 and 7.
• binding/insertion kinetics of SHaPrP (90-231) to lipid membranes.
• changes in membrane integrity and/or permeability upon binding of 
SHaPrP (90-231).
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1.4 Layout o f  this thesis
Chapter 2 will give a background to the spectroscopic techniques used. 
Chapters 3 through to 6 describe the experimental work for this thesis and each starts 
with a brief introduction relevant to the work contained within it. Each chapter has 
separate Material & Methods, Results and Discussion sections. The expression 
purification and subsequent characterisation of recombinant PrP is discussed in 
Chapter 3. The binding of recombinant PrP to lipid membranes monitored by 
fluorescence spectroscopy is presented and discussed in Chapter 4. In Chapter 5 
changes in the structure of PrP upon interaction with lipid membranes are discussed. 
Binding/insertion kinetics of PrP and membrane integrity upon PrP binding are 
examined in Chapter 6. The final chapter (Chapter 7) discusses the general 
conclusions that can be drawn from the work described and discussed in this thesis.
42
Chapter 2: Biophysical Techniques
This chapter will introduce the main biophysical techniques that were used to 
investigate the interaction of SHaPrP (90-231) with lipid membranes. The 
techniques are based upon the absorption or emission of electromagnetic radiation. 
The output is generated in the form of a spectrum, which displays some function of 
radiant intensity versus wavelength or wavenumber.
2.1 Electromagnetic Radiation
2.1.1 General properties o f electromagnetic radiation
Electromagnetic radiation emanating from a source consists of electric and 
magnetic fields that oscillate at right angles to each other and to the direction of 
propagation. Figure 2.1 A shows a single ray of electromagnetic radiation in which 
the oscillations of either the electric or magnetic fields lie within a single plane. 
Since the electric and the magnetic components are always perpendicular to each 
other, it is sufficient, to consider only the electric component when describing the 
electromagnetic wave, however the wave parameters will also apply to the magnetic 
component (Figure 2.IB).
Wave parameters of the electric component:
• Amplitude, A: length of the electric vector at a maximum in the wave.
• Period, p: time in seconds required for the passage of successive maxima 
or minima through a fixed point in space.
• Frequency, v: number of oscillations of the field that occur per second and 
is equal to l/p. Unit of frequency is Hertz (Hz); 1 Hz = 1 s '1.
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A
Electric field
.V
B
Figure 2.1: Wave representation of electromagnetic radiation. (A) Electric and 
magnetic fields at right angles to one another and to the direction of propagation. (B) 
Two-dimensional representation of the electric vector (reproduced from Skoog et al., 
1996).
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• Wavelength, k: linear distance between any two equivalent points on 
successive waves.
• Wavenumber, v: reciprocal of the wavelength in centimetres. The 
wavenumber is a useful unit because, in contrast to wavelength, it is directly 
proportional to the frequency (and thus the energy) of radiation.
The amplitude and frequency of the wave are determined by the intensity of 
the radiation and the energy associated with it respectively. Thus,
Ice A2 
and
E oc v
where /  is the intensity and E the energy. Frequency and wavelength are related by 
the expression
where c is the velocity of propagation of the wave in a vacuum and is independent of 
frequency. The energy of radiation and frequency are directly proportional but 
energy and wavelength are inversely related.
To understand many of the interactions between radiation and matter, it is 
necessary to view electromagnetic radiation in terms of packets of energy called 
photons. The energy of a photon depends upon the frequency of radiation and is 
given by
X
(Eq. 2.1)
(Eq. 2.2)
E = hv (Eq. 2.3)
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where h is Planck’s constant (6.63 x 10 34 J.s). Equation 2.3 can be re-written in 
terms of wavelength and wavenumber as
he —
E = = hcv (Eq. 2.4)
Wavenumber and frequency are directly proportional to energy.
2.1.2 Polarisation o f electromagnetic radiation
Electromagnetic light can be described as unpolarised if the electric 
component oscillates in any direction perpendicular to the direction of propagation. 
By placing a polariser between the radiation source and sample the electric 
component oscillates in the same plane and the beam of radiation is now polarised. 
The three spectroscopic techniques described here are fluorescence, Fourier 
transform infrared (FTIR) and circular dichroism (CD). In the first two unpolarised 
light is absorbed by the sample however, in CD the electromagnetic radiation is 
circularly polarised.
• Circularly polarised light: Plane linearly polarised light consists of right- 
and left-circularly polarised beams of equal intensity. For the formation of circularly 
polarised light the plane linearly polarised beam is split into two plane polarised 
beams that are at right angles to each other and 90° out of phase. The addition of the 
two beams, which are now 90° out of phase results in the electric vector moving in a 
circular manner as it travels in the z  direction. A right-handed-circularly polarised 
beam is shown in Figure 2.2. By alternating the applied voltage of an electric field, 
the emergent beam can be made to alternate between left- and right-circularly 
polarised light (Woody, 1996).
46
Figure 2.2: A right-handed-circularly polarised beam. (A) The electric 
component of perpendicular polarised beams 90° out of phase. (B) The x and y 
components together with their resultants are shown at points along the z-axis which 
are labelled 1-4 in (A). (C) The vector sums when positioned onto a plane normal to 
the z direction show that the tip of the electric component follows a circular path 
when viewed along the direction of propagation, looking toward the light source. 
(D) Right-circularly polarised light, which shows electric component forming right- 
handed helix along the direction of propagation and appears to rotate in a clockwise 
direction. In left-circularly polarised light, the tip of the electric vector forms a left- 
handed helix (reproduced from Woody, 1996).
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2.1.3 The electromagnetic spectrum
The electromagnetic spectrum is made up of a wide range of wavelengths 
and frequencies (and thus energies). The different regions of the spectrum are 
shown in Figure 2.3 and Table 2.1 lists the wavelength and wavenumber ranges for 
different regions of the spectrum that are commonly used in the analysis of proteins 
and peptides.
Table 2.1: Common spectroscopic methods based on electromagnetic 
radiation
Type of Spectroscopy Wavelength
Range
Wavenumber 
Range (cm-1)
Type of Quantum 
Transition
X-Ray absorption, emission, 
and diffraction
0.1-100 A — Inner shell electrons
Ultraviolet (UV) and visible 
absorption, emission and 
fluorescence
180-780 nm 5 x 104-  
1.3 x 104
Valence electrons and 
bonding electrons
Infrared (IR) absorption and 
Raman scattering
0.78-300 pm 1.3 x 104-
3.3 x 101
Rotation/vibration of 
molecules
Electron spin resonance 3 cm 0.33 Spin of electrons in a 
magnetic field
Nuclear magnetic resonance 0.6-10 cm 1.7 x 10-2-  
1 x 103
Spin of nuclei in a 
magnetic field
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Figure 2.3: The electromagnetic spectrum. The radiation energy increases from 
the radio wave end of the spectrum (10 J) to the y-ray (10 J) end. Frequency 
ranges from 10° Hz at the radio wave end of the spectrum to 1024 Hz at the y-ray end 
of the spectrum and wavelength ranges from 103 to 10”11 cm, respectively.
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2.1.4 Absorption o f electromagnetic radiation
Absorption is a process in which a substance in a transparent medium 
selectively attenuates (decreases the intensity) certain frequencies of electromagnetic 
radiation. Quantum theory states that every elementary particle (atom, ion, or 
molecule) has a unique set of energy states, the lowest being the ground state. 
Absorption of a photon of radiation by the elementary particle only occurs if the 
energy of the photon matches exactly the energy difference between the ground state 
and one of the higher energy states of the particle. When this occurs the energy of 
the photon is transferred to the atom, ion, or molecule, converting it to the higher 
energy state, which is now known as the excited state (M*).
M  + hv  —► M*
After a brief period (10-9 to 10~6 s) the excited species relaxes to the ground 
state, as it does it transfers its excess energy to other atoms or molecules in the 
medium. The process causes a small rise in the temperature of the surrounding. 
Relaxation may also occur by the fluorescent or phosphorescent emission of 
radiation.
2.2 The Theory o f  Fluorescence
2.2.1 Fluorescence, quantum yields and lifetimes
A ground state species is raised to a higher electronic state following the 
absorption of energy from electromagnetic radiation in the UV-visible region of the 
spectrum (180-780 nm). If the electron in the higher energy orbital has the opposite 
spin orientation to the electron in the ground state the electrons are paired and the 
electron is not required to change its electron spin orientation to return to the ground
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State, this is a singlet state (S). Fluorescence is the emission, which results from the 
return of a paired electron to the ground state from a higher energy orbital. In a 
triplet state (T) the electrons are unpaired, i.e. their spins have the same orientation 
and the return of an electron in the triplet state from a higher energy orbital requires 
a change in the spin orientation. Phosphorescence is the emission from the transition 
of impaired electron as it returns to the ground state. The absorption and emission 
properties of a fluorophore (fluorescent substance) can be illustrated in energy level 
diagrams (see below). This diagram shows the different processes that usually occur 
following light absorption. The transitions that occur as a result of light absorption 
are represented as vertical lines. Absorption of light is too fast for significant 
displacement of nuclei but adequate for the redistribution of electrons (10-15 sec). So,
So, Si and S2 are the ground, first and second electronic states, respectively. 
Within each electronic state there exists a number of vibrational energy levels 
denoted 0,1, and 2 in So. At room temperature, the fluorophore is in the lowest
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electronic, i.e ground state and vibrational energy level (0). The Boltzmann 
distribution describes the number of molecules in 0 and 1 vibrational states and the 
ratio R of molecules in each state is given by the expression
R ~ e - AE/kT (Eq. 2.5)
where AE is the energy difference, k is the Boltzmann constant, and T is the 
temperature in K. The energy difference between the states So and Si is too large for 
any fluorophore to populate the higher electronic state as a result of thermal energy.
Fluorescence occurs via the following process'. When a solution of a 
fluorophore is illuminated with a beam of light of wavelength X, the molecules 
absorb energy from the beam if the photon energy matches the energy difference 
between the ground level and one of the upper levels (AE). Each molecule absorbs 
one photon at a time and during the absorption process a molecule undergoes a 
transition from the ground state to one of the upper states. Light absorption excites 
the fluorophore into a higher vibrational level of either Si or S2. With most 
molecules this is followed by relaxation via internal conversion to the lowest 
vibrational level of Sj. This occurs at a rate of 10-12 sec and is complete before 
fluorescent emission begins. This means that fluorescence emission occurs from a 
thermally equilibrated state. Fluorescence displays a number of general 
characteristics. There is a shift to longer wavelengths {i.e. lower energy) of the 
emission relative to the absorption wavelength (Stokes' shift). This loss is caused by 
the rapid decay to the lowest Si vibrational level. The rapid relaxation from higher 
electronic and vibrational levels to the lowest vibrational level of S| is also 
responsible for the observed emission spectrum of a fluorophore remaining the same 
irrespective of the excitation wavelength. Further energy losses are due to the return
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of electron to the lowest vibrational level of So. In addition to these effects, 
fluorophores can display further Stokes’ shifts due to the solvent environment.
The quantum yield (Q) of a fluorophore is the ratio of the number of photons 
emitted to the number absorbed and can be defined as
Q =  Y T j -  (Eq. 2.6)
where T is the emissive rate of the fluorophore and k is the rate of radiationless 
decay to So, both T and k depopulate the excited state.
The lifetime (t) of an excited state is the average time the fluorophore spends 
in the excited state before emission and return to the ground state. Lifetime can be 
defined
1
+ k
(Eq. 2.7)
Generally, fluorescence lifetimes are near 10 nsec. The value given for the lifetime 
of fluorescence is an average of the time spent in the excited state.
The intrinsic lifetime of a fluorophore is the lifetime in the absence of 
nonradiative process and is defined as
T o = -p -  (Eq. 2.8)
From these equations the relationship between quantum yield and lifetime 
can be calculated
Q = - J -  (Eq. 2.9)
To
The quantum yield and lifetime of the fluorophore can be modified by any 
factors, which affect either of the rate constants.
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2.2.2 Solvent effects on the fluorescence spectra
The fluorescence emission spectra of fluorophores are sensitive to the 
polarity of their surrounding environment. In general, a decrease in solvent polarity 
of the fluorophore results in a shift of the emission spectrum to shorter wavelengths 
(blue shift). Conversely, an increase in solvent polarity causes a shift of the 
emission maximum to longer wavelengths (red shift) and a possible reduction in the 
quantum yield of the fluorophore. The loss of energy that occurs between absorption 
and emission of fluorescence or Stokes’ shifts can be a result of general and specific 
solvent effects. General solvent effects on the fluorescence spectra result from the 
redistribution of electrons in the surrounding solvent molecules induced by altered 
(generally increased) dipole moment of the excited fluorophore. Generally the 
excited states of fluorophores possess dipole moments (p*) which are larger than in 
the ground state (p). This is because light absorption occurs in a time scale that is 
too short for the displacement of nuclei, but long enough for the redistribution of 
electrons. The absorption of a photon of electromagnetic radiation by a fluorophore 
therefore results in the instantaneous formation of a dipole, which would perturb the 
environment surrounding the fluorophore. The solvent responds by reorganisation 
around the fluorophore subsequent to excitation. This process is called solvent 
relaxation and results in a shift of the emission spectrum to longer wavelengths (i.e 
less energy).
The Lippert equation describes the general solvent effects on the emission 
spectra of fluorophores:
ÛL-r^-2 + A (Eq. 2.10)
a
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where h is Planck’s constant, c is the speed of light, and a is the radius of the cavity 
in which the fluorophore resides, n and e are the refractive index and dielectric 
constant of the solvent, respectively and A, a constant. Absorption and emission 
wavenumbers are va and Vf, respectively. Briefly, an increase in n will decrease 
the energy loss by allowing the ground and excited states to be instantaneously 
stabilised by movement of electrons within the solvent molecules. This decreases 
the energy difference between the ground and excited states. Whereas an increase in 
e results in an increase in va -  Vf because the reorientation of the solvent dipoles 
requires the movement of the entire solvent molecule and not just electrons. Non­
polar solvents, such as hexane, do not possess a dipole moment. Hence there are no 
dipoles to reorient around the excited state of the fluorophore. However, even in 
these cases the absorption and emission maxima do not coincide closely because 
small amount of energy is always rapidly dissipated to solvents. This sensitivity of 
the Stokes’ shift to solvent polarity is the reason why fluorescence emission spectra 
are frequently used to estimate the polarity of the environment surrounding the 
fluorophore.
Specific solvent effects are results of chemical interactions between the 
fluorophore and the solvent molecules, such as hydrogen bonding. Both general and 
specific solvent interactions result in spectral shifts. General solvent effects are 
expected to always be present. In contrast, specific solvent effects will depend upon 
the precise chemical structures of the solvent and the fluorophore.
2.2.3 Fluorophores
Fluorescent substances generally have delocalised electrons present in 
conjugated double bonds. A variety of biological molecules contain naturally
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occurring intrinsic fluorophores. In proteins the indole ring of tryptophan is the most 
highly fluorescent amino acid as it accounts for ~90 % of the total fluorescence from 
proteins. Tyrosine and phenylalanine also make minor contributions to the overall 
intrinsic protein fluorescence. Tryptophan is highly sensitive to the polarity of its 
surrounding environment, therefore emission maxima of proteins are considered to 
reflect the average degree of exposure of the Trp residues to the aqueous phase. 
Spectral shifts are normally observed as a result of binding of ligands, membranes 
and protein dénaturation. Extrinsic fluorophores are substances, which are foreign to 
the system under investigation. These include fluorescein-based compounds, which 
can be used to label non-fluorescent compounds such as lipids.
2.3 Circular Dichroism Spectroscopy
2.3.1 Theory o f circular dichroism
Circular dichroism (CD) is a form of absorption spectroscopy that measures 
the difference between absorption of left circularly polarised (lcp) and right 
circularly polarised (rep) light. The absorbance of lcp light is defined as
where f t  and 1/ are the intensities of lcp light entering the sample and after travelling 
a distance / through a medium containing the molar concentration of the sample and 
8i is the molar extinction coefficient of the sample for lcp light. Circular dichroism 
can therefore be defined as
d i= logio if¡lit) = tiCl (Eq. 2.11)
AA = A i - A r = £ ¡Cl -  £rCl = A zCl (Eq. 2.12)
À8  = £/ — £r (Eq. 2.13)
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Units for Ae are the same as s, namely M 'em
Chiral or asymmetric molecules produce a CD spectrum because they absorb 
left- and right-circularly polarised light to different extents and are therefore 
considered to be optically active.
Most CD instruments measure differential absorbance, however the output is 
often given in ellipticity (0) instead of AA versus k. This measurement relies on the 
two circular components of plane-polarised light having different amplitudes after 
passing through an optically active sample. The sum of the two components no 
longer produces a plane-polarised beam and the direction of electric vector no longer 
traces a circle but instead gives an ellipse. The ellipticity is defined as an angle, 0 
whose tangent is the ratio of the minor and major amplitudes of the ellipse (see 
Figure 2.4).
Ellipticity can be related to AA by
0 (degrees) = 180 x In 10 x AA/4k = 32.98 AA (Eq. 2.14)
To eliminate the effects of pathlength and concentration, 0 is often converted 
to molar ellipticity by
[0] = - ^ p  (Eq. 2.15)
so that [0] has the dimensions of deg cm2 dmol-1.
Therefore from equations 2.12 to 2.14 [0] can be defined as
[0] = 329 8As (Eq. 2.16)
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Figure 2.4: Elliptically polarised light is formed by right- and left-circularly 
polarised light of unequal intensities. Ellipticity is the angle 0, the tangent of 
which is the ratio of the minor to the major axis of the ellipse. The angle a  is known 
as the optical rotation and is the angle between the major axis of the ellipse and the 
plane of polarisation of the initially plane-polarised light (reproduced from Woody, 
1996).
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To be able to compare the ellipticity values, they are usually converted into a 
normalised value. The mostly commonly used unit in protein and peptide work is 
the mean molar ellipticity per residue or mean residue weight (MRW).
[0]MRW = - f -  (Eq. 2.17)
where N is the number of residues in the protein. The CD spectra presented in this 
thesis are all shown as mean molar ellipticity per residue, [0] (deg cm2 dmol-1).
2.3.2 The physical basis o f optical activity
As already discussed the absorption of electromagnetic radiation results in 
the transition of the molecule from the ground state to the excited state. There are 
two types of charge displacement during the transition.
• Linear displacement: This constitutes an electric dipole because of the 
separation of charge and is called an electric transition dipole (p.<).
• Rotation of charge: This would generate a magnetic moment perpendicular 
to the rotation and is called a magnetic transition dipole
The applied electromagnetic radiation interacts with these dipoles to cause 
the changes in the energy states; the electric component interacts with electric 
transition dipole, \xe and the magnetic component interacts with the magnetic 
transition dipole, pOT. In general magnetic transition dipoles are much smaller than 
electric ones since separating charges creates a larger effect than rotating them. 
Optical activity requires an electric dipole transition moment and a magnetic 
transition dipole moment. The combination of the two corresponds to a helical
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displacement of charge. The result is that left- or right-circularly polarised beams 
then interact differently with molecules in solution.
2.3.3 Optically active chromophores
Optical activity is observed only when the environment in which a transition 
occurs is asymmetric. The absorption bands may be such that Ei -  er is positive or 
negative. The electronic transitions that occur involve a number of different 
molecular orbitals. The interaction of atomic orbitals leads to the formation of 
bonding and anti-bonding orbitals (*). Depending on the nature of the overlapping 
atomic orbitals, molecular orbitals may be of the c  type, the electron density being 
concentrated along the intemuclear axis or of the n type, where the electron density 
is concentrated on either side of the intemuclear axis. The relative energies of these 
orbitals and that of a non-bonding orbital n, which may be occupied by electrons not 
participating in bonding, are shown.
Electric Magnetic Optically active
transition
From the diagram it can be seen that the lowest energy and therefore the 
longest wavelength transitions are from the non-bonding orbitals to anti-bonding 71 
orbitals, which give rise to bands in the UV region. Other allowed transitions in 
order of increasing energy (shorter wavelengths) are n -» a* and 7t -» 7t*.
Proteins and peptides are optically active and possess two kinds of 
asymmetry: configurational and conformational. Amino acids residues, except for 
glycine, have intrinsic optical activity because of the L configuration about their a- 
carbon atom and as a result they are chiral molecules. The secondary structures of 
proteins also contribute to optical activity. UV spectra of proteins are divided into 
two regions
• Near-UV CD region (250-300 nm): the aromatic side chains of 
phenylalanine, tyrosine and tryptophan have n -» 7t* transitions in this region (Figure 
2.5A). This region is sensitive to the environment and as a result reflects the tertiary 
structural features in a protein.
• Far-UV CD region (<250 nm): peptide amide group gives rise to the 
transitions observed in the far-UV region. Non-bonding electrons are present on the 
oxygen and also on the nitrogen. 7t-electrons are delocalised over the carbon, 
oxygen and nitrogen atoms. The lowest energy transition of the peptide group is n 
-> n which gives rise to a magnetic transition dipole. The n - * n  causes an electric 
transition dipole. The contributions of the aromatic amino acids in the far-UV CD 
are small compared with those of the peptide group. The far-UV CD spectra of 
proteins gives information about the asymmetric features of the backbone and
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Figure 2.5: CD spectra of protein in the (A) near-UV region and (B) far-UV 
region. (A) Aromatic absorption spectra of tryptophan, tyrosine and phenylalanine. 
(B) CD spectra of a-helix, (3-sheet, (3-tum and unordered structures (reproduced 
from Rodger & Norden, 1997).
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therefore the common types of secondary structure adopted by peptides and proteins 
have distinctive CD spectra (Figure 2.5 B).
• a -helix: the CD spectra of this structural motif is characterised with a 
negative peak at 222 nm («->  ti*). The n -> it* transitions produces a negative band 
near 208 nm and a positive band at about 190 nm. The splitting of the tt —> n* 
absorption bands occurs because the transition dipole moments interact with one 
another.
• p-sheet: proteins and peptides adopting this conformation have a negative 
band at about 217 nm (n -» ti*) and a positive band near 195 nm (n -> n ).
• p-turn: CD spectrum has a positive band near 225 nm (n —> n*) and 
between 200 and 205 nm (n -» n ). However, the CD spectrum of this structural 
motif is not as well characterised as the other structural motifs and may vary 
considerably.
• Unordered/random coil structure: the CD spectra of unordered 
polypeptides are characterised by a strong negative band near 200 nm.
2.4 Infrared Spectroscopy
2.4.1 Physical basis o f infrared spectroscopy
The absorption of electromagnetic radiation in the infrared region (IR) of the 
spectrum does not result in electronic transitions, instead changes in the vibrational 
energy levels of the ground (lowest) electronic state of molecules occurs. 
Molecules, which have a charge separation either across the whole molecule or 
across a specific bond, are said to possess a permanent dipole moment. When a 
molecule vibrates, this permanent dipole also vibrates and can interact with the
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oscillating electric field of incident infrared radiation. Molecules, which do not have 
a permanent dipole moment, do not absorb IR radiation.
2.4.1.1 Diatomic molecules
At room temperature the molecules are in the lowest vibrational level of the 
ground electronic state. The absorption of IR radiation of the correct frequency by a 
bond between two atoms causes transition from the lowest vibrational state to the 
next highest. In a simple diatomic molecule A-B, the only vibration, which can 
occur is a periodic stretching along the A-B bond which is accompanied by a change 
in the dipole moment. Stretching vibrations resemble the oscillations of two bodies 
connected by a spring. For stretching of the bond A-B, the vibrational frequency v 
(cm-1) is given by Hooke’s law
v = (Eq. 2.18)
where c is the velocity of light,/the force constant of the bond and p the reduced 
mass of the system, as defined by
^  mA + mB
where m\ and are the individual masses of A and B.
(Eq. 2.19)
Predictions based on Hooke’s law:
• The greater the strength of the bond (i.e. the larger the value for f) the 
higher the frequency (and hence wavenumber) of the vibration. For example a 
double bond is stronger than a single bond and would therefore appear at a higher 
wavenumber than a single bond.
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• The heavier the masses of the atoms attached to the bond, the lower the 
absorption frequency of the vibration. For example a C-H bond would occur at a 
higher wavenumber than a C-C bond.
2.4.1.2 Polyatomic molecules
In diatomic molecules there is only one mode of vibration, which is the 
stretching of the bond hence only one IR absorption band. If there are more atoms, 
there will be more bonds, and therefore more modes of vibrations. In polyatomic 
molecules the bonds can stretch and bend upon absorption. For a molecule that 
consist of N atoms, there are (3N -  6) ways in which the molecule can vibrate, or 
(3N -  5) if the molecule is linear. The different types of molecular vibrations are 
shown in Figure 2.6 and Table 2.2 shows the wavenumber ranges of characteristic 
vibrations.
Table 2.2: Wavenumbers o f characteristic IR vibrations
Bond Type Stretch (cm-1) Bend (cm-1)
C-H 2700-3300 1300-1500
600-900
O-II 3000-3700 1200-1500
N-H 3000-3700 1500-1700
S-H 2550-2600 700-900
C-C, C-N, C -0 400-1300
C=C, C=N, C=0 1550-1900
C=C, C=N 2100-2400
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VSymmetric Asymmetric
Stretching vibrations
In-plane bending vibrations
Wagging Twisting
Out-of-plane bending vibrations
Figure 2.6: The different types of molecular vibrations that occur upon 
absorption of IR radiation. + indicates motion from the page toward reader; -  
indicates motion away from reader (reproduced from Skoog et al., 1996).
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Although equation 2.18 shows that the force constant,/and the relative 
masses of the bonded atoms constitute the two most important factors determining 
frequency, there are also other factors, which influence the absorption frequency and 
these include:
• Hydrogen bonding: Compounds that contain proton donor groups such as 
O-H and N-H can be involved in intra- or inter-molecular hydrogen bonding in the 
presence of proton acceptors, e.g. O, N. The stiffness of the X-H bond is thereby 
lessened resulting in a lowering of the stretching frequency and the band is shifted to 
lower wavenumbers.
• Adjacent groups: Shifts occur on altering the atoms or structures adjacent 
to a group that gives rise to a particular absorption band.
• Coupled vibrations: Groups in which two or more atoms of an element 
when bonded to a common atom are mechanically coupled, result in a band, which is 
resolved into two components. These correspond to symmetric and asymmetric 
modes of vibration (Figure 2.6).
Molecules absorb IR radiation at characteristic wavelengths determined by 
their atomic composition and bond structure as a result each molecule will produce a 
unique IR absorption spectra.
2.4.2 Protein secondary structure
Infrared spectroscopy has been widely used to determine the secondary 
structure of peptides and proteins. The infrared spectra of peptides and proteins 
exhibit a number of amide bands, which represent different vibrations of the peptide 
group (Goormaghtigh et al., 1994). Nine characteristic amide bands are observed in
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the IR spectra of proteins with the amide I (1600-1700 cm-1) and amide II 
(1500-1580 cm-1) being the two predominant bands. The amide I band is the most 
widely used in secondary structural studies of proteins. Amide I is composed mainly 
(80 %) of C=0 stretching (v) vibration of the peptide group coupled to the in-plane 
bending of the N-H bond and the stretching of the C-N bond (Goormaghtigh et a!., 
1994).
Using synthetic polypeptides it was shown that this band was conformation 
sensitive, the a-helical structure having a maximum near 1655 cm '1 and the p-sheet 
structure having a maximum around 1630 cm-1 (Goormaghtigh et al., 1994). The 
major factors responsible for the conformational sensitivity of the amide I band 
includes hydrogen bonding and coupling between transition dipoles. The latter leads 
to the splitting of the amide I band. The magnitude of this splitting depends on the 
orientation and distance of the interacting dipoles, and therefore provides 
information on the geometrical arrangements of the peptide groups in a polypeptide 
chain. The nature of the hydrogen bonding is determined by the particular secondary 
structure adopted by polypeptide chains. An increase in hydrogen bonding induces a 
shift to lower frequencies for the stretching modes (Krimm & Bandekar, 1986; 
Bandekar, 1992).
Proteins usually fold into complex three-dimensional structures, which 
consist of different types of secondary structural elements. The observed amide I 
band is therefore a complex composite that consist of a number of overlapping 
component-bands representing the secondary structural elements such as a-helices, 
(3-sheets, turns, and non-ordered structures. The bands cannot be resolved by 
altering experimental conditions and therefore other methods are employed to
6 8
separate and identify the different structural components. The use of resolution 
enhancement methods such as Fourier self-deconvolution, which narrows the bands, 
allows the identification of these otherwise hidden component bands. Band fitting 
procedures can then be used to obtain a quantitative assessment of the various 
components of the proteins such as a-helix, (3-sheet and unordered structures 
(Goormaghtigh et al., 1990).
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Chapter 3: Expression and Purification of Syrian
Hamster Prion Protein (SHaPrP) Residues 90-231
3.1 Introduction
Purification of cellular PrPc from brain extracts is difficult and yields are 
low, for example 230 pg of PrP is obtained from 40 g of hamster brain (Pergani et 
al., 1996). The lack of enough pure protein has hindered detailed biophysical 
studies. However, this has changed in the last few years with the development of 
high-level expression systems in bacterial cells. Recombinant (r) prion proteins have 
been successfully expressed and purified from a number of different species; hamster 
(Mehlhom et al., 1996), mouse (Homemann & Glockshuber, 1996; Homemann et 
al., 1997), cow (Negro et al., 1997), chicken (Marcotte & Eisenberg, 1999) and 
human (Swientnicki et al., 1997; Zahn et al., 1997; Jackson et al., 1999a). This 
chapter will describe the expression and purification of the domain of Syrian hamster 
(SHa) PrP comprising residues 90-231. The amino acid sequence of this segment 
corresponds to the protease-resistant core of PrPSc. SHaPrP sequence was chosen for 
the present study for two reasons, the first being that SHaPrPc and SHaPrPSc are the 
most extensively studied prion proteins. Secondly, the Syrian hamster prion protein 
has 93 % amino acid sequence identity with human prion protein (Schatzl et al., 
1995).
3.1.1 Expression plasmid
Recombinant Syrian hamster prion protein was expressed using an alkaline 
phosphatase (phoA) promoter in a protease-deficient strain of Escherichia coli 
{21 Cl). The expression plasmid plngPrP, encoding SHaPrP residues 90-231, was
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obtained from Professor Stanley Prusiner’s laboratory. Construction of PlngPrP is 
described in detail in Mehlhom et al. (1996). A simplified map of the PlngPrP 
plasmid is shown in Figure 3.1. This plasmid is a derivative of phGHl (Chang et al., 
1987) and contains a signal sequence, coding for the E. coli heat-stable enterotoxin II 
(STII). This signal peptide promotes the transport of SHaPrP (90-231) from the site 
of its synthesis in the cytoplasm to the periplasmic space of E. coli cells. The signal 
sequence is cleaved by a signal peptidase and the mature protein is released into the 
periplasmic space. The periplasm offers several advantages for protein targeting. It 
contains approximately 4 % of the total cell protein; thus the target protein can be 
effectively concentrated. The oxidising environment of the periplasm facilitates the 
proper cleaving of the signal peptide during translocation to yield the authentic 
sequence of the target protein. Protein degradation in the periplasm is also less 
extensive (Makrides, 1996). SHaPrP genes of varying lengths including full-length 
mature protein, residues 23 to 231, were also inserted into expression plasmids. 
These were found to give unsatisfactory expression yields compared to SHaPrP 
residues 90-231 (Mehlhom et al., 1996).
The protease deficient strain of E. coli 27C7 was transformed with the 
plngPrP plasmid containing the truncated SHaPrP sequence 90-231. An overnight 
culture was used to inoculate the low-phosphate medium. The recombinant protein 
accumulated as insoluble aggregates in the periplasmic space. Purification of rPrP 
(90-231) followed an adaptation of the method originally described in Mehlhom et 
al. (1996).
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Processing site
5'AACGCGT ATGC A 
Ala Tyr Ala
STII signal peptide
GGTCCAGGA 3' 
Gly Gin Gly
PrP sequence
Figure 3.1: PlngPrP plasmid. PrP sequence coding residues 90-231 was inserted 
between the Mlul and BamHI sites. Processing site for the removal of the STII 
signal peptide is illustrated. The plasmid also contains the ampicillin resistance gene 
(not shown) (adapted from Mehlhom et al., 1996).
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This chapter describes the expression and purification of recombinant 
SHaPrP (90-231). The results of the characterisation of the refolded protein are also 
presented. Recombinant PrP was analysed by gel electrophoresis, immunoblots, 
mass spectroscopy and circular dichroism (CD) to determine the purity, molecular 
mass, and the secondary and tertiary structure of the protein.
3.2 M aterials and Methods
3.2.1 Materials
The following reagents were purchased from BDH (Poole, UK): 
dithiothreitol (DTT), trifluoroacetic acid Hipersolv for HPLC use (TFA), Acrylogel
2.6 acrylamide solution (40 % T total monomer concentration) and HPLC grade 
acetonitrile. Yeast extract was obtained from Difco laboratories (Detroit, USA). 
Triethanolamine was purchased from Lancaster (Morecombe, UK). Protease 
deficient expression strain of E. coli 21 C l was purchased from American Type 
Culture Collection (ATCC 55244). The mouse anti-PrP monoclonal antibody 
(MAB1562 IgG) was purchased from Chemicon International Ltd (Harrow, UK). 
Pre-stained markers were purchased from Novex (San Diego, USA). Dialysis tubing 
with a 7000 molecular weight cut-off was obtained from Medicell International Ltd 
(London, UK). Coomassie protein assay reagent and bovine serum albumin (BSA) 
standards were obtained from Pierce (Illinois, USA). All other chemicals were 
purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated.
Glass beads for the cell homogeniser (0.5-mm diameter) were purchased 
from Glen Creston (Stanmore, UK). The beads were washed with 50 % HC1 
followed by de-ionised water until the pH was neutral and dried in an oven at 40 °C.
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Hiload Superdex 200 was purchased from Pharmacia and Poros R1 resin (20 
pm particle size) for reverse phase chromatography was obtained from PerSeptive 
Biosystems (Hertfordshire, UK).
AP5 expression medium per litre contained; 1.5 g glucose, 11 g casein acid 
hydrolysate, 0.6 g yeast extract, 0.19 g MgSC>4, 1.07 g NH4CI, 3.73 g KC1, 1.2 g 
NaCl, 120 mL 1 M triethanolamine, pH 7.4 and 100 pg/mL ampicillin. The medium 
was filter sterilised through a 0.22-pm membrane.
The following buffers were used during the purification of rPrP:
Buffer A: 25 mM TrisHCl, pH 8.0 containing 5 mM EDTA.
Buffer B: 25 mM TrisHCl, pH 8.0 containing 8 M GdnHCl and 100 mM DTT.
Buffer C: 50 mM TrisHCl, pH 8.0 containing 6 M GdnHCl and 1 mM EDTA.
Buffers for reverse phase HPLC: Buffer 1, H2O/O.I % TFA
Buffer 2, acetonitrile/0.09 % TFA
Buffers C, 1 and 2 were filtered using a 0.22-pm membrane and degassed.
3.2.2 Safety issues
SHaPrP domain 90-231 was expressed in E. Coli within a level 3* 
containment laboratory and all material was handled inside a class III hood within 
the containment laboratory. The cells were harvested and disrupted within the 
containment laboratory. The recombinant prion protein was solubilised in 8 M 
GdnHCl and filtered through a 0.22-pm membrane before removing from the 
containment laboratory. Further purification of rPrP was carried out within a class II
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hood. Pipetting of rPrP solutions or any other operation with the potential of 
creating an aerosol was performed within the class II hood.
Decontamination and disposal of waste was carried out according to the 
guidelines established by the Health and Safety Executive in ‘Precautions for work 
with human and animal Transmissible Spongiform Encephalopathies.’
3.2.3 Expression o f SHaPrP (90-231)
Competent E. coli 27C7 cells were prepared using calcium chloride, the 
method is a variation of that described in Sambrook et al. (1996) volume 1, p i.82. 
Briefly, 100 mL of TY broth was inoculated with E. coli strain 27C7 and incubated 
at 37 °C with vigorous shaking, until the optical density at 600 nm reached a value 
between 0.6 to 0.8. The culture was cooled to 0 °C by storing the tubes on ice for 15 
minutes after which the cells were recovered by centrifugation at 3000 rpm for 5 
minutes at 4 °C. The supernatant was decanted and the cells were resuspended in 50 
mL of freshly made ice cold 100 mM MgCL. Again the cells were recovered by 
centrifugation at 3000 rpm for 5 minutes at 4 °C. The supernatant was decanted and 
the cells were resuspended in 10 mL freshly made ice cold 100 mM CaCh. The 
cells were left on ice for 1 hour before transformation with the plngPrP plasmid.
Competent 27C7 cells (50 (J.L) were transformed with 4 pL of plngPrP 
plasmid (100 ng). The sample and control, i.e. no plasmid, were incubated on ice for 
30 minutes after which they were transferred to a water bath that had been pre­
heated to 42 °C for 2 minutes. This was followed by a further 30-minute incubation 
on ice. LB medium (200 pL) was added to the samples and the cultures were 
incubated for 1 hour at 37 °C. The transformed bacteria were spread on a LB agar
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plate containing 100 pg/mL ampicillin and incubated overnight at 37 °C. Frozen 
stocks of transformed E. coli 27C7 cells were prepared according to Sambrook et al. 
(1989) appendix A5. LB medium (5 mL) was inoculated with a single colony from 
freshly transformed cells and incubated at 37 °C for 3 hours. For storage 1 mL 
aliquots in 20 % (v/v) glycerol were prepared in 2 mL biofreeze sterile 
polypropylene vials and stored at -20 °C until required.
Frozen transformed E. coli 27C7 cells containing the plngPrP plasmid were 
plated onto a LB agar plate containing 100 pg/mL ampicillin and incubated 
overnight at 37 °C. LB medium (5 mL) supplemented with 50 pg/mL ampicillin 
was inoculated with transformed E. coli 21 C l cells and incubated for 3 hours at 37 
°C with vigorous shaking (200 rpm in a rotary shaker). This was followed by a 100- 
fold dilution into AP5 medium. Typically 2-3 litres were cultured at any one time. 
The cultures were incubated at 37 °C with vigorous shaking for 21 h or until the 
optical density at 600 nm reached a value between 1.0 to 1.4. The cells were 
harvested by centrifugation at 10,000 g  for 20 minutes. The resulting cell paste was 
stored at -20 °C.
3.2.4 Purification o f recombinant SHaPrP (90-231)
The purification of rPrP (90-231) followed an adaptation of the method 
originally described in Mehlhom et al. (1996). A schematic diagram of the 
purification of rPrP is outlined in Figure 3.2. The cell paste was resuspended in 
buffer A and centrifuged at 10,000 g for 20 minutes at 4 °C. The supernatant 
containing the soluble periplasmic proteins was discarded. The recombinant protein
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E. coli paste
Resuspend in 25 mM TrisHCl, pH 8.0/5 mM EDTA, 
10,000 xg 20 min
r ~ i
SI PI
i Resuspend in 25 mM TrisHCl, pH 8.0/5 mM EDTA
Cell Homogeniser: 5 x  2-min 
periods spaced by 1-min intervals
30,000 xg 60 min
S2 P2
Resuspend in 25 mM TrisHCl, pH 8.0/5 
mM EDTA
30,000 xg 60 minrri
S3 P3
r 4
Resuspend in 8 M GdnHCl/25 mM 
TrisHCl, pH 8.0/100 mM DTT 
32,000 xg 20 min
S4 P4
I
Superdex 200 size exclusion column
i
Poros RI RP HPLC column
Figure 3.2: Purification protocol for recombinant SHaPrP (90-231). Cell paste 
was resuspended in Tris buffer and centrifuged to remove soluble periplasmic 
proteins. A cell homogeniser was used to disrupt the cells. The pellet (P2) was 
washed once to remove contaminating cytoplasmic E. coli proteins. The pellet (P3) 
was finally solubilised in 8 M GdnHCl. The resulting supernatant (S4) was applied 
to a size exclusion column and the final step in the purification involved reverse- 
phase high performance liquid chromatography.
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remained in the pellet, which was again resuspended in buffer A and disrupted in a 
homogeniser (Bead Beater with a ice jacket, Stratech Scientific Limited) half-full 
with pre-chilled 0.5-mm diameter glass beads, for 5 x 2-min periods spaced by 1- 
min intervals. The suspension was centrifuged at 30,000 g  for 1 hr at 4 °C, after 
which the supernatant was discarded. The pellet was washed once in buffer A and 
centrifuged again at 30,000 g  for 1 hr. The pellet containing rPrP was subsequently 
solublised in 15 to 20 mL of buffer B and centrifuged at 32,000 g  for 20 minutes at 4 
°C. The supernatant was passed through a 0.22-jim membrane. At this stage it was 
possible to take the protein out of the level 3* containment laboratory.
Aliquots of the supernatant (4 mL) containing approximately 30 mg of total 
protein, as determined by Coomassie protein assay (Biorad) using BSA as standards, 
were applied to a Hiload Superdex 200 column (26 mm x 60 cm). The column had 
been pre-equilibrated with buffer C at a flow rate of 2 mL/min. Fractions (4 mL) 
were collected and absorbance at 280 nm was measured. Initially fractions enriched 
for rPrP were identified by SDS polyacrylamide gel electrophoresis. However, later 
the elution profiles were used and those fractions containing the recombinant protein 
were pooled (Figure 3.3A). The combined fractions were incubated at 4 °C for 2-3 
days, during this period oxygen in the air oxidised the two cysteines to form the 
disulphide bond.
Further purification involved reverse-phase high performance liquid 
chromatography (RP HPLC), employing a 4.6 x 100 mm poros R1 perfusion 
chromatography column on a BioCAD SPRINT system (PerSeptive Biosystems, 
Hertfordshire, UK). The column was equilibrated with 8 column volumes of buffer
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Figure 3.3: Purification of recombinant SHaPrP (90—231). (A) Elution profile of 
the solubilised pellet containing rPrP from the SEC column. The arrow indicates the 
peak that was collected. (B) Elution of rPrP from the Poros R1 RP HPLC column 
with a linear gradient of 0-10 % acetonitrile/0.09 % TFA. GdnHCl was washed 
from the column (PI) with buffer 1. P2 was eluted with 1 % acetonitrile and 
contained oxidised rPrP.
79
1 at a flow rate of 5 mL/min. The sample (10 mL) was loaded onto the column, 
followed by a wash step with buffer 1 (5 minutes) this removed the GdnHCl. The 
recombinant protein was eluted with a 90-minute linear acetonitrile gradient from 0 
to 10 % (buffer 2). Fractions (0.2 mL) were collected and those containing purified 
rPrP were identified from the chromatogram and pooled (Figure 3.3B). The column 
was regenerated with buffer 2 .
3.2.5 Refolding o f recombinant SHaPrP (90-231)
Purified recombinant protein was dialysed overnight at 4 °C, against 20 mM 
sodium acetate, pH 5.5 (5 L) using dialysis tubing with a 7000 molecular weight cut­
off. The dialysis tubing had been boiled in a solution of sodium bicarbonate and 
EDTA in 50 % ethanol to remove impurities before use. The buffer was changed the 
following morning (5 L) and the protein was further dialysed for 6  hours. Aliquots 
(0.5 mL) of the purified protein were prepared and snap frozen in liquid nitrogen for 
long term storage at -20 °C. Sample vials were thawed individually when required, 
any insoluble material was separated by centrifugation.
3.2.6 Characterisation o f purified recombinant SHaPrP (90-231)
3.2.6.1 Determination o f protein concentration
Protein concentration was determined spectrophotometrically using a molar 
extinction coefficient 8280 of 24,420 M_1 cm-1 (Gill & von Hippel, 1989).
3.2.6.2 SDS-polyacrylamide gel electrophoresis and Western blotting
Protein samples were analysed by discontinuous SDS-PAGE according to 
Laemmli (1970). Samples were analysed on 15 % mini polyacrylamide gels. Each
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sample was denatured in sample buffer by boiling at 100 °C for 5 minutes. The gel 
was visualised using Coomassie brilliant blue (Sambrook et al.t 1989 volume 1, 
p i8.55). SDS-PAGE requires relatively salt-free protein samples, therefore GdnHCl 
was removed when present from protein samples before analysis by using acetone as 
a precipitating agent. Cold acetone (-20 °C) was added to the protein solution to a 
final concentration of 50 % (v/v) and left on dry ice for 15 minutes. Centrifugation 
resulted in a protein pellet, which was resuspended in de-ionised water and 
precipitated again with cold acetone (Pohl, 1990). The protein pellet was 
resuspended in sample buffer and prepared as above.
For Western blotting the proteins were transferred from an unstained SDS- 
PAGE gel to nitrocellulose membrane, using a mini TransBlot Electrophoretic 
Transfer Cell-System (BioRad) at 100 V for 1 hour. After blocking with 2 % (w/v) 
skimmed milk powder in 10 mM TrisHCl, pH 7.4 containing 0.15 M NaCl and 0.05 
% Tween 20, the membrane was incubated with the mouse anti-PrP monoclonal 
antibody (MAB1562 IgG) at room temperature for 1 hour (1:4000 dilution in the 
above Tris buffer containing 2 % (w/v) skimmed milk powder). Unbound antibody 
was removed from the membrane by intensive washing in the Tris buffer, pH 7.4 (no 
skimmed milk powder) and incubated with the secondary horseradish peroxidase 
conjugated goat anti-mouse antibody (Sigma-Aldrich, Poole, UK). After repeated 
washes the labelled protein was detected by the formation of a coloured product. A 
tablet of chloronaphthol (30 mg) was dissolved in 10 mL of methanol and made up 
to 50 mL with de-ionised water. This solution was added to 50 mL of 20 mM 
TrisHCl, pH 7.5, 1.5 g of NaCl and 50 pL H2O2 (20 volumes). The chloronaphthol 
mix was poured over the drained blot, and the reaction was terminated once the 
bands were visible by washing the membrane in water.
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3.2.6.3 Mass spectrometry
An aliquot (10 pL) of purified rPrP was analysed by electrospray ionization 
(ESI) mass spectrometry using a Quattro II tandem quadrupole instrument 
(Micromass UK Ltd) equipped with a commercial Z-spray ionisation source 
operating in continuous flow nanospray mode. Calibration of the ESI mass 
spectrometer with myoglobin allowed the molecular mass of rPrP to be determined.
Mass spectrometry was kindly performed by Dr Andrew C Gill at the 
Institute for Animal Health, Compton.
3.2.6.4 CD spectroscopy
CD spectra of the far-UV (185-260 nm) and near-UV (250-350) regions 
were recorded on a JASCO J-715 spectropolarimeter. Spectra were obtained for 
samples in 20 mM sodium acetate, pH 5.5 containing 7.5 pM rPrP (0.12 mg/mL) for 
far-UV and 46 pM rPrP (0.74 mg/mL) for near-UV. CD spectra were recorded at 20 
°C using quartz cells of 0.1 mm pathlength for far-UV and 5 mm for near-UV. The 
measurements were recorded with a bandwidth of 1 nm, a scanning rate of 100 
nm/min and a time constant of 1 s. Spectral resolution was 0.5 nm and 16 scans 
were averaged per spectrum. The corresponding spectra for buffer background were 
subtracted from protein spectra.
3.3 Results and Discussion
3.3.1 Expression and purification o f SHaPrP (90-231)
SHaPrP (90-231) was successfully expressed in a protease deficient strain of
82
E. coli. During expression rPrP aggregated into insoluble particles in the 
periplasmic space. After cell disruption in a homogeniser the recombinant protein 
remained in the pellet and was solubised in 8 M GdnHCl containing 100 mM DTT, 
thus reducing the single disulphide bond in PrP. Approximately 50-80 % of the 
recombinant protein was solublised from the pellet. The recombinant protein was 
separated from the high molecular weight E. coli proteins by size exclusion 
chromatography under denaturing conditions. The absence of a reducing reagent 
from the SEC buffer meant that the pooled fractions from the SEC column when 
stored at 4 °C for 2-3 days resulted in formation of the disulphide bond.
RP HPLC was used in the last purification step of recombinant PrP. 
PerSeptive Biosystems POROS R1 column was used instead of a conventional C-4 
column. POROS media allows for higher flow rates to be used during separation, 
thereby reducing the time required to purify large volume samples. The elution time 
of rPrP in reverse-phase chromatography is dependent on the oxidation state of 
Cysl79, and Cys214 (Mehlhom et al., 1996; Zhang et al., 1997; Jackson et al., 
1999a). Mehlhom et al. (1996) reported that oxidised rPrP eluted in earlier fractions 
containing 35 % acetonitrile, while the reduced protein eluted later and was usually 
contaminated with co-eluting proteins. Purification of recombinant PrP under 
oxidising conditions was demonstrated to yield a protein with a high a-helical 
content (Mehlhom et al., 1996; Zhang et al., 1997). However under reducing 
conditions the protein was shown to contain a greater amount of P-sheet structure.
The recombinant protein eluted as a single peak from the POROS R.1 column 
with 1 % acetonitrile. The elution point is very different from the reported value of 
35 % acetontrile from a Vydac C-4 column (Mehlhom et al., 1996). Although R1
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resin [poly(styrene-divinylbenzene)] is suggested to be similar to C-4, the 
chromatographic matrix is qualitatively different from C-4 chains bonded to silica. 
This difference may result in different elution points in the acetonitrile gradient. 
Recombinant PrP was refolded by dialysis against 20 mM sodium acetate, pH 5.5. 
The final yield of rPrP was 10-12 mg per litre of bacterial culture.
3.3.2 Characterisation o f purified recombinant SHaPrP (90-231)
3.3.2.1 Analysis by SDS-PAGE and Western blotting
Electrophoresis and immunoblots confirmed the presence and purity of rPrP 
(Figure 3.4). Mouse anti-PrP monoclonal antibody (MAB1562 IgG) binds to an 
epitope at the unstructured amino-terminus (amino acids 109-112) in hamster PrP. 
The protein appeared as a single band, within the correct molecular weight range 
(16-17 kDa) on SDS-PAGE gels and nitrocellulose membranes. The calculated 
molecular weight for the oxidised protein is 16,241.13 Da.
3.3.2.2 Mass spectrometry
The molecular mass of recombinant SHaPrP (90-231) was verified by ESI 
mass spectrometry as 16,241.70 ± 0.16 Da (Figure 3.5). The calculated mass for the 
oxidised protein is 16,241.13 Da the result is therefore in excellent agreement with 
the expected mass for the oxidised protein containing a disulphide bond.
3.3.2.3 Spectroscopic characterisation o f  recombinant SHaPrP (90-231) 
The far-UV region of the CD spectrum provides a qualitative measure of the
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Figure 3.4: Analysis of recombinant SHaPrP (90-231) by SDS-PAGE and 
Western blotting. (A) Coomassie stained 15 % polyacrylamide gel. Lane: (1) 
molecular mass standards, (2) total cell extract and (3) purified rPrP following RP 
HPLC. (B) Western blot analysis using monoclonal antibody MAB1562 IgG 
following the purification of rPrP. 300 ng of total protein was loaded. Lane: (1) 
molecular mass standards and (2) purified rPrP.
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Figure 3.5: ESI mass spectrometry of purified recombinant SHaPrP (90-231).
Mass spectrum of purified SHaPrP. The inset shows the maximum entropy 
deconvoluted mass spectrum of SHaPrP (90-231). Calculated mass for SHaPrP 
(90-231) assuming formation of the single disulphide bond is 16,241.13 Da and the 
measured mass is 16,241.70 ± 0.16 Da.
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average secondary structure content of a protein. The far-UV CD spectrum of 
refolded recombinant SHaPrP (90-231) exhibits a double minimum at 208 and 222 
nm with a mean molar ellipticity per residue at 222 nm of -8,000 deg cm2 dmol-1 
and a strong positive band near 195 nm (Figure 3.6A). The spectrum is 
characteristic of proteins with high a-helical content (Woody, 1996). This is in good 
agreement with the NMR structure of recombinant SHaPrP (90-231), which shows a 
mainly helical protein with small amount of P-sheet structure (James et al., 1997). 
In contrast, rPrP in 6 M GdnHCl shows a spectrum, which is characteristic of a 
unordered protein, however because of the light scattering defects associated with 
high concentrations of GdnHCl the strong negative band near 200 nm, which is a 
feature of an unordered polypeptide is not resolved.
The far-UV CD spectrum of recombinant human PrP residues 90-231 
displays two minimum at 208 and 222 nm with a mean molar ellipticity per residue
•y _  |
at 222 nm of -10,000 deg cm dmol . Comparison of the CD spectrum of human 
PrP with SHaPrP domains 90-231 indicates that the percentage of a-helical 
structure is remarkably similar in the two proteins (Swietnicki et al., 1997). 
Furthermore, the far-UV CD spectrum of PrP purified directly from hamster brain is 
also indicative of a protein containing mainly a-helical structure (Pan et al., 1993; 
Baldwin et al., 1995). Comparison of the spectroscopic measurements suggests that 
recombinant PrP was refolded into a conformer that resembled native PrPc.
The near-UV CD region (250-330 nm) provides information on the packing 
of aromatic side chains in the protein and generally give rise to a CD band if they are 
tightly packed within the core of a stable folded protein. The overall features of the
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Figure 3.6: CD spectra of recombinant SHaPrP (90-231). (A) Far-UV CD 
spectra of refolded rPrP (solid line) under oxidising conditions at pH 5.5 and 
unfolded rPrP (dotted line) in 6 M GdnHCl. (B) Near-UV CD spectrum of refolded 
rPrP under oxidising conditions at pH 5.5. CD spectrum was recorded at protein 
concentrations of 7.5 pM for far-UV and 46 |iM for near-UV at 20 °C. [0]
represents mean molar ellipticity per residue.
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near-UV CD spectrum of recombinant SHaPrP (90-231) indicate the presence of 
tertiary structure (Figure 3.6B). In the 275-285 nm region the spectrum is 
dominated by tyrosine absorption and in the 260-270 nm region by phenylalanine 
absorption. The distinct positive peak near 292 nm suggests that one or both of the 
tryptophan residues are located in an asymmetric environment (Woody, 1996).
3.3.3 Summary
Recombinant SHaPrP (90-231) was expressed in a protease deficient strain 
of E. coli and purified by two sequential chromatographic procedures: SEC and RP 
HPLC. The protein was refolded under oxidising conditions by dialysis against 
acetate buffer, pH 5.5.
SDS-PAGE and Western blotting confirmed the purity and presence of rPrP. 
Mass spectrometry revealed that purified protein had a molecular weight of 
16,241.70 ±0.16 Da, which is in excellent agreement with oxidised PrP containing a 
disulphide bond between Cysl79 and Cys214.
The far-UV CD spectrum was indicative of a protein with a high a-helical 
content. In addition near-UV CD indicated the presence of a folded state with stable 
tertiary structure. These data taken together provided strong evidence for the 
conformation of oxidised recombinant SHaPrP (90-231) to resemble that of PrPc.
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Chapter 4: Binding of Syrian Hamster Prion Protein
(SHaPrP) Residues 90-231 to Model Lipid Membranes
4.1 Introduction
The three-dimensional structure of several recombinant mammalian prion 
proteins have been solved by nuclear magnetic resonance (NMR) spectroscopy (Riek 
et al., 1996; Donne et al., 1997; James et al., 1997; Garcia et al., 2000; Zahn et al., 
2000). Biophysical studies have been directed to decipher the mechanism of PrPc 
conversion to PrPSc. (Swietnicki et al., 1997; Zhang et al., 1997; Hornemann & 
Glockshuber, 1998; Jackson et al., 1999a,b\ Wildegger et al., 1999). Although the 
above solution studies have all provided valuable information on the complex 
mechanism of PrP conversion they however failed to take into consideration that the 
carboxyl-terminus of PrP is attached to a flexible GPI anchor, which targets the 
protein to cholesterol-sphingolipid rich raft domains within the plasma membrane 
(Vey et al., 1996; Naslavsky et al., 1997).
The precise subcellular site for the formation of PrPSc is unknown. Evidence 
implicates the plasma membrane and endocytic organelles as relevant sites 
(Taraboulos et al., 1995; Vey et al., 1996). Lipid interactions are thus likely to 
feature in the formation and propagation of PrPSc. Furthermore, studies with lipid- 
anchored proteins have shown that in addition to the anchor direct interactions 
between the polypeptide chain and lipid membranes may be involved in membrane 
association (Sigal et al., 1994; Zhou et al., 1994; Arbuzova et al., 1998). It is 
therefore likely that the polypeptide chain of PrP can also participate in direct 
membrane-protein interactions. The flexible character of the GPI anchor of PrP 
provides the protein with dynamic freedom relative to the membrane, thus increasing
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the probability of direct interactions of PrP with lipid membranes (Rudd et al., 
2001). Given that the lipid environment appears to play a crucial role in the cell 
cycle of PrP the biophysical properties of PrP in lipid membranes were investigated.
Few studies have investigated the structural characteristics of PrP when 
associated with model lipid membranes. Morillas et al. (1999) recently described 
conformation changes in human prion protein upon interaction with lipid 
membranes. Binding of various recombinant human PrP variants including full- 
length protein (minus the GPI anchor) to glycerophospholipid vesicles was 
investigated as a function of pH. Human PrP was reported only to bind to mixed 
membranes containing negatively charged lipid PS and zwitterionic lipid PC, with 
the interaction becoming much stronger under acidic conditions. The study 
concluded that even in the absence of the GPI anchor recombinant human PrP had a 
propensity to interact with lipid bilayers. The requirement of negatively charged 
lipids led the authors to suggest that binding of human PrP to membranes is driven 
by electrostatic lipid-protein interactions. However, the involvement of hydrophobic 
lipid-protein interactions was not completely excluded.
De Gioia et al. (1994) examined the lipid binding properties of a synthetic 
peptide spanning residues 106 to 126 of human PrP. This peptide had in a previous 
study been shown to be neurotoxic toward primary cultures of rat hippocampal 
neurons (Forloni et al., 1993). The peptide interacted with neutral lipid vesicles 
(PC/cholesterol) and negatively charged membranes (PG/cholesterol) and the 
association was accompanied by a secondary structural transition from a random coil 
conformation to a predominant P-sheet structure.
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In this chapter, the lipid binding properties of recombinant SHaPrP 
comprising of residues 90-231 have been characterised by monitoring changes in the 
fluorescence properties of PrP. SHaPrP (90-231) contains two tryptophan residues 
at positions 99 and 145 (Figure 4.1) that serve as intrinsic fluorophores. 
Fluorescence quenching experiments further provided information on the solvent 
accessibility of the tryptophan residues for the lipid-free and lipid-bound states of 
PrP.
Specifically, the interactions of SHaPrP (90-231) with a range of lipid 
membrane systems both at pH 7, to represent the pH surrounding the plasma 
membrane and pH 5, which models the acidic environment in endosomes, were 
investigated. In this comparative study, three types of model lipid systems were 
investigated: negatively charged glycerophospholipids (POPG and DOPG), 
zwitterionic glycerophospholipids (POPC, DOPC and DPPC) and mixed membranes 
composed of zwitterionic glycerophospholipids, cholesterol and sphingomyelin. The 
interaction of PrP with mixed membranes composed of DPPC, cholesterol and 
sphingomyelin is of particular interest. This composition of lipids has been shown to 
possess the same properties, such as detergent insolubility as raft domains isolated 
from the plasma membrane and therefore serve as good models of lipid rafts 
(Schroeder et al., 1994, 1998). This systematic study provided a comprehensive 
insight into the nature of lipid-PrP interactions.
4.2 M aterials and Methods
4.2.1 Materials
Glycerophospholipids (POPG, DOPG, POPC and DOPC), cholesterol and
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Figure 4.1: Ribbon diagram of the three-dimensional structure of recombinant 
SHaPrP (90-231). The NMR structure of recombinant SHaPrP (90-231) in 
aqueous solution (James et ai, 1997) indicating the positions of the three oc-helices 
(A, B and C) and the two antiparallel ^-strands (SI and S2). The tryptophan 
residues (Trp99 and Trp 145) are highlighted in ball-and-stick representation. The 
structure was drawn using the program Molscript (Kraulis, 1991) and rendered with 
RASTER3D (Merritt & Bacon, 1997).
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sphingomyelin were purchased from Avanti Polar lipids (Birmingham, AL). DPPC 
was obtained from Sigma-Aldrich (Poole, UK). All other chemicals were obtained 
from Sigma-Aldrich (Poole, UK), unless otherwise stated.
4.2.2 Lipid vesicles
Lipids in chloroform solutions were dried under a rotary evaporator and the 
resulting lipid film left under vacuum overnight to remove all traces of the organic 
solvent. For the preparation of mixed lipid membranes, lipids were co-dissolved in 
chloroform and a lipid film was formed as described above. Small unilamellar lipid 
vesicles were prepared by hydrating the required amount of dried lipid or the lipid 
films with the desired buffer: 20 mM sodium phosphate, pH 7.2 or 20 mM sodium 
acetate, pH 5.0. To avoid oxidative degradation of the lipids, buffers were 
deoxygenated with nitrogen gas and the hydrated lipids were maintained under a 
nitrogen atmosphere. After lipid hydration the resulting multilamellar liposome 
suspension was sonicated in a bath sonicator until a clear suspension of small 
unilamellar vesicles was obtained (typically 6 x l/2 h periods). These preparations 
typically yield vesicles with diameters ranging from 300 to 600 A (Rankin et al., 
1998).
4.2.3 Binding o f recombinant SHaPrP (90-231) to lipid membranes
Binding of recombinant PrP to various lipid vesicles was studied at 20 °C by 
monitoring the shift in the wavelength of the fluorescence emission maxima (A.nm)- 
Binding of PrP to lipid vesicles was investigated at pH 7 and 5. For measurements 
at pH 7, vesicles were prepared in 20 mM sodium phosphate buffer, pH 7.2, whereas 
for measurements at pH 5 vesicles were in 20 mM sodium acetate buffer, pH 5.0.
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The protein concentration was kept constant at 7.5 pM and the lipid concentration 
varied from 10 pM up to 10 mM. Lipid-protein complexes were prepared by adding 
1 part of a 15 pM stock protein solution in 20 mM sodium acetate buffer, pH 5.5, to 
an equal volume of lipid vesicles at pH 7.2 or pH 5.0. The final pH of the lipid- 
protein samples were ~ 6.9 and ~ 5.2, respectively. Lipid-protein samples were 
mixed thoroughly and equilibrated for 2-3 minutes before fluorescence emission 
spectra were recorded on a Photon Technology International spectrofluorimeter. 
Emission spectra were recorded using 4 mm pathlength quartz cells. The excitation 
wavelength was 295 nm (2 nm bandwidth) and emission spectra were recorded from 
300 to 450 nm (2 nm bandwidth). For samples containing raft-like membranes of 
DPPC/chol/SM at pH 7 the concentration of PrP and lipid were changed to 1 pM PrP 
and lipid concentration varied from 1.3 pM to 1.3 mM and a longer pathlength of 1 
cm was used. This was necessary because scattering of light by mixed membranes 
containing saturated lipids, cholesterol and sphingomyelin tends to be higher, which 
distorts the emission spectra of PrP preventing the accurate determination of the 
X-max- The concentration of both protein and lipid was reduced so that the lipid- 
protein ratio remained the same as for the binding studies with single lipid 
membranes i.e. lipid/protein ratio varying from 1.3:1 to 1300:1. Combining the 
lower protein concentration with a longer pathlength allowed for a comparable 
signal-to-noise ratio to be achieved as for spectra recorded with higher protein 
concentrations. Typically, 4 scans were averaged per spectrum in all experiments. 
The corresponding spectra for buffer background or lipid alone were subtracted from 
protein spectra.
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Samples with increasing ionic strengths were prepared by adding aliquots of 
NaCl from a 5 M stock solution prepared in 20 mM sodium phosphate, pH 7.2 to 
either pre-existing lipid-protein complexes or to lipid vesicles alone prior to the 
addition of protein. The lipid-protein samples were prepared as above; protein 
concentration was 7.5 pM and lipid was 1 or 3 mM. The fluorescence spectra were 
recorded as described above and the corresponding backgrounds (buffer for protein 
solutions, or lipid with the equivalent salt concentration) were subtracted from 
protein spectra.
4.2.4 Quenching o f tryptophan fluorescence
Fluorescence quenching experiments were performed in the absence and 
presence of lipid vesicles. One part of a 10 pM stock protein solution in 20 mM 
sodium acetate buffer, pH 5.5, was added to an equal volume of freshly prepared 
acrylamide solution from a 1 M acrylamide stock in 20 mM sodium phosphate, pH 
7.2, or in 20 mM sodium acetate, pH 5.0. For samples containing lipid vesicles one 
part of the stock protein solution was added to an equal volume of lipid vesicles and 
quencher solution at pH 7.2 or pH 5.0. The final protein and lipid concentrations 
were 5 pM and 3 mM, respectively except for mixed membranes composed of 
DPPC/chol/SM where a lower lipid concentration of 1 mM was used to avoid light 
scattering problems. Acrylamide concentration varied from 0-0.3 M.
Tryptophan fluorescence emission spectra were recorded at each quencher 
concentration. The excitation wavelength was 295 nm and emission spectra were 
recorded from 300 to 450 nm. The excitation and emission bandwidths were 2 nm. 
The fluorescence quenching data were analysed according to the Stern-Volmer
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equation (Eq. 4.1) for collisional quenching between the fluorophore and quencher 
(Lakowicz, 1983).
Fo/F = 1 + KSV[Q] = T0 /  t = 1 + kq T0 [Q] (Eq. 4.1)
where, Fo and F are the fluorescence intensities at Xmax in the absence and presence 
of quencher, respectively. Ksv is the Stem-Volmer constant for the collisional 
quenching process, [Q] is quencher concentration, to and t  are fluorescence lifetimes 
of the fluorephore in the absence and presence of the quencher, respectively and kq is 
the rate constant for the bimolecular quenching process. The above equation 
predicts a linear plot of Fo/F versus [Q] for a homogeneously emitting solution. The 
slope of this plot yields the Stem-Volmer constant (Ksv).
4.3 Results
4.3.1 Changes in the tryptophan fluorescence upon binding o f PrP to model 
lipid membranes
The fluorescence emission of most proteins originates from the indole ring of 
the tryptophan residues. Unlike, the emission of tyrosine fluorescence, tryptophan 
fluorescence is highly sensitive to the polarity of its surrounding environment 
(Lakowicz, 1983). As a result, the wavelength of the emission maxima (X,max) of 
proteins can provide information on the average exposure of their tryptophan 
residues to the aqueous phase.
Binding studies of peptides to lipid membranes have confirmed the 
preference of aromatic residues for the lipid-water interface (Deber & Goto, 1996; 
Wimley & White, 1996). A shift in the Xmax to shorter wavelengths and increase in 
the fluorescence intensity are normally associated with the transfer of the tryptophan
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residues from the hydrophilic environment in aqueous solution to the hydrophobic 
lipid phase. Although increases in fluorescence intensity concomitantly occurs with 
binding of peptides and proteins to lipid membranes this measurement does not 
reliably reflect lipid-protein interactions. Deviations from Beer-Lambert law are 
often encountered due to scattering of light by lipid-protein complexes. Shifts in the 
fluorescence wavelength maxima (A,max) of proteins are a more reliable indicator of 
lipid-protein interactions.
SHaPrP (90-231) has two tryptophan residues at positions 99 and 145 
(Figure 4.1), which dominate the fluorescence spectrum, ten tyrosine and three 
phenyalanine residues that make minor contributions to the overall intrinsic protein 
fluorescence. It is often necessary to eliminate this additional source of 
heterogeneity in the fluorescence of proteins. This is generally accomplished by 
using an excitation wavelength of 295 nm, where the absorption of tyrosine and 
phenylalanine is minimal. The fluorescence emission spectrum of SHaPrP (90-231) 
in solution has a maximum intensity (Xmax) at 348 nm. This value is typical of 
tryptophan residues in an aqueous environment (Lakowicz, 1983) and is in good 
agreement with the NMR structure, which shows the iodole rings partially exposed 
on the protein surface.
4.3.1.1 Interaction o f recombinant SHaPrP (90-231) with negatively 
charged membranes
The fluorescence properties of PrP were considerably altered upon addition 
of negatively charged membranes. Representative emission spectra of PrP in the
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presence of POPG membranes at pH 5 and 7 are shown in Figure 4.2. The 
wavelength of the emission maxima (A.max) of PrP at both pH 7 and 5 is shifted to 
shorter wavelengths (blue shift) in the presence of POPG membranes. The observed 
blue shifts reflect the partitioning of the tryptophan residues into a more hydrophobic 
environment and are indicative of PrP binding to POPG membranes. A blue shift of 
A.max of approximately 16 nm was observed with the binding of PrP to POPG 
membranes at pH 5 for a lipid-protein ratio of 1333:1 (7.5 pM PrP and 10 mM 
POPG), whereas a blue shift of about 10 nm was detected upon binding to POPG 
membranes at pH 7 for the equivalent lipid-protein ratio. This implies that the 
tryptophan residues of PrP when bound to negatively charged membranes of POPG 
at pH 5 were less exposed to the hydrophilic aqueous environment presumably due 
to a deeper penetration into the hydrophobic lipid phase.
Binding of PrP to DOPG membranes at pH 7 resulted in a blue shift of 12 
nm, suggesting that the composition of the fatty acid chains have no major influence 
on the binding of PrP to negatively charged membranes.
4.3.1.2 Interaction o f recombinant SHaPrP (90-231) with zwitterionic
membranes
The incubation of PrP with liquid-crystalline zwitterionic membranes of 
DOPC at pH 7 and POPC at both pH 7 and pH 5 (Figure 4.3) showed a negligible 
blue shift in the X.max (1 nm) of PrP, the results indicated a lack of lipid-protein 
interactions. In contrast, a blue shift in the Xmax of PrP with gel-phase zwitterionic 
membranes of DPPC at pH 7 (Figure 4.4) and raft-like membranes composed of 
DPPC, cholesterol and spingomyelin at pH 7 (DPPC/chol/SM, 50:30:20 molar ratio)
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Figure 4.2: Equilibrium fluorescence spectra of SHaPrP (90-231) in solution 
and in the presence of POPG membranes. (A) Emission spectra of PrP in 
solution, pH 7 (solid line) and in the presence of increasing concentrations of POPG, 
pH 7: 0.05 (dashed line), 0.25 (dotted line) and 0.5 mM (dash-dot-dot line). (B) 
Emission spectra of PrP in solution, pH 5 (solid line) and in the presence of 
increasing concentrations of POPG, pH 5: 0.03 (dashed line), 0.05 (dotted line) and 
0.5 mM (dash-dot-dot line). The final protein concentration was 7.5 pM. The 
excitation wavelength was 295 nm and spectra were recorded at 20 °C.
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Figure 4.3: Equilibrium fluorescence spectra of SHaPrP (90-231) in solution 
and in the presence of POPC membranes. (A) Emission spectra of PrP in 
solution, pH 7 (solid line) and in the presence of increasing concentrations of POPC, 
pH 7: 0.01 (dashed line), 2 (dotted line) and 5 mM (dash-dot-dot line). (B) Emission 
spectra of PrP in solution, pH 5 (solid line) and in the presence of increasing 
concentrations of POPC vesicles, pH 5: 0.01 (dashed line), 2 (dotted line) and 5 mM 
(dash-dot-dot line). The final protein concentration was 7.5 pM. The excitation 
wavelength was 295 nm and spectra were recorded at 20 °C.
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Figure 4.4: Equilibrium fluorescence spectra of SHaPrP (90-231) in solution 
and in the presence of DPPC membranes, pH 7. Emission spectra of PrP in 
solution (solid line) and in the presence of increasing concentrations of DPPC: 0.2 
(dashed line), 1.5 (dotted line) and 3 mM (dash-dot-dot line). The final protein 
concentration was 7.5 pM. The excitation wavelength was 295 nm and spectra 
were recorded at 20 °C.
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(Figure 4.5A) was detected. A shift of ~ 11 nm and ~ 9 nm, respectively, was 
observed at a lipid-protein ratio of 1333:1. Interestingly, no significant binding was 
observed with DPPC/chol/SM membranes (50:30:20 molar ratio) at pH 5 (Figure 
4.5B).
No change in the fluorescence properties of PrP were detected with mixed 
membranes composed of DOPC with cholesterol (DOPC/chol, 70:30 molar ratio) 
and cholesterol plus sphingomyelin (DOPC/chol/SM, 50:25:25 molar ratio), 
suggesting a lack of lipid-protein interactions. The results demonstrate that PrP 
exhibits a preference for zwitterionic lipids in the gel-crystalline phase and for raft­
like membranes composed of DPPC/chol/SM at pH 7.
A summary of the different lipid systems studied is given in Table 4.1, in 
which the emission 7,max values of PrP upon addition of the different membranes are 
shown. Figure 4.6 shows the dependence of the blue shift in the emission maxima of 
PrP as a function of lipid concentration. The blue shift was determined by 
subtracting the A.max for PrP in the presence of lipid from the Xmax for PrP in solution 
n  so1 y !'PxVAmax 'Wnax ) •
4.3.1.3 Influence o f ionic strength on PrP-lipid interactions
Binding of PrP to lipid membranes was also examined in the presence of 
high salt concentrations. These experiments were performed in order to examine the 
nature of PrP association with lipid membranes. Binding of human PrP with 
negatively charged membranes was suggested to be predominantly driven by 
electrostatic interactions between the positively charged amino acid
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Figure 4.5: Equilibrium fluorescence spectra of SHaPrP (90-231) in solution 
and in the presence of raft-like membranes of DPPC/chol/SM (50:30:20 molar 
ratio). (A) Emission spectra of PrP in solution, pH 7 (solid line) and in the presence 
of increasing concentrations of DPPC/chol/SM, pH 7: 0.1 (dashed line), 0.5 (dotted 
line) and 0.6 mM (dash-dot-dot line). (B) Emission spectra of PrP in solution, pH 5 
(solid line) and in the presence of increasing concentrations of DPPC/chol/SM, pH 
5: 1 (dashed line), 2 (dotted line) and 5 mM (dash-dot-dot line). The final protein 
concentration was 1 |iM for PrP at pH 7 and 7.5 pM for protein at pH 5. The 
excitation wavelength was 295 nm and spectra were recorded at 20 °C.
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Table 4.1: Lipid-induced changes in the wavelength o f the fluorescence
maximum o f SHaPrP (90-231)a
System pH Lipid-Protein Molar 
Ratio
•^max (nm)
PrP in solution 7 — 348
5 348
PrP + POPG 7 1333:1 338
5 1333:1 332
PrP +DOPG 7 1333:1 336
PrP + POPC 7 1333:1 347
5 1333:1 347
PrP + DOPC 7 1333:1 347
PrP + DOPC/chol* 7 1333:1 348
PrP + DOPC/chol/SM“ 7 1333:1 348
PrP + DPPC 7 1333:1 337
PrP + DPPC/chol/SM^ r 1333:1 339
5 1333:1 347
“Protein concentration was 7.5 |iM and pathlength was 4 mm. *DOPC/chol, 70:30 
molar ratio. “DOPC/chol/SM, 50:25:25 molar ratio. ^DPPC/chol/SM 50:30:20 
molar ratio. ^Protein concentration was 1 jiM and pathlength was 1 cm.
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Figure 4.6: Blue shift of A,max of SHaPrP (90-231) with increasing lipid. PrP
fluorescence was measured in the presence of increasing concentrations of POPG 
vesicles at pH 7 (open circles) and pH 5 (closed circles), DPPC vesicles, pH 7 (closed 
squares), DPPC/chol/SM vesicles at pH 7 (closed triangles) and pH 5 (open triangles). 
The protein concentration was kept constant at 7.5 jiM except for binding to 
DPPC/chol/SM where the concentration of PrP was kept at 1 |iM. The data is displayed 
in both linear (A) and logarithmic (B) scale for the x-axis. The logarithmic scale 
representation highlights the changes at lower lipid concentrations, whereas the linear 
representation highlights the saturation levels at higher lipid concentrations.
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residues of the protein and negatively charged lipid headgroups (Morillas et al., 
1999).
Two different experiments were performed; in the first NaCl was also added 
to the lipid vesicles prior to the addition of PrP and in the second the ionic strength 
of the lipid-PrP complexes was increased. A high lipid-protein ratio of either 133:1 
or 400:1 was used in these experiments to ensure saturation of the lipid binding sites 
with protein.
The addition of NaCl to negatively charged POPG lipid vesicles at pH 7 prior 
to the addition of PrP resulted in the shielding of charges at the membrane and 
protein surfaces. In the presence of salt (0.3 M NaCl) a shift in the Xmax of only 4 nm 
was observed compared to a shift of 11 nm in the absence of salt at pH 7(Figure 4.7). 
This observation suggests that shielding of charges on both the protein and 
membrane surfaces strongly diminished binding of PrP to negatively charged 
membranes.
In another experiment increasing concentrations of NaCl (0-0.3 M) were 
added to PrP-POPG complexes at pH 7. If binding of PrP to negatively charged 
membranes was primarily due to electrostatic interactions between charged groups 
on the surface of PrP and lipid membranes then such interactions would be disrupted 
with increasing amounts of salt. This would eventually result in the emission spectra 
of PrP in the presence of lipid membranes to reach the characteristic spectral 
parameters of protein in solution. However, only a small fraction of the protein 
appeared to be released, as judged by a small red shift in the X.max of 2 nm with 0.2 M 
NaCl relative to the lipid-bound state. Increasing concentrations of NaCl did not 
induce a further shift in the Xmax of PrP (Figure 4.8).
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Figure 4.7: Changes in the tryptophan fluorescence of SHaPrP (90-231) upon 
binding to POPG membranes in the presence of salt. Emission spectra of PrP in 
solution at pH 7 with 0.3 M NaCl (solid line), bound to POPG vesicles (dashed line) 
with no salt and in the presence of POPG vesicles with 0.3 M NaCl (dotted line). 
Concentration of PrP was 7.5 pM and lipid 3 mM. Final pH of lipid-protein 
complex was 7.0. The excitation wavelength was 295 nm and spectra were recorded 
at 20 °C. The numbers above each spectrum show the value of Xmax in nm.
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Figure 4.8: Changes in tryptophan fluorescence of PrP-POPG complexes upon 
addition of salt. Emission spectrum of PrP in solution at pH 7 with 0.25 M NaCl (solid 
line) and bound to POPG vesicles in the absence of salt (dashed line) and in the presence 
of 0.25 M NaCl (dotted line). Concentration of PrP was 7.5 |iM and lipid 1 mM. Final 
pH of lipid-protein complex was 7.0. The excitation wavelength was 295 nm and spectra 
were recorded at 20 °C. The numbers above and below each spectrum show the value of 
Xmax in nm.
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Trp fluorescence measurements in the presence of salt (Figure 4.7) support 
the interpretation that binding of PrP to lipid bilayers composed of negatively 
charged lipids is driven by electrostatic interactions between positively charged 
residues on the protein surface and negative charges on the lipid headgroups. 
However, the salt experiments described in Figure 4.8 showed that PrP is not 
released from the membrane by the addition of salt. This result suggests that once 
the protein is bound to the membrane surface probable structural rearrangements 
occur in the protein that expose hydrophobic surfaces, which then interact with 
hydrophobic regions of the lipid membrane. Based on these results the interaction of 
PrP with negatively charged membranes appears to be a complex process that 
involves a combination of electrostatic and hydrophobic lipid-protein interactions.
Binding of PrP to the rafit-like membranes composed of DPPC, cholesterol 
and sphingomyelin at pH 7 was also investigated in the presence of increasing 
concentrations of salt (0-0.3 M). In contrast, to POPG membranes, where binding 
was significantly diminished in the presence of salt, binding of PrP to the raft-like 
membranes of DPPC/chol/SM at pH 7 was not affected by the addition of salt. 
Furthermore, increase in ionic strength led to an additional increase in fluorescence 
intensity (Figure 4.9) and a further shift in the X.max of 1 nm. In this situation high 
ionic strength did not interfere with the binding process and shielding of the charges 
at the surface of PrP and lipid bilayers slightly increased the lipid affinity of PrP for 
zwitterionic membranes. The addition of salt to pre-formed DPPC/chol/SM-PrP 
complexes at pH 7 failed to dissociate the protein-lipid complexes (Figure 4.10) as 
judged by a lack of change in the emission spectra.
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Figure 4.9: Changes in the tryptophan fluorescence of SHaPrP (90—231) upon 
binding to raft-like membranes of DPPC/chol/SM (50:30:20 molar ratio) in the 
presence of salt. Emission spectra of PrP in solution at pH 7 with 0.3 M NaCl 
(dashed line), PrP bound to DPPC/chol/SM vesicles (solid lines) with increasing 
concentrations of NaCl: 0, 0.2, 0.3 M (lower to upper spectrum). Concentration of 
PrP was 7.5 pM and lipid 1 mM. Final pH of lipid-protein complex was 7. The 
excitation wavelength was 295 nm and spectra were recorded at 20 °C. The 
numbers above and below each spectrum show the value of the Xmax in nm.
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Figure 4.10: Changes in the tryptophan fluorescence of DPPC/chol/SM-PrP 
complexes upon addition of salt. Emission spectra of PrP in solution at pH 7 with 
0.3 M NaCl (dotted line), PrP bound to DPPC/chol/SM vesicles (solid lines) with 
increasing concentrations of NaCl: 0, 0.2, 0.3 M. Concentration of PrP was 7.5 pM 
and lipid 1 mM. Final pH of lipid-protein complex was 7. The excitation 
wavelength was 295 nm and spectra were recorded at 20 °C. The numbers above 
each spectrum show the value of the ^max in nm.
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The results imply that the interaction of PrP to raft-like membranes involves 
hydrophobic interactions. The electrostatic contribution to binding of PrP to the raft­
like membranes appears to be less important.
4.3.2 Acrylamide quenching of PrP fluorescence
To further examine the location of the tryptophan residues of PrP when 
bound to lipid membranes, fluorescence quenching experiments with acrylamide 
were performed. Acrylamide is a neutral but polar quencher and is considered to 
have access to all but the most highly buried tryptophan residues of proteins and 
peptides (Kurzban et al., 1989) and it is also unable to penetrate into the 
hydrophobic core of the lipid bilayer. Therefore, efficient quenching of tryptophan 
fluorescence by acrylamide would indicate the exposure of the residues to the 
aqueous solvent, while protection from the quenching solutions would occur when 
protein tryptophan residues are sequestered away from the aqueous solvent 
(Lakowicz, 1983).
Negatively charged POPG vesicles, zwitterionic vesicles composed of POPC 
and mixed raft-like membranes consisting of DPPC, cholesterol and sphingomyelin 
(50:30:20 molar ratio) were investigated in the fluorescence quenching experiments.
Increasing concentrations of acrylamide gradually quenched the tryptophan 
fluorescence of PrP in aqueous buffer at pH 5 (Figure 4.11 A). In contrast, to PrP in 
solution, the presence of POPG membranes at pH 5 appeared to lead to a smaller 
reduction in the fluorescence intensity (Figure 4.1 IB). Figure 4.12 illustrates the 
emission spectra of PrP at pH 7 in aqueous solution and in the presence of POPG, 
POPC vesicles and raft-like membranes of DPPC/chol/SM at pH 7 in the absence
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Figure 4.11: Quenching of tryptophan fluorescence by acrylamide at pH 5. (A)
Emission spectra of PrP in solution at pH 5 and (B) with POPG membranes with 
increasing concentrations of acrylamide: 0, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30 M 
(upper to lower spectrum). The final protein and lipid concentrations were 5 pM and 
3 mM, respectively.
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Figure 4.12: Quenching of tryptophan fluorescence by acrylamide at pH 7. A-D
emission spectra of PrP in the absence (solid line) and presence of 0.3 M acrylamide 
(dashed line). (A) PrP in solution and with (B) POPG vesicles, (C) DPPC/chol/SM 
vesicles, (D) POPC vesicles. The final protein and lipid concentrations were 5 |iM 
and 3 mM, respectively except for DPPC/chol/SM membranes where lipid 
concentration was 1 mM.
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and presence of 0.3 M acrylamide. For the quenching experiments the protein 
concentration was kept constant at 5 pM. At first inspection the results suggested 
that negatively charged membranes of POPG at both pH 5 and 7 and raft-like 
membranes of DPPC/chol/SM at pH 7, shielded the tryptophan residues of PrP from 
the aqueous quencher solution. Little or no protection appeared to occur with POPC 
membranes, in good agreement with the tryptophan results, which showed no 
significant binding of PrP to POPC membranes.
The fluorescence quenching data were quantitatively analysed according to 
the Stem-Volmer equation for collisional quenching (Equation 4.1). Figure 4.13 
shows the Stem-Volmer plots for acrylamide quenching of tryptophan fluorescence 
of PrP in the absence and presence of the different membrane systems at pH 7 and 5. 
Both protein in solution and in the presence of membranes exhibited linear Stem- 
Volmer plots, suggesting that both tryptophan residues (Trp99 and Trpl45) are 
equally accessible to the quencher (Lakowicz, 1983). The Stem-Volmer quenching 
constants (Ksv) were determined from the slopes of the Stem-Volmer plots and are 
presented in Table 4.2.
Table 4.2 Stern-Volmer quenching constants (Ksv) fo r SHaPrP (90-231) 
in solution and in the presence o f lipid membranesa
System pH Ksv(M-‘) X,max (nm)
PrP 7 5.78 347
5 7.31 347
PrP + POPG 7 2.58 336
5 1.87 333
PrP + DPPC/chol/SMA 7 3.46 343
PrP + POPC 7 5.79 346
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Figure 4.13: Stern-Volmer plots for the fluorescence quenching of SHaPrP 
(90-231) by acrylamide. Fluorescence quenching of PrP in solution at pH 7 (A, C 
& D) and pH 5 (B) (closed circles). (A) Fluorescence quenching in the presence of 
POPG vesicles, pH 7 (open triangles); (B) POPG vesicles, pH 5 (open squares); (C) 
DPPC/chol/SM mixed lipid vesicles, pH 7 (open diamonds) and (D) POPC vesicles, 
pH 7 (downward open triangles). Fluorescence emission spectra of PrP were 
recorded at 20 °C, using an excitation wavelength of 295 nm and the fluorescence 
intensities in the absence (Fo) and presence of acrylamide (F) were determined at the
-^max-
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“Lipid concentrations were 3 mM in 20 mM sodium phosphate buffer pH 7.2 or 20 
mM sodium acetate for pH 5.0 except for the mixed lipid vesicles were the lipid 
concentration was 1 mM. Protein concentration was 5 pM in 20 mM sodium acetate 
pH 5.5. ADPPC/chol/SM 50:30:20 molar ratio. cXmax for PrP in the presence of 0.3 
M acrylamide in solution and with the different lipid systems.
The extent of protection of the Trp residues from acrylamide quencher 
solution is reflected by the Stem-Volmer constants, which decrease when tryptophan 
residues are shielded from the aqueous environment. The Stem-Volmer constant 
indicated that tryptophan residues of PrP in solution at pH 5 are slightly more 
exposed to the aqueous environment compared to the protein at pH 7 (Table 4.2). 
Lower Stem-Volmer constants were derived from the plots of PrP with POPG 
membranes at pH 5 and 7 (Figure 4.13A,B & Table 4.2). This indicates that the 
tryptophan residues of PrP become less accessible to quenching by acrylamide upon 
binding and possibly partially inserting into the POPG lipid bilayer. Binding of PrP 
to raft-like membranes of DPPC/chol/SM, pH 7 produced an intermediate value for 
the Stem-Volmer constant, which still indicated an appreciable protection of the 
tryptophan residues from the quencher relative to protein in solution (Figure 4.13C 
& Table 4.2). Finally in the presence of POPC vesicles at pH 7 an equivalent degree 
of quenching is observed to that of PrP in solution, suggesting that the protein 
remained in the aqueous environment. The extent of protection from acrylamide 
paralleled the magnitude of the lipid-induced blue shifts.
4.4 Discussion
Intrinsic protein fluorescence is a very sensitive tool for monitoring binding 
of proteins and peptides to lipid membranes. In general, tryptophan residues buried
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within a hydrophobic milieu, such as that of lipid membranes exhibit, an increased 
fluorescence intensity and the positions of their emission maxima (^max) are blue 
shifted when compared with surface exposed tryptophan residues (Lakowicz, 1983). 
SHaPrP (90-231) has two tryptophan residues, Trp99 and Trpl45 (Figure 4.1), 
which are partially exposed on the protein surface. In this chapter the fluorescence 
emission of these two Trp residues is used to describe the binding of SHaPrP 
(90-231) to model lipid membrane systems containing a single type of lipid or 
mixtures of different lipids. The binding of PrP to lipid membranes was investigated 
at pH 7, to represent the pH surrounding the plasma membrane and pH 5, to model 
the acidic environment of endosomes. The plasma membrane and endocytic 
organelles have been proposed as relevant sites for PrPSc formation.
The Trp fluorescence results with SHaPrP (90-231), without the GPI anchor, 
shows that PrP binds to negatively charged membranes at both pH 5 and 7 and to 
gel-phase zwitterionic membranes at pH 7. Binding was also observed for raft-like 
membranes composed of DPPC, cholesterol and sphingomyelin (DPPC/chol/SM, 
50:30:20 molar ratio) at pH 7, but not at pH 5. No significant binding was observed 
for liquid-crystalline zwitterionic membranes of DOPC or POPC, nor their mixtures 
with cholesterol and sphingomyelin at pH 7 (Table 4.1 & Figure 4.6).
Like most GPI-anchored membrane proteins, PrP in living cells segregates 
into lipid rafts, which are rich in saturated fatty acid lipids, containing mainly 
phosphatidylcholine lipids, cholesterol and sphingomyelin (Vey et al., 1996; 
Naslavsky et al., 1997). Mixed membranes composed of DPPC, cholesterol and 
sphingomyelin have been shown to serve as good models of lipid rafts (Schroeder et 
al., 1994). Thus in the present study the interaction of PrP with DPPC/chol/SM was
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investigated. Tip fluorescence measurements show that PrP binds to raft-like 
membranes at pH 7 and indicates that a direct interaction of PrP with lipid 
membranes can not be excluded as an additional mode of attachment of PrP to the 
cell surface.
Trp fluorescence measurements in the presence of salt revealed that the 
binding of PrP to liquid-crystalline lipid bilayers composed of negatively charged 
lipids is a complex process that involves both electrostatic and hydrophobic lipid- 
protein interactions. The salt experiments demonstrated that shielding of charges on 
both the protein and membrane surface reduced the affinity of PrP for negatively 
charged membranes (Figure 4.7). These results suggest that electrostatic interactions 
between positively charged residues on the protein surface and negatively charged 
lipid headgroups on the membrane are likely to drive the initial binding of PrP to 
negatively charged membranes. Figure 4.14 shows the primary structure of SHaPrP 
(90-231). The charged amino acids are highlighted: blue for the positively charged 
amino acids lysine, arginine and histidine; red for the negatively charged amino 
acids aspartic acid and glutamic acid. The protein at both pH 5 and 7 is positively 
charged with a net charge at pH 5 of + 9 and at pH 7 of + 4. The difference in the 
charge at the two pHs is attributable to the protonation of the histidine residues (pKa 
is 6.5). Inspection of the distribution of charges on the protein surface revealed a 
cluster of positive charges at the amino-terminus of the protein (Figure 4.15). 
Therefore, one could speculate that the binding of PrP to negatively charged 
membranes is mediated by the binding of the positive face of PrP containing the 
amino-terminus and is driven primarily by electrostatic interactions between protein 
and membrane. This is in good agreement with studies that model PrP interactions 
with negatively charged membranes (Warwicker, 1997 & 1999). In this model the
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positively charged face of PrP that includes helix A has been proposed as the 
membrane binding face. In addition this model suggest that this particular 
orientation of PrP at the membrane surface might favour PrP-PrP interactions across 
the membrane surface and would involve the conserved non-polar domain of PrP. 
The membrane may therefore play a role in the polymerisation of PrP in vivo 
through biasing the orientation and conformation of the protein. The above model 
was based on the solution structure of mouse PrP residues 124-226. A more recent 
model of PrP-membrane interactions also shows the positively charged face of the 
protein oriented toward the membrane (Rudd et al., 2001). However, unlike the 
above study, this model was based on the solution structure of SHaPrP residues 
90-231 and also took in to consideration the GPI anchor and the N-linked sugars. 
This study proposed that the polar carboxyl terminus, which links the protein to the 
GPI anchor, makes very few non-covalent interactions with anchor. This provides 
the protein with considerable dynamic freedom relative to the membrane. This 
model also suggests that the N-linked sugars at Asnl81 and Asnl97 are flexible and 
as a result shield large surface areas of the protein. In general glycosylation 
increases the stability of proteins. The sugar residues may therefore protect PrPc by 
sterically hindering protein-protein interactions that occur during the conversion to 
PrPSc.
The inability of salt to displace PrP from negatively charged membranes 
suggest the involvement of additional hydrophobic lipid-protein interactions 
following the initial charge driven binding (Figure 4.8).
121
Glv-Gln91-Glv-Glv-Glv-Thr-His-Asn-Gln-Trp-Asn-Lvs101-Pro-Ser-Lys-
Prn-Lys-Thr-Asn-Met-Lvs-His111-Met-Ala-GIv-Ala-Ala-Ala-Ala-Gly-Ala-
Vall21-Val-GIy-Gly-Leu-Gly-Gly-Tyr-Met-Leu-Gly131-Ser-Ala-Met-Ser-Arg-
S1P ro-M et-M et-His-______________
Phe,41-Gly-Asn-Asp-Trp-Glu-Asp-Arg-Tyr-Tyr-Arg151-Glu-Asn-Met-Asn-Arg-
Helix A
Tvr-Pro-Asn-Gln-Val161-Tyr-Tyr-Arg-Pro-Val-Asp-Gln-Tyr-Asn-Asnm -Gln-
S2
A«in-Asn-Phe-Val-His-Asp-Cvs-Val-Asn181-Ile-Thr-Ile-Lvs-Gln-His-Thr-Val-
Helix B
Thr-Thr191-Thr-Thr-Lys-Gly-Glu-Asn-Phe-Thr-Glu-Thr201-Asp-Ue-Lys-Ile-
Met-GIu-Arg-Val-Val-Glu2U-Gln-Met-Cys-Thr-Thr-Gln-Tyr-Gln-Lys-GIu221-
Helix C
Ser-GIn-Ala-Tyr-Tyr-Asp-Gly-Arg-Arg-Ser231
Figure 4.14: Amino acid sequence of SHaPrP (90-231). The secondary structural 
components are underlined ( = ) ;  helix A consists of residues 144-156, B 172-193 
and C 200-227. Beta strands ( =  ); SI consists of residues 128-131 and S2 
161-164. The positively charged amino acids are shown in blue, negatively charged 
are in red, polar residues are in green and the remaining are the hydrophobic amino 
acids. The histidine residues are shown in blue and underlined, as they are only 
positively charged at pH 6.5 or below. Sequence was obtained from the protein 
database (PDB) reference 1 BIO.
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Figure 4.15: Different representations of the three-dimensional structure of 
SHaPrP (90-231). (A) Worm representation of the NMR structure of SHaPrP 
(90-231) indicating the amino- and carboxyl-termini. (B-E) Surface views of 
SHaPrP (90-231) coloured according to the electrostatic potential (Nicholls et al., 
1991), with blue for positive charges and red for negative charges. B shows the 
surface potential at pH 7, with the same orientation as A. View C shows the same 
orientation as B after 180° rotation about a vertical axis. D and E are equivalent 
orientations as B and C, respectively but for PrP at pH 5.
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The degree of protection of the Trp residues from acrylamide quenching was 
investigated and these experiments were performed with PrP in the lipid-free and 
lipid-bound states. The acrylamide quenching results revealed a higher Stern- 
Volmer constant for PrP in solution at pH 5 than at pH 7 (Table 4.2), which suggests 
a greater exposure of the Trp residues at pH 5 due to a more open structure. The 
higher charged state at pH 5 can lead to a more open structure due to electrostatic 
repulsions between the ionized groups on the surface of the protein. Such repulsions 
would be minimized in the partially unfolded state and this in turn exposes 
hydrophobic patches onto the protein surface. ANS binding measurements have 
demonstrated the exposure of hydrophobic patches on the surface of PrP at acidic 
pHs (Swietnicki et al„ 1997).
Binding of PrP to negatively charged lipid membranes of POPG at both pH 5 
and 7 resulted in a large blue shift of the Xmax of PrP, indicating a less polar 
environment of the Trp residues of PrP when bound to POPG membranes (Table 4.1 
& Figure 4.6). Binding of PrP to POPG membranes at pH 5 and 7 also resulted in 
lower Stem-Volmer constants, which suggests that the Trp residues were shielded 
from acrylamide quenching in the presence of POPG membranes (Table 4.2). A 
larger blue shift and higher degree of protection was observed with POPG 
membranes at pH 5 than at pH 7. These observations can be correlated with the 
enhanced positively charged surface at pH 5 and the increased exposure of 
hydrophobic patches at the acidic pH, which in turn may lead to a deeper insertion of 
the hydrophobic amino acids of PrP in POPG membranes.
Binding of PrP to zwitterionic membranes in the gel-phase and raft-like 
membranes of DPPC, cholesterol and sphingomyelin at pH 7 resulted in a blue shift
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of the A-max of PrP (Table 4.1 & Figure 4.6). An intermediate protection to 
acrylamide quenching was observed for the raft-like membranes at pH 7, which 
suggests a different orientation of PrP in the mixed membranes relative to the 
orientation in POPG membranes. At pH 5 PrP displays little or no binding to the 
raft-like membranes of DPPC/chol/SM. At this pH PrP has a greater net positive 
charge than the protein at pH 7. The binding of peptides and proteins to lipid 
membranes depends on the balance between hydrophobic and electrostatic 
interactions, and other bilayer effects such as curvature, fluidity of the membrane 
and on the conformational states available to the peptide or protein. Thermodynamic 
studies with peptides have shown that the transfer of positively charged peptides 
from the aqueous phase to the interface of zwitterionic membranes is energetically 
unfavourable (White & Wimley, 1998). This observation may explain the lack of 
binding of PrP to raft-like membranes at pH 5. At neutral pH the net charge of PrP 
is smaller implying that charge interactions were unlikely to drive the binding of PrP 
to gel-phase zwitterionic membranes and raft-like membranes. To further 
investigate the nature of PrP-DPPC/chol/SM interactions, binding was carried out in 
the presence of salt. In contrast, to POPG membranes, where the binding of PrP was 
significantly diminished in the presence of salt, binding of PrP to raft-like 
membranes of DPPC/chol/SM was not affected by addition of salt (Figure 4.9). 
Furthermore, addition of salt to pre-existing lipid-protein complexes failed to 
displace the protein from the lipid membranes (Figure 4.10). These findings suggest 
that the partitioning of PrP into gel-phase zwitterionic membranes of DPPC and raft- 
like membranes at pH 7 involve primarily hydrophobic lipid-protein interactions. 
Therefore, the binding of PrP to raft-like membranes probably involves hydrophobic 
surfaces of PrP.
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No binding was detected between PrP and liquid-crystalline zwitterionic 
membranes of POPC, DOPC and DOPC/chol (70:30 molar ratio) and 
DOPC/chol/SM (50:25:25 molar ratio) membranes at pH 5 and 7 (Table 4.1). 
Binding of PrP to zwitterionic lipids in the gel-crystalline phase and not in the liquid 
crystalline phase suggests that factors other than specific molecular recognition of 
the lipid headgroup structure by PrP regulates binding. Thus implying that other 
physical properties of zwitterionic membranes such as vesicle curvature, lateral 
pressure and fluidity may determine binding.
In summary, the binding studies of SHaPrP (90-231) to model lipid 
membranes show that: (a) PrP binds to negatively charged lipids at both pH 7 and 
pH 5. A larger blue shift in the X,max was observed at pH 5; (b) addition of liquid- 
crystalline zwitterionic membranes of POPC, DOPC and its mixtures with 
cholesterol and cholesterol plus sphingomyelin did not result in any measurable 
spectral changes, which suggests that PrP does not interact with these lipid 
membranes; (c) PrP was found to bind to gel-phase membranes of DPPC and raft­
like membranes composed of DPPC, cholesterol and sphingomyelin at pH 7 and (d) 
no interaction between PrP and the raft-like membranes of DPPC/chol/SM was 
detected at pH 5.
Combining the Trp fluorescence with the acrylamide quenching results a 
model for the binding of PrP to lipid membranes is proposed in Figure 4.16. In this 
model, PrP in solution at pH 5 and pH 7 is represented as two different starting states 
with PrP at pH 5 having a more open structure that exposes hydrophobic surfaces. 
The binding of PrP to negatively charged membranes is driven by electrostatic lipid- 
protein interactions. Once bound at the lipid-water interface PrP undergoes a
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(A) Negatively Charged Membranes
Hydrocarbon Core
Interface
(B) Zwitterionic and Raft-like Membranes
Hydrocarbon Core
Interface
Figure 4.16: Schematic model for PrP-lipid interactions. PrP at pH 5 has a more 
open structure than at pH 7. (A) Binding to negatively charged membranes.
Electrostatic lipid-protein interactions drive PrP to the lipid-water interface. Once 
bound to the surface of negatively charged membranes, PrP undergoes a 
conformational change, which would permit the exposure of hydrophobic residues 
and these would preferably insert into the lipid bilayer. PrP at pH 5 is more buried 
within the lipid bilayer than at pH 7. (B) Binding to zwitterionic lipids in the gel- 
phase and raft-like membranes composed of DPPC/chol/SM. At pH 7 hydrophobic 
lipid-protein interactions drive the protein to the lipid-water interface where PrP 
undergoes a conformational transition. No membrane interaction was detected with 
raft-like membranes at pH 5.
127
conformational change, whereby hydrophobic amino acids, normally buried within 
the protein become exposed. The exposed hydrophobic residues can partially insert 
into the lipid bilayer. The greater blue shift of the Xmax for PrP and the higher 
protection to acrylamide quenching for PrP with POPG membranes at pH 5 point to 
a deeper insertion of the protein in these membranes at pH 5 relative to the inserted 
state at pH 7. Figure 4.16A highlights differences for the binding of PrP to 
negatively charged membranes at pH 5 and 7.
A tentative model for binding of PrP to gel-phase zwitterionic and raft-like 
membranes composed of DPPC/chol/SM at pH 7 is shown in Figure 4.16B. The 
binding of PrP to these membranes is driven by hydrophobic lipid-protein 
interactions. In this model a different orientation of PrP to that illustrated in the 
binding to negatively membranes is proposed. In this orientation, PrP binds to the 
gel-phase zwitterionic membranes and the raft-like membranes though a 
hydrophobic face of the protein resulting in a conformational transition at the lipid- 
water interface. The intermediate protection of PrP from acrylamide quenching, 
when bound to the raft-like membranes at pH 7, suggests that the protein is not as 
buried in the raft-like membranes as when bound to POPG membranes at both pH 5 
and pH 7. At pH 5 PrP does not interact with the raft-like membranes and remains 
in the aqueous environment.
4.5 Conclusions
The Trp fluorescence results shows that PrP binds to negatively charged lipid 
membranes at both pH 5 and 7, gel-phase zwitterionic lipids and to raft-like 
membranes composed of DPPC/chol/SM at pH 7. This finding is of particular 
importance since PrP in cells is localised within cholesterol and sphingomyelin rich
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raft domains. Electrostatic lipid-protein interactions are involved in the initial 
binding of PrP to the surface of negatively charged membranes and hydrophobic 
lipid-protein interactions occur after the initial charge driven binding. Binding of 
PrP to gel-phase zwitterionic membranes and raft-like membranes is driven by 
hydrophobic lipid-protein interactions. Acrylamide quenching of the Trp 
fluorescence revealed a high degree of protection of PrP when bound to negatively 
charged membranes at pH 5 and 7, indicating partial insertion into the lipid bilayer. 
In addition the Trp fluorescence blue shift and protection from acrylamide quenching 
indicate that PrP when bound to negatively membranes is more buried within the 
lipid bilayer at pH 5 than at pH 7. The intermediate protection of PrP from 
acrylamide quenching when bound to raft-like membranes indicates that the protein 
is not as buried in these membranes as with negatively charged membranes.
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Chapter 5: Secondary Structural Changes in Syrian
Hamster Prion Protein (SHaPrP) Residues 90-231 Upon 
Binding to Lipid Membranes
5.1 Introduction
In Chapter 4 the interaction of PrP with various lipid membranes was 
investigated. The fluorescence binding data suggests that PrP undergoes a 
conformational change upon association with negatively charged membranes at pH 5 
and 7, zwitterionic membranes in the gel-crystalline phase and raft-like membranes 
composed of DPPC, cholesterol and sphingomyelin at pH 7. In this chapter changes 
in PrP secondary structure upon interaction with lipid membranes was investigated 
by circular dichroism (CD) and attenuated total reflection Fourier transform infrared 
(ATR FTIR) spectroscopy. Negative-stain electron microscopy was employed to 
examine the morphology of the lipid-PrP complexes.
Although CD and FTIR fail to establish the precise three-dimensional 
location of individual elements they do provide a global insight into the overall 
secondary structure of proteins and are particularly useful in probing structural 
changes induced by events such as membrane and ligand binding. Both techniques 
are extremely useful in providing an alternative or as a complement to X-ray 
crystallography or nuclear magnetic resonance (NMR) spectroscopy and are widely 
used in the study of membrane proteins where high-resolution studies are not always 
feasible.
Far-UV CD provides information on the backbone of proteins. The common 
types of secondary structures adopted by proteins and peptides have distinctive CD 
spectra. The CD spectra of proteins which have more than one type of structure can
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be defined as a linear combination of CD spectra of each contributing secondary 
structural element (e.g. pure a-helix, pure (i-strand) weighed by its abundance in the 
polypeptide chain. Optical artifacts of light scattering and absorption flattening due 
to lipid-protein complexes can sometimes cause distortions in the CD spectra of 
membrane proteins.
The light scattering problems often experienced in CD spectroscopy are 
virtually non-existent with IR techniques because of the long IR wavelengths 
(Goormaghtigh et al., 1999). Furthermore, most lipids do not interfere with the 
protein IR signal, making this an attractive technique for the study of membrane 
proteins. The development of Fourier transform spectrophotometers offers the 
advantage of high sensitivity, resolution and speed of data acquisition. All 
wavelengths are detected and measured simultaneously and subsequently decoded by 
Fourier transformation. Fourier transform infrared spectroscopy represents a 
powerful tool to investigate proteins and lipids together, and thus, it is a very useful 
technique for studying protein structure in a membrane environment. Secondary 
structural information can be obtained by applying a mathematical approach to the 
analysis of the FTIR spectra of proteins and peptides.
Sampling techniques other than transmission are commonly used in FTIR 
studies. Here attenuated total reflection (ATR) was employed to characterise the 
secondary structure of PrP in lipid membranes at pH 5 and 7. In this technique, the 
secondary structure of proteins in a membrane environment is determined from thin 
hydrated films of lipid-protein complexes. A major advantage of ATR FTIR over 
conventional transmission technique is that absorption by water molecules is
131
strongly reduced, as a consequence small amounts of material are required (typically 
10 pg of protein). Other advantages include the analysis of highly turbid samples 
and possibility of determining the orientation of the secondary structures for 
membrane proteins with respect to the bilayer plane (Goormaghtigh et al., 1990, 
1999).
5.2 Materials and Methods
5.2.1 Materials
POPG, POPC, sphingomyelin and cholesterol were purchased from Avanti 
Polar lipids (Birmingham, AL). DPPC was obtained from Sigma-Aldrich (Poole, 
UK). All other chemicals were obtained from Sigma-Aldrich (Poole, UK) unless 
otherwise stated.
5.2.2 Lipid vesicles
Small unilamellar vesicles were prepared as described in Chapter 4; section
4.2.2.
5.2.3 Circular dichroism
Lipid-protein samples were prepared by mixing one part of a 15 pM stock 
PrP protein solution in 20 mM sodium acetate buffer, pH 5.5 to an equal volume of 
lipid vesicles prepared in 20 mM sodium phosphate buffer, pH 7.2 or 20 mM sodium 
acetate, pH 5.0. This resulted in a final pH of the lipid-protein samples ~ 6.9 and ~ 
5.2, respectively. The samples were mixed thoroughly and equilibrated for 2-3 
minutes before recording the far-UV (185-260 nm) CD spectra on a JASCO J-715 
spectropolarimeter using 1 mm pathlength quartz cells. Typically, a scanning rate of
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100 nm/min, a time constant of 1 s, and a bandwidth of 1.0 nm were used. Spectra 
were measured at 20 ± 0.2 °C, with a resolution of 0.5 and 16 scans were averaged 
per spectrum. The corresponding backgrounds (buffer for protein solutions or lipid 
alone) were subtracted from the protein spectra.
5.2.4 Sample preparation for ATR FTIR measurements
Samples were prepared by mixing PrP with the desired lipid in 5 mM sodium 
phosphate, pH 7.2 or 5 mM MES, pH 5.0 to final concentrations of 4 mM lipid and 
24 pM protein. The presence of-COOH containing molecules (e.g., acetate, EDTA, 
TFA) must be avoided because they absorb in the same region as proteins and 
therefore would interfere with the protein signal. For this reason buffers containing 
acetate were substituted. PrP was stored in 20 mM sodium acetate buffer at pH 5.5 
an aliquot was dialysed against 20 mM sodium phosphate, pH 5.7. This resulted in a 
final pH of the lipid-protein samples ~ 7.0 and ~ 5.3, respectively. The lipid-protein 
complexes were incubated for 2-3 minutes and an aliquot of 50 pL in total was 
applied to an 80 x 10 x 4 mm germanium (Ge) plate (Pike Technologies, Madison, 
Wisconsin, USA). Thin films were obtained by slow evaporation of the deposited 
sample under a stream of nitrogen. This procedure results in the formation of 
oriented lipid multilayers on the surface of the Ge plate (Fringeli & Gunthard, 1981; 
Goormaghtigh et al., 1999). A schematic representation of the ATR set-up is shown 
in Figure 5.1. Protein films of PrP without lipid were also prepared in a similar 
manner from their buffer solutions. Typically, films contained 20 pg protein and ~ 
154 pg lipid. Lipid-to-protein molar ratio was 167:1.
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Figure 5.1: Schematic representation of the ATR set-up. The infrared beam is 
directed into a high refractive index medium, which is transparent for the IR 
radiation of interest. Germanium (Ge) was used as the internal reflection element for 
these experiments. The incident beam makes an angle 0 with respect to the normal 
to the Ge surface. Above a critical angle, 0C the light beam is completely reflected 
when it impinges on the surface of the Ge plate. Several internal total reflections 
occur within the Ge plate until the beam reaches the end. At each reflection, the 
beam penetrates the surface of the sample to a depth of a few pm. The intensity of 
the beam is attenuated according to the absorption characteristics of the sample, so 
enabling an absorption spectrum to be recorded (Fringeli & Giinthard, 1981; 
Goormaghtigh et al., 1999).
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In between each sample the Ge plate was cleaned with detergent and then 
rinsed with tap water followed by de-ionised water. The Ge plate was placed in a 
shallow glass vessel containing methanol and then transferred to one containing 
chloroform, after which the Ge plate was wiped with soft tissue paper 
(Goormaghtigh et al., 1999).
5.2.5 ATR FTIR measurements
ATR FTIR spectra were recorded on a Bruker Vector 22 infrared 
spectrophotometer equipped with a triglycine sulphate detector (TGS). Spectra were 
recorded with the Ge plate in a horizontal ATR configuration with an incidence 
angle of 45°, yielding 10 internal reflections. The spectrophotometer was 
continuously purged with N2 to remove spectral contributions of atmospheric water 
vapour. Background spectra of the clean germanium plate were recorded prior to 
collecting sample spectra and the correction was done automatically after sample 
measurement was completed. Each spectrum was an average of 256 scans and all 
spectra were recorded with a nominal resolution of 2 cm-1. Measurements were 
performed at room temperature. Spectra of the corresponding lipid backgrounds 
were also recorded. Atmospheric water spectrum was measured in the absence of a 
protein film on the Ge plate. The background was collected with the sample 
compartment purged with N2 and the sample spectrum was acquired with a non- 
purged sample chamber, the resulting spectrum of atmospheric water was obtained.
5.2.6 Analysis o f FTIR spectra
The infrared spectra of proteins and peptides exhibit nine characteristic 
amide bands, which represent different vibrations of the peptide group. Amide I
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(1600-1700 cm-1) and amide II (1500-1580 cm '1) bands are the two predominant 
bands of the IR spectra of proteins and peptides. The amide I band is the most 
widely used in secondary structural studies of proteins. Amide I is composed mainly 
(80 %) of C=0 stretching (v) vibration of the peptide group coupled to the in-plane 
bending of the N-H bond and the stretching of the C-N bond (Goormaghtigh et al., 
1994).
Using synthetic polypeptides it was shown that this band was conformation 
sensitive, the a-helical structure having a maximum near 1655 cm-1 and the (5-sheet 
structure having a maximum around 1630 cm-1 (Goormaghtigh et al., 1994). 
However, the strong overlap of the different secondary structural components such 
as a-helices, P-sheets, turns, and non-ordered structures usually results in a broad 
featureless amide I band. The different structural elements can be separated by the 
use of resolution enhancement methods such as Fourier self-deconvolution 
(Goormaghtigh et al., 1990).
Prior to analysis the FTIR spectra were corrected for the following:
• Subtraction of water vapour from the traces: Even though the sample 
chamber was continually purged with N2, spectral contributions of atmospheric 
water were still present. The removal of traces of water vapour was carried out 
using OPUS software version 3 (Bruker) in an interactive mode. Water absorbance 
bands were subtracted from the protein spectra in the region between 1800-1400
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• Baseline correction: Straight baselines were passed through each spectra in 
the 1800-1400 cm-1 region using OPUS software version 3 (Bruker) in an 
interactive mode.
Two approaches were employed to analyse the FTIR data:
• Difference spectroscopy: This method has been used to report on the 
relative changes in the secondary structure of proteins, as conditions are changed 
(Gray & Tamm, 1997, 1998; Raussens et al., 1999). In this case difference 
spectroscopy was used to determine the secondary structural changes in PrP upon 
binding to lipid membranes.
The spectra were rescaled to a constant amide I area computed between 1711 
to 1584 cm-1. Peak integration of the amide I region was performed with OPUS 
software version 3 (Bruker). The difference spectra of PrP associated to lipid 
membranes minus PrP in solution were calculated using Igor (Wavemetrics, Lake 
Oswego, Oregon).
• Fourier self-deconvolution: Fourier self-deconvolution was applied to 
increase the resolution of the spectra in the amide I region. The resolution 
enhancement that results from the deconvolution highlights the different structural 
components by decreasing the widths of the infrared bands, allowing for increased 
separation and thus better identification of the overlapping component bands. 
Fourier self-deconvolution was carried out using software written by Dr Erik 
Goormaghtigh at the Université Libre de Bruxelles, Belgium. The self­
deconvolution was carried out using a Lorentzian line shape for the deconvolution 
and a Gaussian line shape for the apodization, as described by Kauppinen et al.
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(1981). The input parameters for deconvolution and apodization were chosen 
according to work described by Goormaghtigh et al. (1990). It is essential that the 
parameters chosen do not lead to an under or over estimation of the secondary 
structural components. The parameters chosen were 30 cm-1 full-width at half- 
height Lorentzian line shape and a Gaussian line shape with a full-width at half­
height of 15 cm-1 for apodization this resulted in a resolution enhancement factor 
(K) of 2. K is defined as the ratio of full-width at half-height of the deconvoluting 
Lorentzian to the full-width at half-height of the Gaussian used for apodization.
Table 5.1 shows the frequency limits for the commonly occurring structures 
in proteins. The frequency limits were used as guidelines for assigning the structural 
components of PrP. The amide I band positions are often good indicators of 
secondary structures in a large number of proteins, however there are some 
exceptions. For example a-helical structures normally absorb in the 1661-1648 
cm-1 region, but some helical structures have been found to absorb in the 1630-1640 
cm-1, region which is normally assigned to [3-sheet structure (Heimburg et al., 1996).
Table 5.1: Assignment o f the IR frequency regions for the different secondary 
structures in proteinsa
Structure Frequency Region 
(cm-1)
a-helix 1661-1648
P-sheetA 1689-1682
1638-1628
Low-frequency P-sheetc 1628-1615
p-tums 1682-1661
Random 1645-1638
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°Cabiaux et al., 1989. Ap-sheet structure is characterised by two absorption bands 
between 1689-1682 cm-1 and 1638-1628 cm-1. cFor this study the distinction 
between p-sheet and low-frequency P-sheet (LF p-sheet) structure is made since the 
latter has been found to be associated with the formation of intermolecular hydrogen 
bonding in monomer-monomer interaction and is usually observed with protein 
aggregation and gel formation (Jackson & Mantsch, 1991; Goormaghtigh et al., 
1994). This is of particular significance in the present study, since structural 
analysis of amyloid fibrils have revealed the importance of intermolecular hydrogen 
bonding between the polypeptide backbone (Sunde et al., 1997; Liu et al., 2000).
5.2.7 Electron microscopy
Protein and vesicles-protein samples, prepared as described for FTIR 
experiments were diluted to a concentration of 0.050 mg/mL, applied to electron 
microscope grids coated with carbon film and stained with 2 % uranyl acetate. The 
preparations were examined using a Philips CM 120 electron microscope with an 
accelerated voltage of 100 kV. Electron micrographs were taken at a magnification 
of x 45 000 under low dose conditions. Electron microscopy was performed by Dr 
Catherine Venien-Bryan at the University of Oxford.
5.3 Results
5.3.1 Circular dichroism spectroscopy
The far-UV CD spectrum of SHaPrP (90-231) in solution at pH 7 and 5 
showed a double minimum at approximately 208 and 222 nm with molar ellipticity 
per residue values o f-9324 and -8597 deg cm2 dmol-1, respectively, for PrP at pH 7 
and -8486 and -8560 deg cm2 dmol-1 for PrP at pH 5 (Figure 5.2 & 5.3). The
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Figure 5.2: Far-UV CD spectra of SHaPrP (90-231) in solution and with lipid 
membranes at pH 7. Spectra of PrP in solution (solid line) and in the presence of 
lipid membranes (dashed line): (A) POPG, (B) DPPC/chol/SM (50:30:20 molar 
ratio), (C) DPPC and (D) POPC. Measurements were carried out at 20 °C on 
samples containing 7.5 jiM protein and 1 mM lipid.
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Figure 5.3: Far-UV CD spectra of SHaPrP (90-231) in solution and with lipid 
membranes at pH 5. Spectra of PrP in solution (solid line) and in the presence of 
lipid membranes (dashed line): (A) POPG, (B) DPPC/chol/SM (50:30:20 molar 
ratio) and (C) POPC. Measurements were carried out at 20 °C on samples 
containing 7.5 pM protein and 1 mM lipid.
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results are indicative of a protein containing mainly a-helical structure. This is in 
good agreement with published CD spectra (Mehlhom et al., 1996; Zhang el al., 
1997) and the NMR structure of SHaPrP (90-231) (James et al., 1997) which shows 
a mainly a-helical (44 %) protein with a small amount of P-sheet (4 %) structure.
Binding of PrP to negatively charged membranes of POPG at pH 5 and 7 
induced a spectral change in the shape of the CD spectra. Less pronounced bands at 
208 and 222 nm were observed and a single minimum at about 220 nm was detected 
(Figure 5.2A & 5.3A). The minimum was also more defined for PrP in POPG 
membranes at pH 5 compared to pH 7. The spectral changes suggest that binding of 
PrP to negatively charged membranes results in an increase in the P-sheet structure.
Incubation of PrP with liquid-crystalline zwitterionic membranes of POPC at 
pH 7 and 5 and raft-like membranes of DPPC/chol/SM at pH 5 showed no 
measurable change in the far-UV CD spectra of PrP (Figure 5.2D & 5.3B,C). These 
results are consistent with the absence of lipid-protein interactions as revealed by the 
Trp fluorescence binding data. In contrast, binding of PrP to gel-phase zwitterionic 
membranes of DPPC and its mixtures with cholesterol and sphingomyelin at pH 7 
was accompanied by changes in the far-UV CD spectra (Figure 5.2B,C). An 
increase in the negative ellipticity at 208 and 222 nm was observed, which suggests 
an increase in the a-helical structure of PrP upon binding to DPPC and raft-like 
membranes at pH 7.
5.3.2 ATR FTIR spectroscopy
ATR FTIR has been successfully used to investigate the structure of soluble 
and membrane proteins. FTIR relies on the analysis of the vibration bands of
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proteins and particularly on the amide I band (vC=0 of the peptide bond) whose 
frequency of absorption is dependent upon the secondary structure.
The FTIR spectra of PrP in the absence and presence of different lipid 
membranes are presented in Figure 5.4. The amide I and amide II bands arising 
from the protein peptide group can be seen between 1700-1600 cm-1 and 
1580-1510 cm-1, respectively. The band at 1770-1705 cm-1 is due to the lipid 
carbonyl stretching vibration (vC=0).
The FTIR spectrum of PrP in solution at pH 5 exhibited an amide I band with 
maximum absorption at about 1657 cm-1, which indicated the main component of 
the secondary structure to be a-helical. The spectra of PrP at pH 7 revealed a 
broader amide I band centred around 1654 cm-1 again suggesting the presence of a- 
helical structure. A shoulder at ~ 1631 cm-1 was also observed for protein at pH 5 
and 7 and reflected the presence of some (3-sheet structure (Figure 5.4).
The FTIR spectra for PrP associated to POPG membranes at pH 5 and 7 
showed an amide I band with maximum absorption at ~ 1657 and 1654 cm-1, 
respectively, which suggested the presence of significant amount a-helical structure. 
The band at 1631 cm-1 observed for PrP in solution is more defined upon association 
with POPG membranes at both pH 5 and 7, which indicates that the association of 
PrP with negatively charged membranes is accompanied by an increase in (3-sheet 
structure (Figure 5.4A,B). In contrast, incubation with gel-phase zwitterionic 
membranes of DPPC and raft-like membranes composed of DPPC/chol/SM at pH 7 
resulted in a more symmetrical and less broad amide I band with maximum 
absorption at ~ 1654 cm-1, which suggests that a-helical structure is more prominent
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Figure 5.4: FTIR spectra of SHaPrP (90-231) in absence and presence of lipid 
membranes. PrP in the absence of lipid at (A) pH 5 and (B-D) pH 7 (solid line). 
PrP bound to lipid vesicles (dashed line): (A) POPG, pH 5, (B) POPG, pH 7, (C) 
DPPC, pH 7 and (D) DPPC/chol/SM (50:30:20 molar ratio), pH 7. The amide I, 
amide II and the lipid carbonyl stretching band are indicated. The amide I region has 
been normalized to a constant area. Spectra were recorded with a 2 cm-1 resolution 
and 256 scans were averaged for each spectrum.
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in PrP with these membranes. Furthermore, the disappearance of the shoulder at 
1631 cm-1 suggests a reduction in the P-sheet structure of the protein upon binding 
to DPPC and raft-like membranes at pH 7 (Figure 5.4C,D).
While the position of the amide I band initially revealed the dominant 
structures that were present in PrP further structural details were obscured by 
overlapping of the several spectral components associated with the different 
secondary structural elements. Fourier self-deconvolution was employed to resolve 
these overlapping spectral bands. The amide I region of the infrared spectrum of PrP 
and deconvoluted spectra of the corresponding traces are presented in Figures 5.5 & 
5.6. Protein in the absence of lipid at pH 5 and 7 now clearly revealed three distinct 
components: the 1657 cm-1 main band assigned to a-helix and the 1628 cm '1 
corresponding to low-frequency p-sheet structure, and the small component at 1692 
cm '1, tentatively assigned to the high frequency component of the p-sheet structure 
(Figure 5.5B,D & 5.6B,D). The positions of the p-sheet absorption bands matches 
well the absorption bands of known anti-parallel p-sheet polypeptides 
(Goormaghtigh et al., 1994) and indicate that the p-strands are in an anti-parallel 
configuration as seen in the NMR structure (James et al., 1997). The shoulder at 
1677 cm-1 indicates the presence of P-turns.
PrP with negatively charged membranes composed of POPG at pH 5 and 7 
exhibits an a-helical band at ~ 1657 cm-1, bands at ~ 1627 and ~ 1692 cm-1 assigned 
to low-frequency p-sheet structure and a P-tum band at ~ 1677 cm-1 (Figure 
5.5B,D). The band at ~ 1627 cm-1 is more defined and intense than that observed in 
solution, which confirmed the earlier indication suggesting an increase in low- 
frequency P-sheet structure of PrP upon binding to POPG membranes.
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Figure 5.5: Normalized amide I region of the FTIR spectra of SHaPrP (90-231) 
in the absence and presence of POPG membranes. A and C are original spectra 
of PrP in the absence of lipid at (A) pH 5 and (C) pH 7 (dashed line) and bound to 
POPG membranes at pH 5 (A) and (C) pH 7 (solid line). (B) and (D) Same spectra 
as A and C after Fourier self-deconvolution. Spectra have been deconvoluted with a 
resolution enhancement factor, K=2 (see Materials and Methods section 5.2.6).
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The deconvoluted amide I band of PrP in the presence of DPPC membranes 
and its mixtures with cholesterol and sphingomyelin at pH 7 revealed bands at ~ 
1654, 1627, 1693 and 1677 cm-1 which were assigned to a-helix, low-frequency P- 
sheet and P-tums structures, respectively (Figure 5.6B,D). The band assigned to the 
low-frequency P-sheet structure was not as prominent as that in the presence of 
POPG vesicles and PrP in solution (Figure 5.5B,D and 5.6B,D) which suggested a 
decrease in p-sheet structure in PrP upon binding to DPPC and raft-like membranes 
at pH 7.
Valuable information on relative changes in the secondary structure of 
proteins as the environment changes may be obtained through difference 
spectroscopy. Difference spectra were calculated from the recorded FTIR spectra in 
the amide I region. Before subtraction the FTIR spectra were rescaled to a constant 
amide I area. Figure 5.7A shows the difference spectra of PrP in the presence of 
POPG membranes at pH 5 and 7 minus PrP in the absence of lipid at the 
corresponding pH. Positive deviations at ~ 1656 and ~ 1626 cm-1 were detected and 
imply that PrP exhibits greater intensity at these frequencies in the presence of 
POPG membranes at both pH 5 and 7. The results suggest that binding of PrP to 
negatively charged membranes induce a-helical and low-frequency P-sheet 
structures. The magnitude of the observed changes suggests that PrP bound to 
POPG membranes at pH 7 has a greater amount of a-helical structure compared to 
pH 5.
The difference spectra of PrP in the presence of DPPC and raft-like 
membranes of DPPC/chol/SM at pH 7 produced a spectra with positive deviations at
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Figure 5.6: Normalized amide I region of the FTIR spectra of SHaPrP (90-231) 
in the absence and presence of DPPC and raft-like membranes. (A) and (C) are
original spectra of PrP in the absence of lipid at pH 7 (dashed line) and bound to (A) 
DPPC membranes at pH 7 and (C) raft-like membranes of DPPC/chol/SM at pH 7 
(solid line). (B) and (D) Same spectra as A and C after Fourier self-deconvolution. 
Spectra have been deconvolved with a resolution enhancement factor, K=2 (see 
Materials and Methods section 5.2.6).
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Figure 5.7: FTIR difference spectra in the amide I region of SHaPrP (90—231).
Difference spectra PrP bound to lipid membranes minus PrP in the absence of lipid
(A) PrP bound to POPG vesicles, pH 5 (dash-dot-dot line) and at pH 7 (dotted line).
(B) PrP bound to DPPC vesicles, pH 7 (dashed line) and DPPC/chol/SM (50:30:20 
molar ratio), pH 7 (dotted line).
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~ 1657 cm_l(Figure 5.7B). An additional negative absorption band at ~ 1626 cm-1, 
was also detected with DPPC membranes. The prominent positive band at 1657 
cm-1 indicates that PrP contains a larger fraction of a-helical structure when 
associated to DPPC membranes and the raft-like membranes at pH 7 compared to 
protein in solution. The negative intensity at 1626 cm '1 observed with DPPC 
membranes suggests a decrease in low-frequency p-sheet structure.
5.3.3 Structural changes monitored over time
The FTIR samples were incubated at 20 °C for up to 18 days and monitored 
for further structural changes. The amide I region of the FTIR spectra of PrP 
incubated with lipid membranes are displayed in Figure 5.8. The shape of the amide 
I band remained virtually unaltered upon incubation with DPPC and raft-like 
membranes of DPPC/chol/SM at pH 7. The a-helical component at ~ 1657 cm-1 
still dominated the amide I band, which suggests that gel-phase zwitterionic 
membranes of DPPC and rafit-like membranes of DPPC/chol/SM at pH 7 induces a 
stable a-helical conformation of PrP. A slight increase in the intensity at ~ 1626 
cm-1 with POPG membranes at pH 5 and 7 was observed and suggests a further 
increase in the low-frequency p-sheet structure in PrP upon incubation with 
negatively charged membranes.
5.3.4 Electron microscopy
The incubated lipid-PrP samples and protein in solution were also examined 
using negative-stain electron microscopy. The electron micrographs of PrP in
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Figure 5.8: Structural changes of SHaPrP (90-231) in the absence and presence 
of lipid membranes following incubation at 20 °C. PrP in the absence of lipid at 
(A) pH 5 and (B) pH 7. PrP bound to (C) POPG membranes at pH 5, (D) POPG 
membranes at pH 7, (E) DPPC membranes at pH 7 and (F) DPPC/chol/SM mixed 
membranes at pH 7. The samples were incubated at 20 °C.
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solution, both at pH 7 and 5 following incubation at 20 °C for 18-days, showed small 
uniform round aggregates, which were larger at pH 5 ~ 11.3 ± 1.8 nm (Figure 5.9A 
& B). The electron micrograph of PrP in the presence of POPC vesicles at pH 5 also 
revealed small round aggregates (Figure 5.9E) similar to those formed by PrP in 
solution at pH 5. In contrast, the electron micrograph of PrP with POPG vesicles at 
pH 5 (Figure 5.9C) revealed extensive aggregation of PrP around the lipid vesicles. 
The electron micrograph of PrP bound to the raft-like vesicles of DPPC/chol/SM at 
pH 7 (Figure 5.9D) shows no indication of protein aggregation around the lipid 
vesicles and unlike with POPC vesicles there also appeared to be less protein in 
solution. These observations are consistent with the fluorescence binding data 
(Chapter 4) where binding of PrP was observed to the raft-like membranes at pH 7, 
and no association was detected with POPC membranes. An electron micropgraph 
of the raft-like vesicles alone is also shown in Figure 5.9F, intact lipid vesicles were 
observed.
5.4 Discussion
Far-UV CD and ATR FTIR spectroscopy were employed to characterise the 
structural properties of SHaPrP (90-231) in solution and in negatively charged, 
zwitterionic and raft-like membranes at pH 5 and 7. Binding of PrP to negatively 
charged membranes of POPG, gel-phase zwitterionic membranes of DPPC and raft- 
like membranes of DPPC/chol/SM (50:30:20, molar ratio) results in significant 
structural changes in the protein.
The far-UV CD spectra of PrP in solution at pH 5 and 7 were very similar 
and displayed double minima at 208 and 222 nm (Figure 5.2 & 5.3) which indicated 
a relatively high content of a-helical structure. The FTIR results were also
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Figure 5.9: Electron micrographs of SHaPrP (90-231) in solution and in the 
presence of lipid membranes. (A) PrP in solution, pH 7, (B) PrP in solution, pH 5; 
PrP in the presence of (C) POPG vesicles, pH 5, (D) DPPC/chol/SM vesicles, pH 7 
and (E) POPC vesicles, pH 5. (F) DPPC/chol/SM vesicles in the absence of PrP, pH 
5. Samples were negatively stained using 2 % uranyl acetate. EM images were 
taken after incubation at 20 °C. Bar, 200 nm.
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consistent with this interpretation, which revealed an amide I band centred around 
1657 cm-1 (Figure 5.4), a frequency assigned to a-helical structure. This is in good 
agreement with the NMR structure of SHaPrP (90-231), which revealed a mainly a- 
helical protein (44 %) with a small amount of p-sheet (4 %) structure (James et ah,
1997). The deconvoluted FTIR spectra of PrP at pH 5 and 7 shows the presence of 
P-sheet structure, however the low frequency of the p-sheet component ~ 1626 cm"1 
(Figure 5.5B,D) suggested that the p-strands were forming strong intermolecular 
hydrogen bonds. This component in the FTIR spectra has been previously observed 
in aggregated or oligomerized proteins (Cabiaux et ah, 1989; Wang et ah, 1996). 
Although ATR FTIR has been successfully used in the determination of secondary 
structure for soluble proteins (Goormaghtigh et ah, 1990), the slow evaporation of 
the aqueous protein sample during formation of the protein film on the germanium 
plate may cause aggregation of the some of the protein molecules. Low-frequency 
P-sheet component in the FTIR spectra has been observed for apocytochrome c and 
cytochrome c. In solution these proteins have been shown to be largely disordered 
and helical structures, respectively. However, the ATR FTIR spectrum showed the 
presence of aggregated p-sheet structure. It was concluded that this component was 
likely to result from the folding of unstructured domains of the proteins under the 
constraints of the FTIR films (Bryson et ah, 2000). This explanation may also apply 
to PrP. The NMR structure of SHaPrP (90-231) shows the amino-terminus to be 
unstructured (James et ah, 1997) and this region of the protein may form P-sheet 
structure during film formation, in which the p-strands form strong intermolecular 
hydrogen bonds. No visible signs of aggregation were detected prior to film 
formation. Furthermore, the presence of P-sheet structure was not evident from the 
solution CD spectra of PrP (Figure 5.2 & 5.3).
154
Binding of PrP to negatively charged membranes induces conformational 
changes in the protein. The far-UV CD spectra of PrP with negatively charged 
membranes of POPG at both pH 5 and 7 showed less defined a-helical bands at 208 
and 222 nm and noticeable changes in the overall lineshape of the CD spectra were 
observed (Figure 5.2A & 5.3 A). The spectra of PrP with POPG membranes at pH 5 
and 7 appear to have a higher contribution from a single dichroic minimum at about 
220 nm. The spectral changes in the CD spectra of PrP in POPG membranes at both 
pH 5 and 7 are indicative of a higher content of (3-sheet structure. This interpretation 
is further supported by the ATR FTIR results, which after spectral deconvolution 
revealed an increase in the intensity of the p-sheet component at about 1626 cm-1 
(Figure 5.5B,D). The low-frequency of the p-sheet structure in PrP indicated that 
the p-strands was forming strong intermolecular hydrogen bonds between 
oligomerised or aggregated protein at the surface or in lipid membranes.
Further information on structural changes in PrP upon binding to POPG 
membranes was obtained by difference spectroscopy. The difference spectra 
obtained from the subtraction of PrP in POPG membranes from PrP in solution at the 
corresponding pHs (Figure 5.7A) suggest that binding is accompanied by increased 
aggregated P-sheet structure, evidenced by the positive band at ~ 1626 cm-1. In 
addition, the positive band at 1656 cm-1 suggests an increase in a-helical structure 
(Figure 5.7A). The incubation of PrP with POPG membranes at pH 5 and 7 induced 
a further increase in the low-frequency P-sheet structure (Figure 5.8C,D). The 
aggregation of PrP in the presence of POPG membranes is clearly evident from the 
electron micrographs (Figure 5.9B), which shows extensive aggregation around
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POPG vesicles, confirming the FTIR and CD data, which revealed an increase in 
aggregated p-sheet structure.
The low-frequency P-sheet component observed in the FTIR spectra of PrP 
in POPG membranes has been previously seen in the FTIR spectra of purified 
infectious prion rods consisting of the N-terminally truncated domain (residues 
90-231) from scrapie-infected hamster brains (Caughey et al., 1991; Gasset et al, 
1993; Pan et al., 1993). These studies revealed that procedures that result in a 
decrease in the low-frequency P-sheet structure diminished scrapie infectivity. Thus 
supporting the hypothesis that the conversion of PrPc to PrPSc and the acquisition of 
infectivity are consequences of a structural transition, which results in the conversion 
of soluble a-helical protein to an insoluble P-sheet state.
Binding of PrP to gel-phase zwitterionic membranes of DPPC and raft-like 
membranes of DPPC/chol/SM (50:30:20 molar ratio) at pH 7 induces 
conformational changes in the protein. The far-UV CD spectra of PrP with DPPC 
and raft-like membranes at pH 7 shows a marked increase in the intensity of the 
dichroic bands at 208 and 222 nm, indicative of a higher content of a-helical 
structure (Figure 5.2B,C). No changes in the far-UV CD spectra of PrP were 
observed with POPC membranes at both pH 7 (Figure 5.2D) and pH 5 (Figure 5.3C) 
and with raft-like membranes at pH 5 (Figure 5.3B) consistent with the absence of 
lipid-protein interactions as revealed by Trp fluorescence (Chapter 4).
The ATR FTIR results clearly shows an increase in the a-helical content of 
PrP upon binding to gel-phase zwitterionic membranes of DPPC and raft-like lipid 
membranes of DPPC/chol/SM at pH 7 (Figure 5.4C.D). Deconvolution of the amide
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I band of the ATR FTIR spectra of PrP in the presence of these lipids revealed the a- 
helical band at ~1654 cm-1. In addition, the intensity of the low-frequency p-sheet 
band at —1627 cm-1 was less than that for PrP in the absence of lipid at pH 7 (Figure 
5.6B,D) which suggests that the interaction was accompanied by a loss in aggregated 
P-sheet structure. This observation was also confirmed by difference spectroscopy, 
which revealed a positive band at ~ 1657 cm-1, a frequency assigned to a-helical 
structure (Figure 5.7B). In addition, the difference spectra of PrP bound to DPPC 
membranes at pH 7 showed a negative band at 1626 cm-1, confirming the earlier 
interpretation that interaction is accompanied by a loss in p-sheet structure and an 
increase in the a-helical content of PrP. No further spectral changes in the ATR 
FTIR spectra of PrP incubated with DPPC membranes and raft-like membranes at 
pH 7 for 18 days at 20 °C were evident, which suggests that the induced a-helical 
structure in PrP is stable.
No evidence for protein aggregation was detected from the electron 
micrographs of PrP and the raft-like membranes at pH 7 (Figure 5.8D). The results 
taken together suggest that PrP is most likely to adopt a stable a-helical structure 
within the raft domains in the plasma membrane.
In summary, the far-UV CD, FTIR and electron microscopy results suggests 
that: (a) binding of PrP to negatively charged membranes of POPG at pH 5 and 7 is 
accompanied by an increase in both a-helical and aggregated P-sheet structures with 
visible protein aggregation seen under the electron microscope; (b) interaction of PrP 
with zwitterionic gel-phase membranes of DPPC and raft-like lipid membranes of 
DPPC/chol/SM induces stable a-helical structure in PrP with a loss in the aggregated
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p-sheet structure, and no signs of protein aggregation were detected from the EM 
images.
5.5 Conclusions
The present structural study of PrP revealed some important features of its 
interaction with lipid bilayers, which may be of relevance to the structural transitions 
that occur during the conversion of PrPc to PrPSc. Both CD and FTIR data shows 
that the interaction of PrP with raft-like membranes induces stable a-helical 
structure. The interaction of PrP with negatively charged membranes at both pH 5 
and 7 was accompanied by an increase in the low-frequency P-sheet structure, which 
suggests that the binding of PrP to negatively charged membranes induces protein 
aggregation or oligomerisation at the surface or in the lipid membranes. These 
findings were further supported by electron microscopy. Extensive protein 
aggregation was observed with POPG vesicles, aggregated structures were absent 
from the EM images of PrP with raft-like membranes.
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Chapter 6: Membrane Binding/Insertion Kinetics of
Syrian Hamster Prion Protein (SHaPrP) Residues 90-231  
and PrP-Induced Membrane Destabilisation
6.1 Introduction
The precise mechanism of PrP-induced cell death remains unclear. In vitro 
studies have demonstrated that PrP is neurotoxic to cultured neurons (Forloni et al., 
1993; Brown et ah, 1996). Various hypotheses have been postulated to explain 
neuronal cell death. These include increased oxidative stress as a consequence of 
depleted levels of PrPc (Brown et ah, 19976). Others have proposed a mechanism 
for prion neurotoxicity through a direct perturbation of the plasma membrane of 
nerve cells as a consequence of PrPSc accumulation (Pillot et ah, 1997; Lin et ah, 
1997). The results presented in this chapter provide a further insight into PrP-lipid 
interactions in particular to changes in the lipid bilayer integrity and/or permeability. 
The data discussed here was obtained from two fluorescence-based techniques. The 
first involved incorporating a lipid probe at the membrane surface, to monitor in real 
time the interaction of PrP with lipid membranes. The second approach involved 
following PrP-induced release of a fluorescent dye encapsulated in lipid vesicles.
6.1.1 Fluorescent probes at membrane surfaces
The localisation of the fluorescent probe fluorescein-phosphatidyl- 
ethanolamine (FPE) at the membrane surface has been used to measure in real time 
the interactions of peptides or proteins with membranes (Wall et ah, 1995; Golding 
et ah, 1996; Cladera et ah, 1999; Wolfe et ah, 1998). Figure 6.1 shows a schematic 
representation of the FPE method. The addition or removal of charged peptides or
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Figure 6.1: Schematic representation of the FPE method. (A) FPE is incorporated 
into the outer leaflet of preformed large unilamellar vesicles. Binding of positively 
charged peptide or protein causes increased electropositive potential at the surface of 
the membrane, which affects the protonation state of FPE and results in an 
enhancement of the fluorescence intensity of the probe. Insertion of the peptide 
would involve the loss of the charged species from the membrane surface and a 
decrease in the fluorescence signal. (B) Chemical structure of FPE. The protonation 
state of the acidic group of the xanthene ring system in FPE is affected during the 
binding and insertion of charged species (Wall et ul., 1995).
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proteins causes changes to the electrostatic potential of the membrane surface and 
affects the protonation state of FPE, leading to changes of the fluorescence intensity 
of FPE. Figure 6.2 displays the excitation and emission spectra of FPE and a kinetic 
trace obtained from rapidly mixing melittin with FPE-labelled lipid vesicles (Wolfe 
et al., 1998). The binding of positively charged melittin to PC labelled membranes 
led to an increase in the fluorescence intensity and the insertion of the protein into 
the bilayer was represented by a decrease in fluorescence. In the current study the 
outer-leaflet of preformed vesicles were labelled with FPE and the kinetics of the 
interaction of SHaPrP (90-231) with FPE-labelled lipid membranes were 
investigated by stopped-flow fluorescence.
6.1.2 Fluorescent dye release assay
Numerous studies have demonstrated that the interaction of peptides or 
proteins with lipid membranes alters the structure and changes the lipid bilayer 
permeability (Defrise-Quertain et al., 1989; Wimley et al., 1994; White & Wimley, 
1998; Vogt & Bechinger, 1999). Membrane integrity maybe examined by dye 
release assays in which a fluorescent dye is encapsulated in lipid vesicles at 
concentrations at which its fluorescence is self-quenched. Addition of a membrane- 
destabilizing molecule would result in the release of the fluorescent dye to the 
external medium, leading to an increase in fluorescence caused by the dilution of the 
dye and the consequent relief of self-quenching. The integrity of lipid membranes 
upon binding of SHaPrP (90-231) was studied by following the release of the 
fluorescent dye calcein from lipid vesicles.
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Figure 6.2: Fluorescence properties of FPE. (A) Excitation (red) and emission 
(blue) spectra of FPE. The spectra were recorded with 3 (iM FPE in 20 mM sodium 
phosphate, pH 7.2. The excitation spectrum of FPE has maximum intensity (A.max) at 
~ 490 nm and a fluorescence emission A.max of ~ 518 nm. The stopped-flow 
experiments described in this chapter involved monitoring the changes in 
fluorescence emission above 515 nm. (B) Representative kinetic trace obtained with 
melittin (reproduced from Wolfe et al., 1998). The binding and insertion events are 
highlighted.
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6.2 M aterial and Methods
6.2.1 Materials
POPG, POPC, sphingomyelin and cholesterol were purchased from Avanti 
Polar lipids (Birmingham, AL). DPPC was obtained from Sigma-Aldrich (Poole, 
UK). FPE and calcein were purchased from Molecular Probes, Oregon, USA. All 
other chemicals were obtained from Sigma-Aldrich (Poole, UK) unless otherwise 
stated.
6.2.2 FPE-labelling and stopped-flow measurements
6.2.2.1: FPE-labelling of lipid vesicles
The incorporation of FPE into the outer-leaflet of preformed vesicles was 
carried out according to Wall et al. (1995). Lipid films were prepared of the desired 
lipid or lipid mixtures as described in Chapter 4, Section 4.2.2. Large unilamellar 
vesicles were prepared by hydrating the lipid film with 20 mM sodium phosphate at 
pH 7.2, containing 280 mM sucrose. Lipid suspensions were subjected to 5 cycles of 
freeze-thawing and extruded ten times through 100 nm pore diameter polycarbonate 
filters (Nucleopore, CA, USA) using a Lipex extrusion apparatus (Lipex, Vancouver, 
Canada) at a pressure of 250 psi. An aliquot of the FPE probe was added from a 
stock ethanolic solution (5 mg/mL) to a level of 0.2 % w/w of the total lipid and 
incubated for 1 h at 20 °C in the dark. Typically, ~ 6 pL of the stock ethanolic FPE 
solution was added to about 1.5 mL of a 20 mM lipid solution. Non-incorporated 
FPE was removed from the FPE-labelled vesicles by gel filtration using Sephadex 
PD 10 columns equilibrated with 25 mL of 20 mM sodium phosphate at pH 7.2, 
containing 280 mM sucrose. FPE-labelled vesicles were retained on the column
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whilst free FPE was washed out in the flow through. The FPE-labelled vesicles were 
eluted with 3.5 mL of the phosphate buffer. The above procedure has been reported 
to incorporate 30-50 % of the externally added FPE into the outer leaflet of 
preformed vesicles (Wall et al., 1995). Labelled vesicles were stored at 4 °C and 
used within one week.
6.2.2.2: Check o f the asymmetric labelling o f lipid vesicles with FPE
The following method was used to check that only the outside leaflet of 
vesicles was labelled. For a given preparation of FPE-labelled vesicles the 
fluorescence intensity at 518 nra was monitored following excitation at 490 nm 
(Figure 6.2A). The fluorescence intensity changes upon addition of 10 pL of 10 mM 
CaCh to 200 pM lipid vesicles were monitored over time. Once the fluorescence 
emission intensity had stabilised, 6 pL of 3 pM solution of ionophore A23187 
prepared in de-ionised H2O was added and further changes in the fluorescence signal 
were noted. The addition of an ionophore would render the membrane permeable 
and facilitate the movement of the cations across the membrane. Further increase 
would be detected if the probe were also located on the internal leaflet. The 
fluorescence emission was recorded on a Photon Technology International 
spectrofluorimeter, using 4 mm pathlength quartz cells. Excitation and emission 
bandwidths were both set at 2 nm.
6.2.2.3: Stopped-flow fluorescence spectroscopy
FPE-labelled vesicles were rapidly mixed with an equal volume of PrP in a 
Micro Volume Stopped-Flow Reaction Analyser SX.18MV (Applied Photophysics 
Ltd., Leatherhead, UK), equipped with a modified T mixer and a 2 x 1 x 10 mm
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flow-cell (Figure 6.3). A computer-triggered pneumatic ram was set up to drive a 
specified volume of the contents of two syringes into a T-mixer, where the solutions 
were rapidly mixed before entry into the optical cell. Electromagnetic radiation from 
a 150 W xenon arc lamp and a monochromator were used for excitation at 490 nm 
(4.2 nm bandwidth) along the 10 mm axis of the optical cell. A photomultiplier tube 
detected the fluorescence signal over time. In stopped-flow measurements a high- 
pass filter with a cut-off at 515 nm was placed between the optical cell and 
photomultiplier, this prevented excitation light getting into the detector and 
swamping the fluorescence signal. Figure 6.2A shows the excitation and emission 
spectra of FPE. The fluorescence emission Xmax of FPE occurred at 518 nm 
therefore, by including a 515 nm filter in the stopped-flow spectrofluorimeter a 
majority of the fluorescence emission is detected. Kinetics were measured by 
monitoring the emission from the 2-mm face of the cell over a time scale up to 10 s. 
The dead time for the stopped-flow instrument for 1:1 mixing of two solutions was ~ 
3 ms.
Both lipid and protein were in 20 mM sodium phosphate buffer, pH 7.2 
containing 280 mM sucrose. Final lipid concentration was 200 pM and protein 
concentration varied from 2 to 10 pM. Measurements were preformed at 20 °C.
One thousand data points were acquired in a logarithmic time. The 
advantage of using a logarithmic timebase is that data points are highly concentrated 
early on in the acquisition time i.e. where a fast kinetic phase may occur. The traces 
resulting from the 1:1 mixing of FPE-labelled vesicles and PrP were acquired and
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Triggcr/Stop
Drive Ram
Figure 6.3: Schematic representation of the single-mixing mode configuration of 
the stopped-flow spectrofluoriineter. The solutions from drive syringes C and F 
are driven into the optical cell by a computer driven pneumatic ram. Light of a 
specified excitation wavelength enters the optical cell and a photomultiplier tube 
detects the fluorescence signal over time.
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stored digitally using the accompanying Applied Photophysics software. For each 
set of experimental conditions four traces were averaged.
• Data analysis: The time courses for PrP-induced fluorescence changes of 
FPE were normalised to the initial fluorescence level of FPE-labelled vesicles 
without protein prior to data analysis. The kinetic parameters were obtained by 
fitting the fluorescence traces, to the sum of exponentials, using a non-linear least- 
squares algorithm to the equation:
Observed signal =
where At and k, are the amplitude 
component /. The amplitude of the fluorescence trace comprised of the amplitudes 
of the various fluorescence components, A,olai=  IA/ 1 + 1A2 1 + 1 Aj | .... | A„ I and the 
fractional amplitude was expressed as a percentage of the total observed amplitude 
defined as
X
^   ^ A te -ty  + offset (Eq. 6.1) 
i= l
and rate, respectively, of the fluorescent
x 100
For each PrP concentration the kinetic traces were initially fitted to the 
lowest number of exponentials. If the residuals were obviously non-random then an 
improvement in the fit was sought by allowing additional components to fit the data.
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6.2.3 Calcein release
6.2.3.1: Preparation of lipid vesicles loaded with calcein
Lipid vesicles containing 60 mM calcein in their aqueous core were prepared 
by hydrating the desired lipid film with the required buffer (50 mM MOPS buffer at 
pH 7.2, 10 mM EDTA or 50 mM sodium acetate buffer at pH 5.0, 10 mM EDTA) 
containing 60 mM calcein. At this concentration the calcein fluorescence is self- 
quenched. Lipid suspension was extruded as described earlier, using 100-nm pore 
membranes. Non-encapsulated calcein was removed by gel filtration using 2 mL 
columns packed with sephadex G-50. The columns were equilibrated with 1 mL x 3 
of the required buffer (MOPS buffer, pH 7.2 or acetate buffer, pH 5.0) and 
centrifuged at 2000 rpm for 3-mins for each wash and a final spin at 3000 rpm for 
45-secs. 100 pL of the lipid sample was applied to the columns. The columns were 
span again at 2000 rpm for 2-mins. The calcein-loaded vesicles were excluded from 
the column whereas the free calcein was retained.
The integrity of the lipid vesicles loaded with calcein in the absence of 
protein was determined by monitoring the spontaneous release of calcein and was 
found to be less than 1 % over 10-mins. The stability of the prepared vesicles was 
also monitored by comparing the fluorescence intensities of the calcein loaded 
vesicles in the absence of protein at the start and the end of the experiments and in 
all cases the fluorescence intensity did not differ by more than 5 %.
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6.2.3.2: PrP-induced release o f calcein from lipid vesicles
The release of calcein from lipid vesicles upon binding of PrP was monitored 
by calcein fluorescence emission at 512 nm over a time scale of 500 s after manually 
mixing 5 parts of lipid vesicles with 1 part of protein solution (5:1 v/v). The protein 
was in 20 mM sodium acetate pH 5.5 and lipid vesicles loaded with calcein were in 
50 mM MOPS, pH 7.2 or 50 mM sodium acetate, pH 5.0, both buffers contained 10 
mM EDTA. The final pH of the lipid-protein samples were 7.15 and 5.11, 
respectively. The deadtime of these measurements was 24 ± 4 s. The excitation 
wavelength was 490 nm and both the excitation and emission slits were set to 1 nm. 
Experiments were performed at 20 °C. Release of calcein to the external medium 
was detected by an increase in fluorescence. The final lipid concentration was 50 
pM and protein concentrations varied from 10 to 500 nM. The fraction of calcein 
release (Rf) was calculated according to
Rf = (F -  F0)/(Ftot -  F0) (Eq. 6.2)
where F is the fluorescence intensity 500 s after adding the protein, Fo is initial 
fluorescence intensity and Ftot is the total fluorescence intensity observed after 
release of all calcein by disrupting the vesicles with Triton X-100 to a final 
concentration of 0.5 % (v/v).
For the stopped-flow measurements the excitation wavelength was set at 490 
nm and emission was detected using a high-pass filter with a cut-off at 515 nm and 
an electronic filter with a time constant of 100 ps. Kinetics were measured by 
monitoring the emission over a time scale up to 200 s. Manual-mixing and stopped-
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flow experiments were performed at 20 °C. Data analysis was carried out using 
Applied Photophysics software and Igor (Wavemetrics, Lake Oswego, Oregon).
The kinetic parameters (rates and amplitudes) of calcein release, were 
obtained by non-linear least-squares analysis using a minimum number of 
exponential phases. The fluorescence changes, monitored over time, following 
manual mixing of vesicles and protein (deadtime 24 ± 4 s) and in stopped-flow 
measurements operating at a reduced drive pressure, which resulted in a deadtime of 
~ 4.5 ms were fitted to equation 6.1.
6.3 Results
6.3.1 FPE-detected membrane binding and insertion kinetics
FPE-labelled membranes have been successfully used to obtain valuable 
information on binding and insertion events of charged peptides and protein into 
lipid bilayers (Wall et al., 1995; Golding et al., 1996; Wolfe et al., 1998). In the 
current study PrP was rapidly mixed with FPE-labelled POPG membranes. The 
observed fluorescence changes are associated with changes in the electrostatic 
potential surrounding FPE upon binding and insertion of PrP.
The asymmetric labelling of lipid vesicles with FPE was determined prior to 
the stopped-flow experiments. The protocol followed was established by Wall et al. 
(1995), and relies on the addition of cations to the outer side of the membrane, which 
changes the membrane surface electrostatic potential and induce an enhancement of 
the fluorescence intensity of FPE. The vesicles were then rendered permeable by 
addition of an ionophore (A23187), which facilitated the equilibrium
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of the cation concentration across the membrane. If the lipid vesicles were 
symmetrically labelled then a further increase of fluorescence would be detected on 
addition of the ionophore. Figure 6.4 shows the fluorescence changes of FPE- 
labelled POPG vesicles after the addition of calcium ions and ionophore A23187. 
An increase in the fluorescence intensity was detected upon addition of calcium ions. 
However, no further increase was detected following the introduction of the 
ionophore, indicating that only the outsides of the lipid vesicles were labelled with 
FPE. Furthermore, the labelled vesicles appeared to be stable over a time scale of a 
week, no transmembrane flipping of externally located FPE was observed over this 
period.
The FPE-detected kinetics of binding and insertion of PrP into POPG- 
labelled membranes were studied at a protein concentration range of 2-10 pM and 
lipid concentration of 200 pM. FPE-detected kinetics monitored in stopped-flow 
measurements for the interaction of PrP with POPG membranes at pH 7 are 
displayed in Figure 6.5A, where the changes in fluorescence are plotted on a 
logarithmic time scale. The kinetic traces were all fitted to three exponentials and a 
summary of rates and amplitudes at various protein concentrations is presented in 
Table 6.1. Stopped-flow control measurements in which POPG membranes without 
FPE were rapidly mixed with PrP at pH 7 are shown in Figure 6.5B. No change in 
the signal was detected in these experiments, which is consistent with the notion that 
the fluorescence changes observed with POPG-labelled vesicles are due to the 
fluorescence changes of FPE as a result of PrP interaction. Figure 6.6 shows the 
FPE-detected kinetic trace from stopped-flow measurements in which 200 pM FPE- 
labelled POPG membranes were rapidly mixed with 7 pM PrP and the residuals
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Time (s)
Figure 6.4: Determination of the asymmetric incorporation of FPE into lipid 
vesicles. Fluorescence intensity was recorded at 518 nm following excitation at 490 
nm. At the arrow marked Ca2+, 10 mM CaCk was added and arrow labelled 
ionophore, 3 pM A23187 was added.
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Fgure 6.5: Representative kinetics for the interaction of SHaPrP (90-231) with
FPE-Iabelled POPG membranes, pH 7. (A) The fluorescence of FPE was
monitored at 20 °C in stopped-flow measurements after rapidly mixing protein 
solution with FPE-labelled vesicles. Final lipid concentration was 200 |iM and PrP 
concentrations were: (1)2, (2) 3, (3) 5, (4) 7 and (5) 10 pM. Relative fluorescence 
was normalised to the initial fluorescence level of FPE-labelled POPG vesicles 
without protein. The experimental data is shown in red and fits are in black. The 
fluorescence changes associated with binding and insertion events are highlighted. 
(B) Controls: (1) POPG membranes no FPE, (2) PrP (10 pM) binding to POPG 
membranes, pH 7 (no FPE), (3) initial fluorescence level of FPE incorporated into 
POPG membranes, pH 7. The dead time of the instrument was ~3 ms and the data 
that is shown from 1-3 ms was acquired prior to the mixing of lipid and protein 
solutions. Data are displayed on a logarithmic timescale.
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Table 6.1: Kinetic parameters fo r  membrane binding and insertion o f  SHaPrP (90—231) with POPG membranes at pH  7*
[PrP] pM ki (s"1) At (%)6 fe (S'1) a 2 (%)b M s '1) Ai(%)b a mc
2 161+6 47 24 + 4 10 0.06 ±0.01 43 1.99
3 183+4 63 23 ± 2 14 0.25 ±0.01 23 2.58
5 243 +4 67 23 + 1 14 0.16 ±0.01 19 3.60
7 295 ± 7 76 22 ±1 14 0.50 ±0.03 10 4.50
10 330 + 6 82 22 ±1 11 0.30 ±0.02 7 5.08
"Rates (h) and amplitudes (A,) were calculated from stopped-flow measurements at 20 °C using FPE-labelled membranes at a 
constant lipid concentration of 200 |iM. ^Fractional amplitude expressed as percentage of total observed amplitude (/ft(*)- cTotal 
observed amplitude defined as A  tot ¡Ai  I + \ A 2 1 +  ¡Ai  I .
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Figure 6.6: Kinetics of FPE-detected binding and insertion of PrP into POPG 
membranes, pH 7. The experimental data (red) and fit (black) are shown in the top 
panel. Residuals obtained from fitting the fluorescence trace to the sum of three 
expontentials are shown in the bottom panel and this shows the difference between 
the calculated and experimental data. Lipid and PrP concentration were 200 and 7 
|lM, respectively. Data are displayed on a logarithmic timescale.
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obtained from fitting the kinetic data to the sum of three exponentials are also 
displayed.
The three kinetic phases detected in the stopped-flow experiments 
have the following properties:
• Fast phase: This phase is associated with an increase of fluorescence 
occurring over 3-6 ms. Both the rate constant (k\) and amplitude (A\) associated 
with this initial phase increase with protein concentration (Figure 6.7 and Table 6.1). 
The amplitude (A i) of this fast phase accounts for the largest fraction of the total 
fluorescence change (47 % with 2 pM PrP and 82 % with 10 pM, Table 6.1). The 
rate constant increased more or less linearly up to about 8 pM PrP (Figure 6.7A). 
This phase is assigned to binding of positively charged PrP (+ 4) to the membrane 
surface.
• Intermediate phase: This component occurs within 50 ms and is associated 
with a decrease in the fluorescence intensity with rate constant (fo) and amplitude 
(A2) independent of protein concentration (Figure 6.7C,D & Table 6.1). This phase 
indicates a loss of the protein or positively charged regions of PrP from the 
membrane surface and represents the insertion of PrP into POPG membranes.
• Slow phase: An increase in the fluorescence intensity of FPE occurred 
during this phase and extends over several seconds (2-17 s). The amplitude (/I3) 
associated with this phase decreases with protein concentration and rate (¿3) 
increases with protein concentration (Figure 6.7E,F & Table 6.1). This slow phase 
following the binding and insertion of PrP into lipid membranes is probably 
associated with lipid rearrangement.
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Figure 6.7: The dependence of FPE-detected kinetic parameters for the binding and 
insertion of PrP into POPG membranes on PrP concentration. Rates (&0 (solid 
symbols) and amplitude (Ai) (open symbols), for the fast phase (circles), intermediate 
phase (triangles) and slow phase (squares) are plotted as a function of PrP concentration. 
Amplitudes are expressed as fractional amplitudes (percentage of total observed 
amplitude, see Materials and Methods). (A) £i, (B) Ai, (C) fo. (D) Aj, (E) ki and (F) Ay
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In order to access role of the membrane surface charge density on the binding 
and insertion of PrP, FPE-detected kinetic measurements were carried out with 
membranes of POPC containing only 30 % negative charge. The fluorescence 
binding results presented in Chapter 4 shows that PrP has a weak affinity for liquid- 
crystalline membranes composed of POPC. This means that the binding of the 
protein to membranes composed of POPC/POPG is mediated through electrostatic 
interactions between negatively charged lipid headgroups of POPG and positively 
charged amino acids in the protein. The changes in the fluorescence emission of 
FPE were monitored over a time range up to 10s after rapid mixing with PrP. The 
FPE-detected kinetics were studied at a PrP concentration range of 2-10 pM and 
lipid concentration of 200 pM. The kinetic traces are shown in Figure 6.8, where the 
changes in fluorescence are plotted on a logarithmic time scale. Kinetic parameters 
were obtained by non-linear least-squares analysis using a minimum number of 
exponential phases and a summary of rates and amplitudes at various PrP 
concentrations is presented in Table 6.2. The results show that the interaction of PrP 
with mixed membranes of POPC and POPG at pH 7 (POPC/POPG, 70:30 molar 
ratio) monitored by FPE kinetics only revealed two phases of increasing 
fluorescence.
• Fast phase: An increase of fluorescence was detected during this phase 
(12-18 ms) and was assigned to the binding of PrP to POPC/POPG membranes. 
The rate (k\) and amplitude 04 0 associated with this phase were found not to be 
strongly dependent on the protein concentration (Table 6.2).
• Slow phase: The slow phase also associated with an increase in the 
fluorescence intensity of FPE occurs over 1-3 s. The rate (ki) increased with protein
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Figure 6.8: Representative kinetics for the interaction of SHaPrP (90-231) with 
FPE-labelled POPC/POPG membranes (70:30 molar ratio), pH 7. (A) The
fluorescence of FPE was monitored at 20 °C in stopped-flow measurements after 
rapidly mixing protein solution with FPE-labelled vesicles. Final lipid concentration 
was 200 |iM and PrP concentrations were: (1) 2, (2) 3, (3) 5, (4) 7 and (5) 10 pM. 
Relative fluorescence was normalised to the initial fluorescence level of FPE-labelled 
POPC/POPG vesicles without protein. The experimental data is shown in red and fits 
are in black. The fluorescence change associated with binding is highlighted. (B) 
Controls: (1) POPC/POPG membranes no FPE, (2) PrP (5 pM) binding to POPC/POPG 
membranes, pH 7 (no FPE), (3) initial fluorescence level of FPE incorporated into 
POPC/POPG membranes, pH 7. The dead time of the instrument was ~3 ms and the 
data that is shown from 1-3 ms was acquired prior to the mixing of the lipid and protein 
solutions. Data are displayed on a logarithmic timescale.
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Table 6.2: Kinetic parameters for membrane binding o f  SHaPrP (90—231) with POPC/POPG membranes at pH  7 (70:30 
molar ratio)“
[PrP] pM *, (s-‘) Ax (%)b fc (s '1) a 2 (%)b Atotc
2 56 ±3 73 0.34 ±0.08 27 0.30
3 81 ±1 79 0.29 ±0.03 21 0.75
5 78 ±1 74 0.37 ±0.02 26 0.95
7 65 ±1 71 0.79 ±0.03 29 1.40
10 71 ±1 72 0.83 ±0.03 28 1.44
"Rates (k{) and amplitudes (Ai) were calculated from stopped-flow measurements at 20 °C using FPE-labelled membranes at a 
constant lipid concentration of 200 pM. fractional amplitude expressed as percentage of total observed amplitude (Atot). cTotal 
observed amplitude defined as Atot = \Ai I + U 2 I.
180
concentration, however, no dependence was observed with the amplitude (A2) (Table 
6.2). This phase is probably associated with lipid rearrangement following the 
binding of PrP..
A reduction in the surface charge density of lipid membranes slowed the 
binding of PrP and in contrast with POPG membranes, no fluorescence decrease was 
detected following the initial increase, which would have suggested the insertion of 
PrP into lipid membranes. This result indicates that PrP remains at the membrane 
surface and that high negative surface charge density is required for the insertion 
event.
6.3.2 Calceirt release
The ability of PrP to destabilise membranes was assessed using a dye release 
assay. The assay involves encapsulating calcein in lipid vesicles at a concentration 
where its fluorescence is self-quenched. A significant increase in the fluorescence 
intensity would occur upon the release of calcein into the surrounding medium. This 
approach has been widely used to characterise the membrane destabilisation induced 
by the binding of proteins and peptides (Defrise-Quertain et al., 1989; Butko el al., 
1996; Vogt & Bechinger, 1999) and in the present study was used to investigate the 
membrane destabilising properties of SHaPrP (90-231).
The integrity of negatively charged membranes of POPG, zwitterionic 
membranes of POPC and raft-like membranes of DPPC/chol/SM (50:30:20, molar 
ratio) at pH 5 and 7 upon PrP binding was studied by following the release of calcein 
from these vesicles.
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Binding of PrP to POPG membranes at pH 5 and 7 led to an increase in the 
fluorescence intensity, indicating that calcein was released from lipid vesicles. 
Figure 6.9 shows representative spectra of PrP binding to POPG loaded vesicles at 
pH 7. An increase in calcein fluorescence was detected with increasing 
concentrations of PrP. Figure 6.10 summarises the extent of calcein release from 
various lipid systems, as a fraction of total release upon detergent solubilisation of 
lipid vesicles. Binding of PrP to POPG membranes, at a lipid-protein ratio of 100:1 
led to a total release of calcein from the lipid vesicles at pH 5 and 7. At equivalent 
lipid-protein ratios, only 25-30 % calcein was released from POPC membranes and 
no release was observed from the raft-like membranes of DPPC, cholesterol and 
sphingomyelin at pH 5 and 7. Furthermore, incubation of PrP with the raft-like 
membranes over a 12 h period did not lead to any release of calcein.
The kinetics of calcein release were monitored over a time scale up to 500 s 
after manually mixing loaded vesicles and PrP. Representative kinetic traces for 
POPG loaded vesicles at pH 5 and 7 are displayed in Figure 6.11 and kinetic 
parameters for all lipid systems studied are shown in Table 6.3. These 
measurements revealed that the release of calcein induced upon binding of PrP is 
very fast. With POPG membranes at pH 7, only a small fraction (< 20 %) of the 
total expected fluorescence change was observed (Ai, Table 6.3) and at pH 5 the 
release occurred within 24 ± 4 s i.e. during the deadtime of these measurement (Ao, 
Table 6.3). Release of calcein from POPC vesicles at pH 5 also occurred within the 
deadtime of these measurements, whilst 25 % of the expected fluorescence signal 
was observed after manually mixing POPC loaded vesicles at pH 7 with PrP.
182
Figure 6.9: Illustration of a series of fluorescence spectra of calcein release upon 
binding of SHaPrP (90-231). Fluorescence spectrum of calcein loaded vesicles in 
the absence of PrP (dashed line) and with increasing concentration of PrP (solid 
line): 50, 100, 200, 250, 500 nM from bottom to top spectrum. The excitation 
wavelength was 490 nm and spectra were recorded at 20 °C.
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Figure 6.10: Summary of the extent of PrP-induced release of calcein from 
various lipid membranes. Calcein release is represented as a fraction of total 
release upon detergent solubilisation of vesicles for POPG (circles), POPC (squares) 
and raft-like membranes of DPPC/chol/SM (triangles) at pH 7 (open symbols) and 
pH 5 (solid symbols). Data points are the mean value of two measurements on 
separate samples and error bars show their standard deviations. Lines are for 
guidance only and have no theoretical significance.
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Figure 6.11 : Representative kinetic traces of PrP-induced release of calcein from 
POPG membranes. (A) Release of calcein from POPG vesicles at pH 7 was 
measured by manually mixing protein in solution with POPG vesicles loaded with 
calcein (deadtime ~ 24 s). PrP concentrations were: (1)0, (2) 50, (3) 250 and (4) 500 
nM. (B) Equivalent measurements at pH 5. The experimental data is shown in red 
and the fits are in black.
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Table 6.3: Kinetics o f PrP-induced calcein release from lipid membranes4
Membrane System Ao(%)b h (s) Ai(%)
POPG, pH 7 82 20-170 18
POPG, pH 5 100 C C
POPC, pH 7 75 > 1 0 0 25
POPC, pH 5 100 c C
DPPC/chol/SM, pH 7 no release no release no release
DPPC/chol/SM, pH 5 no release no release no release
"Time constant (ii) and amplitudes (A i) were calculated from the changes in calcein 
fluorescence emission with time after manually-mixing protein and lipid vesicles 
loaded with calcein. *Burst phase amplitude associated with an early release of 
calcein during the deadtime of these measurements, ~ 24 s, (see Figure 6.11) and 
expressed as a percentage of the total expected fluorescence signal. cPhase not 
observed.
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In order to resolve the missing amplitudes of the manual mixing experiments 
stopped-flow fluorescence measurements were carried out. The drive pressure of the 
stopped-flow instrument was reduced to minimise any pressure-driven calcein 
release. Representative kinetics traces of calcein release from POPG membranes at 
pH 7, observed in stopped-flow measurements are shown in Figure 6.12. The traces 
were found to fit to the sum of 3 exponential phases and kinetic parameters are 
summarised in Table 6.4.
• Fast phase: This phase occurred at 335-700 ms with a rate (fa) decreasing 
with protein concentration (3.0 s_1 at 150 nM PrP; 1.5 s_l at 500 nM PrP, Table 6.4). 
The amplitude (A i) associated with this phase increased with protein concentration 
(^ 41 = 19 % for 150 nM PrP increasing to 36 % for 500 nM PrP, Table 6.4).
• Intermediate phase: This phase was observed over 2-4 s and 35 to 50 % of 
the total amplitude was associated with this phase. The rate (fa) and amplitude (A2) 
did not show a strong dependence on the protein concentration (Table 6.4).
• Slow phase: This phase occurred between 14-45 s and the rate and 
amplitude observed with this phase decreased with protein concentration (4 3 = 45 %, 
fa = 0.07 s-1 for 150 nM PrP decreasing to 27 % and 0.02 s-1, respectively, at 500 
nM PrP, Table 6.4).
The slow phase detected in the stopped-flow measurement corresponds to the 
phase observed in the manual-mixing experiments, more importantly the missing 
amplitude observed in the manual-mixing experiments was resolved and the fast 
release of calcein was found to be a biphasic process.
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Figure 6.12: Representative kinetic traces of PrP-induced release of calcein from 
POPG membranes at pH 7 monitored in stopped-flow measurements. PrP
concentrations were: (1) 50, (2) 150, (3) 200, (4) 250 and (5) 500 nM and lipid 
concentration was 50 fiM. Fluorescence changes were detected above 515 nm and 
excitation wavelength of 490 nm (deadtime ~ 4.5 ms). Traces were fitted to the sum 
of three exponentials. The experimental data is shown in red and the fits are in 
black.
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Table 6.4: Kinetic parameters for PrP-induced release o f calcein from POPG membranes at pH  7°
[PrP] nm h  (s '1) Ax (% f h  (s '1) A 2 (%)* * 3  (s"1) Ai (%)* Atotc
50 6.9010.02 14 0.15510.006 16 0.0013 1 0.007 69 0.49
150 3.0010.01 19 0.43710.010 35 0.068510.0007 45 0.62
200 2.9010.03 20 0.32810.004 41 0.0529 1  0.0004 38 0.92
250 2.3710.04 24 0.38110.005 49 0.03341 0.0004 27 1.71
500 1.4610.01 36 0.259 1 0.004 39 0.02261 0.0002 27 1.84
"Rates (£,) and amplitudes (Ai) were calculated from stopped-flow measurements at 20 °C using POPG loaded vesicles at a constant lipid 
concentration of 50 jiM. fractional amplitude expressed as percentage of total observed amplitude (vft<*)- cTotal observed amplitude defined
as/ft<*= M il + M2I+ M3L
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6.4 Discussion
Studies have demonstrated that peptide or protein binding to lipid membranes 
can alter the lipid bilayer integrity and/or permeability (White & Wimley, 1994). Lin at 
al. (1997) demonstrated that the binding of a synthetic peptide of PrP comprising 
residues 106-126 formed ion-permeable channels in lipid membranes and speculated 
that these channels may mediate cell death through changes in cellular ion homeostasis. 
In this chapter PrP binding and insertion kinetics into lipid bilayers is investigated by 
asymmetrically incorporating the fluorescent probe FPE onto the surface of lipid 
vesicles. The results were correlated with membrane destabilisation effects, measured 
by the release of a fluorescence dye from lipid vesicles.
Binding of changed peptides and proteins to lipid membranes causes changes of 
the electrostatic potential at the membrane surface. By locating a fluorescent probe such 
as FPE, which is sensitive to the membrane surface potential, it is possible to follow the 
binding and insertion of peptides and proteins into membranes in real time (Wall et al., 
1995).
Stopped-flow experiments in which PrP was rapidly mixed with negatively 
charged FPE-labelled membranes of POPG at pH 7, revealed three clearly resolved 
fluorescence kinetic phases. An enhancement of fluorescence was observed in the fast 
phase (3-6 ms, Figure 6.5A and Table 6.1) and the rates and amplitudes associated with 
this phase displayed a clear dependence on the protein concentration, consistent with an 
increased electropositive surface potential caused by the binding of positively charged 
PrP (Figure 6.7A,B and Table 6.1). The binding of PrP to negatively charged
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membranes has been shown to be driven by electrostatic interactions between positively 
charged residues on the protein surface and negatively charged lipid headgroups on the 
membrane (Chapter 4). Most of the positive charged amino acids are clustered at the 
amino-terminus of PrP and this is the region that is most likely to bind to negatively 
charged membranes. The results from this study are consistent with this proposal, in 
which the positively charged amino-terminus binds to negatively charged membranes 
and brings the charged residues in close proximity to the membrane surface. This 
causes changes of the electrostatic potential at the membrane surface and leads to 
changes in the protonation state of FPE resulting in an increase in the fluorescence 
intensity of the probe.
The initial increase in fluorescence intensity was followed by a decrease, 
characterised by a time consistent of ~ 50 ms (Figure 6.5A and Table 6.1). The rate 
constants and amplitudes of this phase were found to be independent of protein 
concentration (Figure 6.7C, D and Table 6.1). This phase is assigned to the loss of a 
region of positive charged amino acids from the membrane surface, which in turn led to 
changes in the electrostatic potential at membrane surface and subsequently affected the 
protonation state of FPE resulting in a decrease in the fluorescence signal. This 
observation is consistent with the partial insertion of PrP into lipid membranes. This 
phase need not represent a transmembrane conformation of PrP and probably reports on 
the partial insertion of PrP into the lipid bilayer.
A slow phase associated with an increase in fluorescence was observed with a 
time constant of 2-17 s (Figure 6.5 and Table 6.1). The kinetic parameters associated 
with this phase displayed a dependence on PrP concentration. The amplitude decreases
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with protein concentration and rate increases with PrP concentration (Figure 6.7 and 
Table 6.1). This phase might be associated with rearrangement of the lipid bilayer 
following the binding and insertion of PrP.
To examine the role of membrane surface charge density on the binding and 
insertion of PrP, the kinetics of PrP interaction with FPE-labelled membranes containing 
30 % negative charged POPG lipids (POPC/POPG, 70:30 molar ratio), at pH 7 was 
investigated. FPE-detected kinetics shows two kinetic events: A fast phase of increasing 
FPE fluorescence associated with the binding of PrP to POPC/POPG membranes. The 
result shows that the binding of PrP to POPC/POPG membranes was slower compared 
to POPG membranes. For POPC/POPG membranes binding occurred over 12-18 ms 
compared to 3-6 ms for POPG bilayers (Table 6.1 & 6.2). Further both the rate (¿i) and 
amplitude (A\) associated with this phase were independent of PrP concentration, which 
suggests that the negatively charged lipid binding sites on the membrane surface were 
saturated at the lowest protein concentration (2 pM) and increase in the PrP 
concentration resulted in no further binding. In contrast, with POPG membranes the 
insertion phase, which is associated with a decrease in the fluorescence signal of FPE 
following the initial increase, was not observed. A slow phase of further increase in the 
fluorescence intensity that occurs over 1-3 s was detected (Figure 6.8 and Table 6.2), 
and is probably due lipid rearrangement around PrP.
Changes in membrane integrity and/or permeability following the binding of PrP 
were investigated by monitoring the release of the fluorescent dye (calcein) from lipid 
vesicles. In this technique lipid vesicles were prepared containing calcein at a high
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enough concentration at which its fluorescence was self-quenched (60 mM). Release of 
the dye resulted in an increase in the fluorescence signal of calcein caused by the 
dilution of the dye and a consequent relief of self-quenching. The results from the 
calcein release assay showed that binding of PrP to negatively charged membranes of 
POPG at pH 5 and 7 led to total release of calcein from loaded vesicles, indicating a 
strong destabilization of the lipid bilayer (Figure 6.10). Studies with peptides and 
proteins have demonstrated that binding to lipid membranes can alter the bilayer 
integrity by two mechanisms. The first involves the insertion of peptides and proteins 
into the bilayer and the formation of pores, which perturbs the lipid membrane and 
destabilises the lipid bilayer organisation (Matsuzaki et al., 1994; Tejuca et al., 1996). 
The second perturbs the membrane in a detergent-like manner (Butko et al., 1996; Vogt 
& Bechinger, 1999). The precise mechanism of PrP-induced membrane destabilisation 
is not known, however the FPE kinetics, showed evidence for partial insertion of PrP 
into negatively charged lipid membranes.
Under the same experimental conditions PrP did not induce the release of calcein 
from raft-like mixed membranes composed of DPPC, cholesterol and sphingomyelin at 
pH 5 and 7 (Figure 6.10) and this observation remained unaltered over a 12 h period. 
This result indicates that the binding of PrP to raft-like membranes of DPPC/chol/SM 
does not destabilise the lipid bilayer. Surprisingly, PrP induced the release of 25-30 % 
of calcein from POPC membranes (Figure 6.10). The Trp fluorescence binding data 
presented in Chapter 4 suggests that PrP has a weak affinity for POPC membranes. The 
result from the destabilisation study with POPC membranes does not contradict this 
finding and may reflect the difference in the sensitivity of the two methods used, with
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the calcein release assay being more sensitive in detecting PrP-POPC interactions than 
shifts in the Xmax of PrP (Chapter 4).
The kinetics of calcein release were investigated and stopped-flow 
measurements revealed that the kinetics were more complex than originally expected 
(Figure 6.12 & Table 6.4). The release of calcein from negatively charged POPG 
membranes showed three main kinetic phases associated with an increase of 
fluorescence (Table 6.4): (1) a fast phase occurring at 335-700 ms, (2) an intermediate 
phase with a time constant of 2-4 s and (3) a slow phase occurring over 14-45 s.
Combining the FPE kinetics and the results from the calcein release experiments, 
a proposed mechanism for the interaction of PrP with negatively charged membranes of 
POPG at pH 5 and 7 is illustrated in Figure 6.13A. In this scheme, subscript W 
represents protein in an aqueous environment, a subscript S indicates a membrane 
surface associated state and a state inserted in lipid membranes is labelled with a 
subscript M. PrPw has the reported solution structure as determined by NMR (James et 
al., 1997) and PrPs is likely to have an altered conformation on association with lipid 
membranes. PrP\i inserts into the hydrophobic core of the lipid bilayer and results in 
membrane destabilisation. Binding of PrP to the surface of negatively charged 
membranes (PrPw-> PrPs) is most likely to be diffusion-controlled and driven largely 
by favourable electrostatic interactions between positive residues on the protein and the 
negative charged lipid headgroups.
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Figure 6.13: Proposed kinetic model for the interaction of SHaPrP (90-231) with 
lipid membranes. (A) Interaction of PrP with negatively charged membranes of POPG 
at pH 5 and 7 and (B) with raft-like membranes composed of DPPC, cholesterol and 
sphingomyelin at pH 7. PrPw represents the protein in aqueous solution, PrPs indicates 
a state associated with membrane surface and PrPM denotes a membrane-inserted state.
195
After binding to the membrane surface the protein partially inserts into the lipid bilayer 
(PrPs PrPM). Insertion of PrP into lipid membrane is most likely to be responsible 
for the destabilision of the lipid bilayer, leading to the release of calcein from POPG 
vesicles.
A model for the interaction of PrP with the raft-like membranes composed of 
DPPC, cholesterol and sphingomyelin is also shown in Figure 6.13B. Although no FPE 
kinetic data is available for this membrane system due to difficulty in labelling the 
membranes, the calcein release, Trp fluorescence binding and Trp quenching data 
presented in Chapter 4, supports the interpretation that the protein is likely to remain at 
the membrane surface. This surface associated state does not lead to the destabilisation 
of the lipid bilayer.
6.5 Conclusions
The results presented in this chapter suggests that binding of PrP to negatively 
charged membranes causes perturbation of the lipid bilayer, which results in total 
release of the vesicle contents. The results do not elucidate on the molecular mechanism 
of PrP-induced destabilisation. However, the FPE kinetics shows evidence for partial 
insertion of PrP into POPG membranes. In contrast, PrP did not induce the release of 
calcein from raft-like mixed lipid membranes, which suggest that the binding of PrP 
does not alter the integrity of these membranes.
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Chapter 7: General Discussion and Conclusions
7.1 Binding o f  PrP to Lipid Membranes Induces Protein 
Structural Changes and can A lter the Bilayer Integrity
PrP in living cells is GPI anchored to raft domains that are rich in cholesterol 
and sphingolipids on the exoplasmic side of the membrane (Vey et al., 1996; 
Naslavsky et al., 1997). Previous studies have shown that the lipid environment of 
PrP may play an important role in the degradation of PrPc and also in the formation 
of PrPSc (Taraboulos et al., 1995; Vey et al., 1996; Naslavsky et al., 1997). 
Evidence from scrapie-infected cells in culture indicated a direct interaction of PrPSc 
with the plasma membrane, other than via its GPI anchor (Stahl et al., 1990; Safar et 
al., 1991; Lehmann & Harris, 1995). In addition the plasma membrane has been 
proposed as a cellular site for the conversion of PrPc to PrPSc (Taraboulos et al., 
1995; Naslavsky et al., 1997). This has led to suggestions that membrane-PrP 
interactions could be involved in the conversion of the a-helical conformation of PrP 
to the aggregated p-sheet rich structure. However, very few studies have 
investigated the biophysical properties of membrane-associated PrP. In the current 
study the structural properties of membrane associated Syrian hamster prion protein 
(SHaPrP) comprising residues 90-231 is investigated.
Binding of PrP in an a-helical conformation resembling PrPc, to various 
model membrane systems was studied at pH 7 to represent the pH surrounding the 
plasma membrane and pH 5 to model the acidic environment of endosomes. 
Evidence implicates endocytic organelles (Borchelt et al., 1992; Arnold et al., 1995) 
and the plasma membrane (Vey et al., 1996; Naslavsky et al., 1997) as sites for PrPSc 
formation, but it is unclear which provides a more favourable environment for
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conversion. The two tryptophan residues present at positions 99 and 145 in SHaPrP 
(90-231 ) were used as intrinsic fluorescence probes to monitor the binding of PrP to 
model lipid membranes. The Trp fluorescence results presented in Chapter 4 shows 
that PrP binds to gel-phase zwitterionic membranes of DPPC and raft-like 
membranes composed of DPPC, cholesterol and sphingomyelin at pH 7. The 
interaction of PrP with raft-like membranes was driven by predominantly 
hydrophobic lipid-protein interactions. Binding of PrP to raft-like membranes led to 
an intermediate protection to acrylamide quenching (Chapter 4). This result together 
with the shift in the fluorescence of PrP suggests that in these membranes PrP is 
likely to be surface associated.
The binding of PrP to raft-like membranes at pH 7 suggest that in addition to 
the carboxyl-terminal linked GPI anchor, direct interactions between the polypeptide 
chain of PrP and lipid membranes may be involved in membrane attachment of PrP 
to the cell surface. In contrast, no significant binding of PrP to raft-like membranes 
at pH 5 and liquid-crystalline zwitterionic membranes of DOPC or POPC, nor their 
mixtures with cholesterol and sphingomyelin at pH 7 and 5 was observed. These 
results suggest that PrP has a preference for gel-phase zwitterionic membranes and 
raft-like membranes at pH 7.
Far-UV CD and ATR FTIR spectroscopy revealed that an increase in the a- 
helical structure of PrP accompanied the interaction of PrP with raft-like membranes 
(Chapter 5). No visible signs of PrP aggregation were detected from the electron 
micrographs of PrP with the raft-like membranes (Chapter 6). These finding are 
consistent with the interpretation of the CD and FTIR results, which shows an 
increase in the a-helical structure of PrP and no evidence of aggregated fl-sheet
198
structure. The calcein release data presented in Chapter 6 suggests that the binding 
of PrP to raft-like membranes did not destabilise the lipid bilayer, thus supporting a 
proposal where PrP is surface associated to raft-like membranes. These results taken 
together suggest that for the preferred localisation of PrP in raft domains within the 
plasma membrane hydrophobic lipid-protein interactions induce the formation of 
stable a-helical structure in PrP. This state rich in a-helical structure is likely to be 
surface associated and as a result does not affect the integrity of the lipid bilayer.
The Trp fluorescence binding and acrylamide quenching data (Chapter 4) 
shows that PrP binds to negatively charged lipid membranes of POPG at both pH 7 
and 5. The interaction of PrP with lipid bilayers composed of negatively charged 
lipids was shown to be driven by electrostatic interactions between positively 
charged residues on the protein surface and negatively charged lipid headgroups. 
Inspection of the surface electrostatic potential of the structure of SHaPrP (90-231) 
revealed that most of the positive charges are clustered at the unstructured amino- 
terminus (Chapter 4). This region is therefore most likely to participate in the 
interaction with negatively charged membranes. The high degree of protection from 
acrylamide quenching, the large shifts in the fluorescence of PrP and the resistance 
of PrP to be released from negatively charged membranes by salt provided evidence 
for hydrophobic lipid-protein interactions following the initial charge driven 
association. Therefore, binding of PrP to the surface of negatively charged 
membranes appears to result in structural changes in the protein, which in turn lead 
to the exposure of hydrophobic residues that partially insert into the hydrophobic 
domain of the lipid bilayer. Further evidence for the partial insertion of PrP into 
POPG membranes was provided by FPE-detected kinetics (Chapter 6). In addition, 
the larger shift in the fluorescence of PrP and high degree of protection to
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acrylamide quenching (Chapter 4) suggest that PrP in POPG membranes at pH 5 is 
more deeply inserted than at pH 7. Binding of PrP to POPG membranes at pH 5 and 
7 led to total release of calcein from loaded vesicles, which indicates that the binding 
and the partial insertion of PrP into POPG membranes strongly destabilises the lipid 
bilayer structure.
Far-UV CD and ATR FTIR spectroscopy (Chapter 5) revealed that the 
interaction of PrP with negatively charged membranes was accompanied by an 
increase in both a-helical and p-sheet structure compared to the NMR structure of 
SHaPrP (90-231) in solution (James et al., 1997). Furthermore the low-frequency of 
the p-sheet component detected during the FTIR experiments suggest that PrP was in 
an aggregated state when bound to negatively charged membranes. Electron 
microscopy revealed protein aggregation around the lipid vesicles. This observation 
is consistent with the interpretation of the CD and ATR FTIR data, which shows an 
increase in aggregated p-sheet structure of PrP. The results presented in this thesis 
suggest that the binding of PrP to negatively charged membranes driven by 
electrostatic lipid-protein interactions promotes the formation of aggregated p-sheet 
structure in PrP. This state in partially inserted into the hydrophobic domain of the 
lipid bilayer and leads to membrane destabilisation.
Equilibrium intermediates showing spectral characteristics of P-sheet 
proteins have been detected at acidic pH’s during guanidine hydrochloride- and urea- 
induced unfolding transitions of various recombinant prion proteins (Swietnicki et 
al., 1997; Zhang et al., 1997; Homemann & Glockshuber, 1998; Jackson et al., 
1999a, b). The results presented in this thesis also demonstrate the induction of p- 
sheet structure in PrP upon binding to negatively charged membranes. These
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structural changes are likely to result from electrostatic interactions with the 
negatively charged lipid headgroups of POPG. In addition, the accumulation of 
protons near the negatively charged lipid headgroups has been shown to result in a 
lower local pH near the membrane surface compared to the bulk pH (Prats et al., 
1986). This could also contribute to the observed protein structural changes, as seen 
in the refolding/unfolding of PrP in solution at acidic pH.
The increase in P-sheet structure of PrP is also consistent with a previous 
study in which the binding of peptide spanning residues 106-126 of human PrP to 
negatively charged membranes was investigated. Binding of this peptide was shown 
to be accompanied by a structural transition from a random coil in solution to p- 
sheet structure when bound to negatively charged membranes (De Gioia et al., 
1994). The recent NMR structure of human PrP shows amino acids 106 tol26 to lie 
within the unstructured amino-terminus of PrP (Zahn et al., 2000) and the above 
finding suggests that this region is folded upon binding to membranes. This 
observation implies that the additional structure of SHaPrP (90-231) observed 
during the binding to lipid membranes is likely to arise from the folding of the 
unstructured amino-terminus.
7.2 Biological Implications
TSE diseases are a group of human and animal neurodegenerative disorders, 
in which the central pathogenic event, is the post-translational conversion of the 
normal cellular a-helical form of a host protein, prion protein (PrPc) into an 
abnormal disease-causing p-sheet form, PrPSc. In the brains of most humans and 
animals that have died of TSE diseases, amyloid plaques containing PrPSc are
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detected. The accumulation of an abnormal p-sheet protein is also associated with a 
number of other neurodegenerative disorders such as amyloid P-protein (Ap) in 
Alzheimer’s disease, islet-associated polypeptide (IAPP) in type II diabetes, a- 
synuclein in Parkinson’s disease and huntingtin in Huntington’s disease (review 
Rochet & Lansbury, 2000). Therefore information of the various events that lead to 
the formation of P-sheet aggregates from otherwise soluble proteins is essential not 
only in TSE diseases but may also help our understanding of processes that facilitate 
the development of other neurodegenerative disorders.
TSE diseases can be sporadic, inherited, or infectious disorders. The cause of 
sporadic forms of the disease is unknown; hypotheses include somatic mutation of 
the PrP gene and spontaneous conversion of wild type PrPc to PrPSc. To date, 20 
different mutations in the human PrP gene have been linked with inherited prion 
diseases (Prusiner, 1998). The molecular event that facilitates the spontaneous 
conversion of wild type and mutant PrPc to the infectious isoform is not known. 
Thermodynamic studies of recombinant PrP containing disease related mutations 
indicated that inherited prion diseases cannot be rationalised by a lowered stability of 
PrPc (Swietnicki et al., 1998; Liemann & Glockshuber, 1999). An aberrant 
association of PrPc containing specific point mutations, with cellular membranes has 
been proposed as an alternative hypothesis to explain spontaneous development of 
prions in inherited diseases.
\
The results presented here show that PrP binds to membranes, which 
resembles the lipid composition of rafts in the plasma membrane, where PrP is 
localised. The interaction appears to favour the folding of the unstructured amino- 
terminus of PrP, resulting in a protein with a higher content of a-helical structure
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compared with the reported NMR structure in solution (James et al., 1997). This a- 
helical rich state of PrP when bound to raft-like membranes did not alter the integrity 
of the lipid bilayer structure. No evidence of PrP aggregation when bound to the 
raft-like membranes at pH 7 was detected from the electron micrographs. The 
results suggest that the direct interaction of PrP with rafts domains would have the 
advantage of stabilizing an a-helical conformation of PrP without destabilising the 
plasma membrane.
Interestingly, no binding was detected for PrP with the raft-like membranes 
of DPPC/chol/SM membranes at pH 5. This observation may reflect the behaviour 
of PrPc following internalisation into the cell. Cell surface proteins and lipids first 
appear in early endosomes following re-entry into the cell (Gruenberg & Maxfield, 
1995). The overall lipid composition of the early endosomes is similar to that of the 
plasma membrane (Van Meer, 1989). The low pH of the endosomes has been shown 
to cause the dissociation of protein ligands from their receptors. This may also be 
advantageous for the degradation of PrP in that it remains in solution and does not 
bind to the lipid rafts, which would facilitate the release of the protein from the 
membrane surface in readiness for proteolytic degradation.
At present, the molecular events that initiate PrPSc aggregation are still 
unknown; however evidence suggests that the cellular membranes are involved in 
this process. The association of scrapie infectivity with membranes was emphasized 
early on in TSE research (reviewed in Prusiner, 1989). Studies of scrapie infected 
brains have demonstrated that the highest titers of infectious PrPSc are associated 
with membrane fractions (Safar et al., 1990). Furthermore aggregates of PrP 27-30, 
which are formed during the purification of scrapie prions were found to retain
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infectivity when incorporated into detergent-lipid-protein complexes as well as 
liposomes and a significant increase in infectivity was also observed (Gabizon et al., 
1988of,Z>). Electron micrographs presented in this study revealed that negatively 
charged lipids at both pH 7 and 5 induced PrP aggregation, while no visual signs of 
protein aggregation was detected with the raft-like membranes at pH 7.
The plasma membrane of most cells typically contains an outer surface that is 
rich in cholesterol, sphingomyelin and zwitterionic PC glycerophospholipids. In 
contrast the inner surface contains negatively charged glycerophospholipids (van 
Meer, 1989). Under normal circumstances PrP is localised in lipid-rafts in the 
external leaflet of the plasma membrane and this environment appears to protect the 
protein from aggregation. The results presented in this thesis also show that binding 
of PrP to raft-like lipid membranes favours an a-helical conformation. However, 
during the intematisation of PrP either for degradation or recycling back to the 
plasma membrane, PrPc may be exposed to negatively charged domains of cell 
membranes and this change in the lipid environment may trigger a conformational 
change in PrP , resulting in an increased p-sheet structure and protein aggregation. 
The results presented in this thesis show that the electrostatic interactions between 
PrP and negatively charged lipids promote the formation of aggregated P-sheet 
structures of PrP. Cellular membranes have also been proposed to play a role in the 
development of Parkinson’s disease (Jo et al., 2000) and Alzheimer’s disease 
(McLaurin et al., 1998). Lipid membranes have been shown to induce the formation 
of p-sheet structure in Ap protein and the hydrophobic surface of membranes has 
been proposed to facilitate the polymerisation of Ap in the development of 
Alzheimers disease.
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The precise mechanism of PrP-induced cell death remains unclear. In vitro 
studies have demonstrated that PrP is neurotoxic to cultured neurons (Forloni et al., 
1993; Brown et al., 1996). Various hypotheses have been postulated to explain 
neuronal cell death. These include increased oxidative stress as a result of depleted 
levels of PrPc (Brown et al., 19976). Others have proposed a mechanism for prion 
neurotoxicity through a direct perturbation of the plasma membrane of nerve cells as 
a consequence of PrPSc accumulation (Pillot et al., 1997; Lin et al., 1997). Several 
studies have also proposed neurotoxicity in Alzheimer’s and Parkinson’s disease to 
be mediated by a direct interaction of AP (McLaurin et al., 1996; Pillot et al., 1996; 
Koppaka & Axelsen, 2000) and a-synuclein (Jo et al., 2000) respectively with lipid 
membrane.
The binding of a synthetic peptide of PrP comprising residues 106-126 has 
been demonstrated to form ion permeable channels in the lipid bilayer and these 
channels have been speculated to mediate cell death through changes in cellular ion 
homeostasis (Lin et al., 1997). The results presented here show that PrP in lipid rafts 
acquires a higher a-helical content and this membrane-associated state does not 
induce membrane destabilisation. However, the interaction of PrP with negatively 
charged membranes led to an increase in P-sheet structure, compared to the NMR 
structure in solution (James et al., 1997). This membrane state of PrP was found to 
destabilise the bilayer structure of membranes, therefore the segregation of PrP to 
negatively charged membrane domains could potentially lead to leakage of cell 
contents and would eventually cause cell death. The findings presented here support 
previous studies that propose a mechanism for neurotoxicity through a direct 
interaction of PrPSe and/or PrP intermediates with neuronal membranes.
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The PrP-lipid interactions and the formation of P-sheet structure may 
partially explain some of the pathological finding reported for prion diseases. The 
simplest implication would be that PrP surface binding to negatively charged lipids 
may explain the association of PrPSc plaques with neuronal and microglial 
membranes that are sometimes detected in the brains of humans and animals.
7.3 In Summary
The results presented in this thesis show that interaction of PrP with lipid 
membranes falls into two categories:
(1) Binding of PrP to raft-like membranes of DPPC/chol/SM at pH 7 is 
driven by hydrophobic lipid-protein interactions, which promotes the formation of 
stable a-helical structure in PrP. No signs of PrP aggregation were detected from 
the electron micrographs of PrP with the raft-like membranes. The intermediate 
protection from acrylamide quenching and the shift in PrP fluorescence suggest that 
this state richer in a-helical structure is likely to be surface associated and as a result 
does not lead to membrane destabilisation, as monitored by calcein release.
(2) Binding of PrP to negatively charged membranes is driven by 
electrostatic lipid-protein interactions, which induces the formation of aggregated p- 
sheet structure in PrP. Extensive aggregation of PrP was evident from the electron 
micrographs of PrP with negatively charged membranes. Additional hydrophobic 
lipid-protein interactions take place after the initial charge driven binding. The high 
degree of protection to acrylamide quenching, large shifts in the fluorescence of PrP 
and the insertion phase detected in FPE kinetics point to the partial insertion of PrP 
into the hydrophobic core of the lipid bilayer. Calcein release data suggests that this 
membrane-inserted state induce a strong destabilisation of the lipid bilayer structure.
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